Substituted pyrimidine-fused ring inhibitor, and preparation method therefor and use thereof

By developing new alternative pyrimidine cyclocyclic inhibitors to target KRAS mutations, the problem of insufficient efficacy of existing drugs in the treatment of KRAS mutations has been solved, and effective inhibition and efficacy of KRAS mutations have been achieved.

WO2024235225A1PCT designated stage expired Publication Date: 2024-11-21SUZHOU ZELGEN BIOPHARML +1

Patent Information

Application Number
PCT/CN2024/093105
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-04-02
Filing Date
2024-05-14
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing drugs have not been effective in targeting a variety of cancers caused by KRAS mutations, especially mutations such as KRAS G12C, G12D, and G12V, resulting in poor treatment effects and lack of effective drugs for multiple KRAS mutations.

Method used

A new class of substituted pyrimidine cyclocyclic inhibitors was developed to prepare compounds with better pharmacodynamic properties through specific chemical structures and synthetic methods for targeting KRAS mutations, including specific compound structures and preparation methods. Combined with the use of inert solvents and metal catalysts, the efficient synthesis of compounds is achieved.

Benefits of technology

These compounds showed significant inhibitory effects on KRAS mutations, improved pharmacodynamic and pharmacokinetic properties, reduced toxic side effects, and had broader clinical application potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024093105_21112024_PF_FP_ABST
    Figure CN2024093105_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a substituted aminopyrimidine-fused ring inhibitor, and a preparation method therefor and the use thereof. Specifically, the compound in the present invention has the structure as shown in formula (I0). Further disclosed in the present invention are a method for preparing the compound and the use of the compound as a KRAS mutation inhibitor. The compound has a good inhibitory effect on KRAS mutations and has better pharmacodynamic and pharmacokinetic properties and a lower toxicity and fewer side effects.
Need to check novelty before this filing date? Find Prior Art

Description

Substituted pyrimidocyclic inhibitors and their preparation method and application Technical Field

[0001] The present invention belongs to the field of medicine, and in particular relates to a substituted pyrimidocyclic inhibitor, a preparation method and an application thereof. Background Art

[0002] RAS mutations cause approximately a quarter of all human tumors, resulting in nearly one million deaths each year. Within the RAS family, KRAS mutations account for 85% of all RAS mutations. KRAS mutations are found in nearly 90% of pancreatic cancers, 30-40% of colon cancers, and 15-20% of lung cancers (primarily non-small cell lung cancer).

[0003] KRAS protein, a small GTPase encoded by the KRAS gene, is an important regulator of cell growth. Once activated, KRAS activates multiple signaling pathways, promoting cell proliferation. The most common sites of KRAS protein mutation are codons 12, 13, and 61, with mutations at codon 12 being the most common. The most common KRAS G12 mutations are G12A, G12C, G12D, G12V, and G12S. Mutations such as G12C, G12D, and G12V occur primarily in NSCLC, CRC, and pancreatic cancer. To date, no drugs have been approved for simultaneous targeting of multiple KRAS mutations.

[0004] Because KRAS mutant target proteins are pathologically associated with a variety of diseases, particularly lung cancer, pancreatic cancer, and colorectal cancer, novel KRAS mutant inhibitors are currently needed for clinical treatment. Highly active KRAS mutant inhibitors could more effectively treat KRAS mutation-induced cancers and other diseases, while potentially reducing off-target effects, thus creating a more pressing clinical need.

[0005] Summary of the Invention

[0006] The object of the present invention is to provide a novel class of compounds having an inhibitory effect on KRAS mutation and / or better pharmacodynamic properties and uses thereof.

[0007] In the first aspect of the present invention, there is provided a compound of formula (I0), its stereoisomers, tautomers, crystalline forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs

[0008] Where,

[0009] Select from the following groups:

[0010] In another preferred embodiment, a compound of formula (I), its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs is provided:

[0011] in,

[0012] Select from the following groups: Preferably, Select from the following groups:

[0013] In another preferred embodiment, ring B is selected from the following substituted or unsubstituted groups: C6-C 14 Aryl, 5-14 membered heteroaryl; wherein the substitution refers to substitution by one or more R;

[0014] R 1a are independently selected from the group consisting of substituted or unsubstituted hydrogen, deuterium, C1-C 10 Alkyl, C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group, C3-C 20 Cycloalkyl C1-C6 alkylene, 4-20 membered saturated or unsaturated heterocyclic C1-C6 alkylene; wherein the substitution refers to substitution by one or more R;

[0015] R 1b are independently selected from the group consisting of substituted or unsubstituted hydrogen, deuterium, C1-C 10 Alkyl, C1-C 10 Alkoxy, C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group, C1-C 10 Alkoxy C1-C6 alkylene, C3-C 20 Cycloalkyl C1-C6 alkylene, 4-20 membered saturated or unsaturated heterocyclic C1-C6 alkylene; wherein the substitution refers to substitution by one or more R;

[0016] R 1c Independently selected from the following groups: substituted or unsubstituted: C1-C 10 Alkyl, C1-C 10 Alkoxy, C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group, C1-C 10 Alkoxy C1-C6 alkylene, C3-C 20 Cycloalkyl C1-C6 alkylene, 4-20 membered saturated or unsaturated heterocyclic C1-C6 alkylene; wherein the substitution refers to substitution by one or more R;

[0017] or R 1a and R 1c Connected to form a 4-7 membered ring;

[0018] R 2 Selected from the following substituted or unsubstituted groups: C6-C 14 Aryl, 5-14 membered heteroaryl; wherein the substitution refers to substitution by one or more R;

[0019] R 3 Each is independently selected from the following substituted or unsubstituted groups: H, deuterium, halogen, cyano, ester, amine, amide, sulfone, urea, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C1-C6 alkyloxy, C3-C6 cycloalkyloxy, 4-6 membered heterocyclyloxy; wherein the substitution refers to substitution by one or more R;

[0020] m is an integer of 0, 1, 2, 3, 4, 5 or 6;

[0021] X is selected from the group consisting of: bond, O, NH, N(C1-C3 alkyl), C≡C;

[0022] Y is selected from: a bond, a substituted or unsubstituted C1-C6 alkylene; wherein the substitution refers to substitution by one or more R;

[0023] 1) Z is selected from:

[0024] Wherein, ring W1 is selected from the following groups: substituted or unsubstituted: C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group; wherein, the substitution refers to substitution by one or more R;

[0025] R 4Selected from: H, deuterium, alkenyl, fluoroalkenyl, ethynyl, C1-C6 alkyl, deuterated C1-C6 alkyl, halogenated C1-C6 alkyl, (C3-C6 cycloalkyl) C1-C6 alkyl, (4-6 membered heterocyclyl) C1-C6 alkyl, (C1-C6 alkoxy) C1-C6 alkyl, (C3-C6 cycloalkyloxy) C1-C6 alkyl, (4-6 membered heterocyclyloxy) C1-C6 alkyl, (C1-C6 alkyl) vinyl, deuterated (C1-C6 alkyl) )vinyl, halo(C1-C6 alkyl)vinyl, (C1-C6 alkyl)ethynyl, deuterated(C1-C6 alkyl)ethynyl, halo(C1-C6 alkyl)ethynyl, (C3-C6 cycloalkyl)ethynyl, (4-6 membered heterocyclyl)ethynyl, C1-C6 alkoxy, deuterated C1-C6 alkoxy, haloC1-C6 alkoxy, C3-C6 cycloalkyloxy, 4-6 membered heterocyclyloxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C6-C 10 aryl, 5-10 membered heteroaryl, halogen, nitro, hydroxy, oxo (=O), cyano, ester, amine, amide, sulfone or urea;

[0026] n is an integer selected from: 0, 1, 2, 3, 4, 5 or 6;

[0027] or

[0028] 2) Z is selected from: -L4-Q2 or

[0029] wherein the ring W2 is selected from the group consisting of substituted or unsubstituted C3-C6 cycloalkylene, 4-6 membered saturated or unsaturated heterocyclylene; wherein the substitution refers to substitution by one or more R;

[0030] Each L4 is independently selected from the group consisting of a substituted or unsubstituted bond, a C1-C6 alkylene group, and a deuterated C1-C6 alkylene group; wherein the substitution refers to substitution with one or more R groups;

[0031] Each Q2 is independently selected from the following groups: substituted or unsubstituted: C1-C6 alkoxy, C3-C 10 Cycloalkyloxy, 4-10 membered heterocyclyloxy, C3-C 10 Cycloalkyl C1-C6 alkyleneoxy, 4-10 membered heterocyclic C1-C6 alkyleneoxy, C3-C 10 Cycloalkyl, 4-10 membered heterocyclic group, NHR 9 NR 9 R 10 ; R 9 and R 10 Each independently selected from the following groups: substituted or unsubstituted C1-C6 alkyl, C3-C 10 Cycloalkyl, 4-10 membered heterocyclic group, (C3-C10 cycloalkyl)C1-C6 alkylene, (4-10 membered heterocyclic)C1-C6 alkylene, or R 9 and R 10 The N atom to which it is connected together forms a substituted or unsubstituted 4-10 membered heterocyclic group; wherein the substitution refers to substitution by one or more R;

[0032] Each R is the same or different and is independently selected from the group consisting of: H, deuterium, alkenyl, fluoroalkenyl, ethynyl, C1-C6 alkyl, deuterated C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylene, halogenated C1-C6 alkylene, (C3-C6 cycloalkyl)C1-C6 alkyl, (4-6 membered heterocyclyl)C1-C6 alkyl, (C1-C6 alkoxy)C1-C6 alkyl, (C3-C6 cycloalkyloxy)C1-C6 alkyl, (4-6 membered heterocyclyloxy)C1-C6 alkyl, (C1-C6 alkyl)vinyl , deuterated (C1-C6 alkyl) vinyl, halogenated (C1-C6 alkyl) vinyl, (C1-C6 alkyl) ethynyl (such as -C≡C-CH3), deuterated (C1-C6 alkyl) ethynyl, halogenated (C1-C6 alkyl) ethynyl, (C3-C6 cycloalkyl) ethynyl, (4-6 membered heterocyclyl) ethynyl, C1-C6 alkoxy, deuterated C1-C6 alkoxy, halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, 4-6 membered heterocyclyloxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C6-C 10 aryl, 5-10 membered heteroaryl, halogen, nitro, hydroxy, oxo (=O), cyano, ester, amine, amide, sulfone or urea.

[0033] In another preferred embodiment, R 1a are independently selected from the group consisting of substituted or unsubstituted hydrogen, deuterium, C1-C 10 Alkyl, C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group, C3-C 20 Cycloalkyl C1-C6 alkylene, 4-20 membered saturated or unsaturated heterocyclic C1-C6 alkylene; wherein, the substitution refers to substitution by one or more R; R 1b are independently selected from the group consisting of substituted or unsubstituted hydrogen, deuterium, C1-C 10 Alkyl, C1-C 10 Alkoxy, C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group, C1-C 10 Alkoxy C1-C6 alkylene, C3-C 20 Cycloalkyl C1-C6 alkylene, 4-20 membered saturated or unsaturated heterocyclic C1-C6 alkylene; wherein, the substitution refers to substitution by one or more R; R 1cIndependently selected from the following groups: substituted or unsubstituted: C1-C 10 Alkyl, C1-C 10 Alkoxy, C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group, C1-C 10 Alkoxy C1-C6 alkylene, C3-C 20 Cycloalkyl C1-C6 alkylene, 4-20 membered saturated or unsaturated heterocyclic C1-C6 alkylene; wherein the substitution refers to substitution by one or more R; the remaining variables are as defined above.

[0034] In another preferred embodiment, the compound has a structure represented by formula (II-A) or formula (II-B):

[0035] Where,

[0036] Ring B, R 1a 、R 1b 、R 1c 、R 2 、R 3 , X, Y, Z and m are defined as above.

[0037] In another preferred embodiment, the compound has a structure represented by formula (III-A1), formula (III-A2) or formula (III-B1), formula (III-B2):

[0038] In the formula, ring B, R 1a 、R 1b 、R 1c 、R 2 、R 3 、R 4 , X, Y, W1, W2, L4, Q2, m and n are defined as above.

[0039] In another preferred embodiment, the compound has a structure represented by Formula (III-A1) or Formula (III-B1).

[0040] In another preferred embodiment, X is O.

[0041] In another preferred embodiment, the compound has a structure represented by formula (IV-A1), formula (IV-A2), formula (IV-B1), or formula (IV-B2):

[0042] Where,

[0043] Ring B, R 1a 、R 1b 、R 1c 、R2 、R 3 、R 4 , Y, W1, W2, L4, Q2, m and n are defined as above.

[0044] In another preferred embodiment, the compound has a structure represented by Formula (IV-A1) or Formula (IV-B1).

[0045] In another preferred embodiment, R 1a C1-C 10 Alkyl; R 1b is hydrogen; and R 1c C1-C 10 Alkyl; preferably, R 1a is a C1-C4 alkyl group; R 1b is hydrogen; and R 1c is a C1-C4 alkyl group; more preferably, R 1a is methyl; R 1b is hydrogen; and R 1c It is a methyl group.

[0046] In another preferred embodiment, the compound has a structure represented by formula (V-A1), formula (V-A2), formula (V-B1), or formula (V-B2):

[0047] In the formula, ring B, R 2 、R 3 、R 4 , Y, W1, W2, L4, Q2, m and n are defined as in claim 1;

[0048] In another preferred embodiment, the compound has a structure represented by formula (V-A1) or formula (V-B1).

[0049] In another preferred embodiment, the compound has a structure represented by formula (VI-A1) or formula (VI-B1):

[0050] In the formula, ring B, R 2 、R 3 , m and n are as defined in claim 1, each R 5 are the same or different, and are each independently selected from hydrogen or deuterium.

[0051] In another preferred embodiment, the compound has a structure represented by formula (VII-A1) or formula (VII-B1):

[0052] Where,

[0053] P 1 、P 2 、P3 Each independently selected from CH, CF, C-Cl, C-CN, C-CF 3 , or N;

[0054] Ring B, R 1a 、R 1b 、R 1c 、R 3 、R 4 , X, Y, W1, W2, L4, Q2, m and n are defined as in claim 1;

[0055] In another preferred embodiment, the compound has a structure represented by formula (VII-B1).

[0056] In another preferred embodiment, Y is CH2 or CD2.

[0057] In another preferred embodiment, for and / or for

[0058] In another preferred embodiment, R 3 The same or different, each independently selected from the following group: H, deuterium, halogen, cyano, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C1-C6 alkoxy.

[0059] In another preferred embodiment, R 3 are the same or different, each independently selected from halogen.

[0060] In another preferred embodiment, W1 is selected from: substituted or unsubstituted 4-7 membered monocyclic heterocyclic group, substituted or unsubstituted C3-C7 monocyclic cycloalkyl group, substituted or unsubstituted 6-10 membered bicyclic heterocyclic group, substituted or unsubstituted C6-C 10 Bicyclic cycloalkyl, substituted or unsubstituted 7-12 membered tricyclic heterocyclic group, substituted or unsubstituted C7-C 12 tricyclic cycloalkyl, preferably, W1 is a substituted or unsubstituted 8-12 membered N-containing heterocyclic group, wherein the substitution refers to substitution by one or more R, and R is defined as above;

[0061] Preferably, Selected from:

[0062] wherein n' is an integer of 0, 1, 2, 3, 4, 5, or 6; R, R 4 and n are defined as above, R, R 4 It can be substituted on any ring of a polycyclic ring (such as a bridged ring or a spiro ring);

[0063] More preferably, Selected from:

[0064] wherein n' is an integer of 0, 1, 2, 3, 4, 5 or 6; R, R 4 and n are as defined above, and R may be substituted on any ring of a polycyclic ring (eg, a bridged ring or a spiro ring).

[0065] In another preferred embodiment, Selected from:

[0066] Or choose from:

[0067] wherein n' is an integer of 0, 1, 2, 3, 4, 5, or 6; R, R 4 and n are defined as above, R, R 4 It can be substituted on any ring of a polycyclic ring (such as a bridged ring or a spiro ring);

[0068] More preferably, Selected from:

[0069] wherein n' is an integer of 0, 1, 2, 3, 4, 5 or 6; R, R 4 and n are as defined above, and R may be substituted on any ring of a polycyclic ring (eg, a bridged ring or a spiro ring).

[0070] In another preferred embodiment, for Preferably, each R is independently hydrogen or deuterium.

[0071] In another preferred embodiment, L4 is selected from: a bond, CH2, CD2, CH(CH3).

[0072] In another preferred embodiment, Q2 is selected from: NHCH3, N(CH3)2,

[0073] In another preferred embodiment, Selected from:

[0074] In another preferred embodiment, for Preferably, Selected from:

[0075] In another preferred embodiment, R 2 is selected from the following groups: substituted or unsubstituted phenyl, naphthyl, 5-6 membered monocyclic heteroaryl (such as pyridyl), 9-10 membered bicyclic heteroaryl (such as indazolyl, benzothiazole, benzothiophene, benzofuran), wherein the substitution is substituted by one or more groups selected from the following groups: halogen, hydroxyl, cyano, NH2, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C2-C6 alkenyl, C2-C6 alkynyl (such as ethynyl or propynyl), ester, amino, amide, sulfone, urea, sulfonamide, C3-C6 cycloalkyl O-, 4-6 membered heterocyclyl O-, C3-C6 cycloalkyl OH (hydroxy-substituted C3-C6 cycloalkyl), 4-6 membered heterocyclyl OH (hydroxy-substituted 4-6 membered heterocyclyl); preferably, R 2 Selected from:

[0076] Or choose from:

[0077] Or choose from:

[0078] Or choose from:

[0079] In another preferred embodiment, R 2 The present invention is selected from the group consisting of substituted or unsubstituted phenyl, 5-6 membered monocyclic heteroaryl (preferably the 5-6 membered monocyclic heteroaryl contains only 1, 2 or 3 nitrogen atoms as heteroatoms, such as pyridyl), or naphthyl, wherein the substitution is as defined above.

[0080] In another preferred embodiment, when R 2 If the carbon atom connected to the rest of the molecule is a chiral carbon atom, the chiral carbon atom is in the R configuration or the S configuration.

[0081] In another preferred embodiment, ring B is selected from the following substituted or unsubstituted groups: phenyl, naphthyl, 5-6 membered monocyclic heteroaryl (such as pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl), 9-10 membered bicyclic heteroaryl (such as indazolyl, benzothiazole, benzothiophene, benzofuran), wherein the substitution is substituted by one or more groups selected from the following groups: halogen, hydroxyl, cyano, NH2, C1-C6 alkyl, halogenated C1-C6 alkyl, C 1-C6 alkoxy, halogenated C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C2-C6 alkenyl, C2-C6 alkynyl, ester, amino, amide, sulfone, urea, sulfonamide, C3-C6 cycloalkylO-, 4-6 membered heterocyclylO-, C3-C6 cycloalkylOH (hydroxy-substituted C3-C6 cycloalkyl), 4-6 membered heterocyclylOH (hydroxy-substituted 4-6 membered heterocyclyl); preferably, ring B is selected from:

[0082] In another preferred embodiment, ring B is selected from the following group of substituted groups: phenyl, 6-membered monocyclic heteroaryl (such as pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl); and the substitution refers to being substituted by one NH2 (preferably, the NH2 is substituted at the ortho position where the phenyl or 6-membered monocyclic heteroaryl ring B is connected to the rest of the molecule) and optionally substituted by one or more substituents selected from the following group: halogen, hydroxyl, cyano, NH2, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, C3-C6 ring Alkyl, 4-6 membered heterocyclyl, C2-C6 alkenyl, C2-C6 alkynyl, ester, amino, amide, sulfone, urea, sulfonamide, C3-C6 cycloalkyl O-, 4-6 membered heterocyclyl O-, C3-C6 cycloalkyl OH, 4-6 membered heterocyclyl OH; preferably, the substitution refers to substitution by one NH2 and 0 or one or more substituents selected from the following group: halogen, hydroxyl, cyano, NH2, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy.

[0083] In another preferred embodiment, ring B is selected from:

[0084] In another preferred embodiment, R 1a is selected from the group consisting of H, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, halogenated C3-C6 cycloalkyl, halogenated 4-6 membered heterocyclyl, C1-C6 alkoxy C1-C6 alkylene, halogenated C1-C6 alkoxy C1-C6 alkylene, C3-C6 cycloalkyl C1-C6 alkylene, 4-6 membered heterocyclyl C1-C6 alkylene; preferably, R 1ais selected from the group consisting of H, methyl, ethyl, isopropyl, cyclopropyl, oxetanyl, CH2cyclopropyl, CH2CH2OCH3, CH(CH3)CH2OCH3. More preferably, R 1a Selected from the group consisting of methyl and ethyl.

[0085] In another preferred embodiment, R 1b independently selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, halogenated C3-C6 cycloalkyl, halogenated 4-6 membered heterocyclyl, C1-C6 alkoxy C1-C6 alkylene, halogenated C1-C6 alkoxy C1-C6 alkylene, C3-C6 cycloalkyl C1-C6 alkylene, 4-6 membered heterocyclyl C1-C6 alkylene; preferably, R 1b are independently selected from the group consisting of H, methyl, ethyl, isopropyl, cyclopropyl, and oxetanyl. 1b For H.

[0086] In another preferred embodiment, R 1c independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, halogenated C3-C6 cycloalkyl, halogenated 4-6 membered heterocyclyl, C1-C6 alkoxy C1-C6 alkylene, halogenated C1-C6 alkoxy C1-C6 alkylene, C3-C6 cycloalkyl C1-C6 alkylene, 4-6 membered heterocyclyl C1-C6 alkylene; preferably, R 1c are independently selected from the group consisting of methyl, ethyl, isopropyl, cyclopropyl, and oxetanyl. 1c It is a C1-C6 alkyl group (such as methyl, ethyl).

[0087] In another preferred embodiment, R 1a Selected from the group consisting of methyl, ethyl, R 1b Selected from H, and R 1c Selected from methyl.

[0088] In another preferred embodiment, when R 1b and R 1c If different, then R 1b and R 1c The attached carbon is in the R configuration or the S configuration.

[0089] In another preferred embodiment, ring B, R 1a 、R 1b 、R 1c 、R 2 、R 3 、R 4, X, Y, W1, W2, L4, Q2, m and n have the groups corresponding to the specific compounds in the examples.

[0090] In another preferred embodiment, ring B, R 1a 、R 1b 、R 1c 、R 2 、R 3 、R 4 , X, Y, W1, W2, L4, Q2, m and n have the groups corresponding to the following specific compounds.

[0091] In another preferred embodiment, the compound is selected from the following group:

[0092] Or choose from:

[0093] Or choose from:

[0094] Or choose from:

[0095] Or choose from:

[0096] Or choose from:

[0097] Or choose from:

[0098] Or choose from:

[0099] Or choose from:

[0100] Or choose from:

[0101] Or choose from:

[0102] Or choose from:

[0103] Or choose from:

[0104] Or choose from:

[0105] Or choose from:

[0106] Or choose from:

[0107] In another preferred embodiment, the compound is preferably the compound prepared in the examples.

[0108] In a second aspect, the present invention provides a method for preparing a compound of formula (I), its stereoisomers, tautomers, crystalline forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs, comprising the steps of:

[0109] (i) reacting a compound of formula XI with a compound of formula X-II in an inert solvent in the presence of a base, with or without a Pd catalyst, and with or without a condensing agent to obtain a compound of formula X-III;

[0110] (ii) reacting the compound of formula X-III with the compound of formula X-IV in an inert solvent in the presence of a base and Pd or other metal catalyst to obtain a compound of formula XV;

[0111] (iii) reacting a compound of formula XV with a compound of formula X-VI in an inert solvent in the presence of a base with or without a Pd catalyst to obtain a compound of formula I;

[0112] LG1, LG2, LG3, LG4, and LG5 are leaving groups, each independently selected from the group consisting of: H, OH, halogen, OTf, OTs, OMs, -B(OH)2, -B(KBF3), -Sn( n Bu)3, wait;

[0113] The Pd catalyst is selected from: Pd(OAc)2, Pd(dba)2, Pd2(dba)3, XPhos PdG2, RuPhos PdG2, XantPhos-Pd-G2, cataCXium A-Pd-G2, XPhos PdG3, RuPhos PdG3, PdG3, SPhos PdG3, tBuXPhos-Pd-G3, XantPhos-Pd-G4, BrettPhos PG4, SPhos PdG4, cataCXium A-Pd-G4, Rockphos PdG4, etc.;

[0114] R 1a 、R 1b 、R 1c 、R 2 、R 3 , Ring A, Ring B, X, Y, Z, and m are as defined above.

[0115] In a third aspect, the present invention provides a pharmaceutical composition comprising one or more compounds according to the first aspect, their stereoisomers, tautomers, crystalline forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs; and a pharmaceutically acceptable carrier.

[0116] In another preferred embodiment, the pharmaceutical composition further comprises a drug selected from the group consisting of: PD-1 inhibitors (such as nivolumab, pembrolizumab, pidilizumab, cemiplimab, JS-001, SHR-120, BGB-A317, IBI-308, GLS-010, GB-226, STW204, HX008, HLX10, BAT 1306, AK105, LZM 009 or biosimilars thereof), PD-L1 inhibitors (such as durvalumab, atezolizumab, avelumab, CS1001, KN035, HLX20, SHR-1316, BGB-A333, JS003, CS1003, KL-A167, F 520, GR1405, MSB2311 or biosimilars of the above drugs, etc.), CD20 antibodies (such as rituximab, obinutuzumab, ofatumumab, veltuzumab, tositumomab, 131I-tositumomab, ibritumomab, 90Y-ibritumomab, 90In-ibritumomab, ibritumomabtiuxetan, etc.), CD47 antibodies (such as Hu5F9-G4, CC-90002, TTI-621, TTI-622, OSE-172, SRF-231, ALX-148, NI-1701, SHR-1603, IBI188, IMM01), ALK inhibitors (such as Ceritinib, Alectinib, Brigatinib, Lorlatinib, Ocatinib), PI3K inhibitors (such as Idelalisib, Duvelisib, Dactolisib, Taselisib, Bimiralisib, Omipal isib, Buparlisib, etc.), BTK inhibitors (such as Ibrutinib, Tirabrutinib, Acalabrutinib, Zanubrutinib, Vecabrutinib, etc.), EGFR inhibitors (such as Afatinib, Gefitinib, Erlotinib, Lapatinib, Dacomitinib, Icotinib, Canertinib, Sapitinib, Naquotinib, Pyrotinib, Rociletinib, Osimertinib, etc.), VEGFR inhibitors (such as Sorafenib, Pazopanib, Regorafenib, Sitravatinib, Ningetinib, Cabozantinib, Sunitinib, Donafenib, etc.), HDAC inhibitors (such as Givinostat, Tucidinostat, Vorinostat, Fimepinostat, Droxinostat, Entinostat, Dacinostat, Quisinostat, Tacedinaline, etc.), CDK inhibitors (such as Palbociclib, Ribostat, etc.), ciclib, Abemaciclib, Milciclib, Trilaciclib, Lerociclib, etc.), MEK inhibitors (such as Selumetinib (AZD6244), Trametinib (GSK1120212), PD0325901, U0126, Pimasertib (AS-703026), PD184352 (CI-1040), etc.), mTOR inhibitors (such as Visusertib, etc.), SHP2 inhibitors (such as RMC-4630, JAB-3068, TNO155, etc.), SOS1 inhibitors (such as BI 1701963) or a combination thereof.

[0117] In a fourth aspect, the present invention provides a use of the compound as described in the first aspect, its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs, or the pharmaceutical composition as described in the third aspect, for preparing a drug for preventing and / or treating a disease associated with the activity or expression of a KRAS mutation, preferably, the disease is a tumor or a disorder.

[0118] In another preferred embodiment, the disease is selected from the following group: lung cancer, breast cancer, prostate cancer, esophageal cancer, colorectal cancer, bone cancer, kidney cancer, gastric cancer, liver cancer, colon cancer, melanoma, lymphoma, blood cancer, brain tumor, myeloma, soft tissue sarcoma, pancreatic cancer, skin cancer.

[0119] In another preferred embodiment, the KRAS mutation is selected from the following group: G12D, G12V, G12R, G12S, G12A, G12C, or a combination thereof. Preferably, the KRAS mutation is selected from the following group: G12D, G12V, G12R, or a combination thereof. More preferably, the KRAS mutation is G12V.

[0120] In a fifth aspect, the present invention provides a non-diagnostic, non-therapeutic method for inhibiting KRAS mutations, comprising the steps of administering to a subject in need thereof an effective amount of the compound as described in the first aspect, its stereoisomers, tautomers, crystalline forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs, or administering the pharmaceutical composition as described in the third aspect.

[0121] In another preferred embodiment, the subject is a mammal, preferably a human.

[0122] In a sixth aspect, the present invention provides a method for inhibiting KRAS mutant activity in vitro, comprising the steps of contacting the compound according to the first aspect, its stereoisomers, tautomers, crystalline forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs, or the pharmaceutical composition according to the third aspect with a protein or cell, thereby inhibiting the activity of the KRAS mutant.

[0123] In another preferred embodiment, the cells are selected from the group consisting of macrophages, intestinal cells (including intestinal stem cells, intestinal epithelial cells), or a combination thereof.

[0124] In another preferred embodiment, the cells are from rodents (such as mice and rats) or primates (such as humans).

[0125] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. DETAILED DESCRIPTION

[0126] After long and in-depth research, the inventors unexpectedly prepared a new class of compounds with inhibitory effects on KRAS mutations and / or better pharmacodynamics, on the basis of which the inventors completed the present invention.

[0127] the term

[0128] In the present invention, unless otherwise specified, the terms used have the general meanings commonly known to those skilled in the art.

[0129] The term "alkyl" refers to a straight chain or branched chain alkane or cyclic hydrocarbon group (including hydrocarbon groups connected to other parts through carbon atoms on the ring or non-ring), preferably a straight chain or branched chain alkane group, containing 1-20 carbon atoms, such as 1-18 carbon atoms, especially 1-18 carbon atoms, preferably 1-10 carbon atoms (C1-C10), more preferably 1-6 carbon atoms (C1-C6) or 1-3 carbon atoms (C1-C3). Typical "alkyl" includes methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, isobutyl, Pentyl, isopentyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl and the like. In the present invention, alkyl also includes substituted alkyl. "Substituted alkyl" means that one or more positions in the alkyl are substituted, especially 1-4 substituents, which can be substituted at any position. Typical substitutions include, but are not limited to, one or more of the following groups: such as hydrogen, deuterium, halogen (for example, a monohalogen substituent or a polyhalogen substituent, the latter such as a trifluoromethyl group or an alkyl group containing Cl3), nitrile, nitro, oxygen (such as =O), trifluoromethyl, trifluoromethoxy, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aromatic ring, OR a SR a 、S(=O)R e 、S(=O)2R e 、P(=O)2R e 、S(=O)2OR e ,P(=O)2OR e NR b R c NR b S(=O)2R e NR b P(=O)2R e 、S(=O)2NR b R c 、P(=O)2NR b R c 、C(=O)OR d 、C(=O)R a 、C(=O)NR b Rc 、OC(=O)R a 、OC(=O)NR b R c NR b C(=O)OR e ,NR d C(=O)NR b R c NR d S(=O)2NR b R c NR d P(=O)2NR b R c NR b C(=O)R a , or NR b P(=O)2R e , where R appears here a R may independently represent hydrogen, deuterium, C1-C6 alkyl, C3-C8 cycloalkyl, C2-C6 alkenyl, C3-C6 cycloalkenyl, C2-C6 alkynyl, 5-14 membered heterocyclic ring or C6-C14 aromatic ring, b 、R c and R d can independently represent hydrogen, deuterium, C1-C6 alkyl, C3-C8 cycloalkyl, 5-14 membered heterocyclic ring or C6-C14 aromatic ring, or R b and R c Together with the N atom, it can form a heterocyclic ring; R e and C-C alkyl, C-C cycloalkyl, C-C alkenyl, C-C cycloalkenyl, C-C alkynyl, 5-14 membered heterocyclic ring or C-C aromatic ring. The above typical substituents, such as alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocyclic ring or aromatic ring, may be optionally substituted.

[0130] The term "alkylene" refers to a group formed by removing a hydrogen atom from an alkyl or substituted alkyl group, such as methylene (e.g. or -CH2-), ethylene (such as ), propylene (such as ), isopropylidene (such as ), butylene (such as ), pentylene (such as ), hexamethylene (such as ), heptylene (such as ), In addition, the term also includes a methylene group of an alkylene group (such as C1-C18 alkylene) replaced by a cycloalkylene group (such as C3-C20 cycloalkylene), for example, "C1-C18 alkylene C3-C20 cycloalkylene" or "C3-C20 cycloalkylene C1-C18 alkylene". In the present invention, alkylene also includes substituted alkylene, and the substituent can be a halogenated group (such as -CHF- or -CF2-), hydroxyl, cyano, nitro, etc.

[0131] The term "C1-C18 alkylene C3-C20 cycloalkylene" or "C3-C20 cycloalkylene C1-C18 alkylene" has the same meaning and refers to a group formed by removing two hydrogen atoms from a cycloalkylalkyl or alkylcycloalkyl group, such as etc. Preferably, C1-C6 alkylene is C3-C6 cycloalkylene. In the present invention, "C1-C18 alkylene C3-C20 cycloalkylene" or "C3-C20 cycloalkylene C1-C18 alkylene" also includes substituted "C1-C18 alkylene C3-C20 cycloalkylene" or "C3-C20 cycloalkylene C1-C18 alkylene", and the substituent may be halo, hydroxyl, cyano, nitro, etc.

[0132] In the present invention, the term "alkenyl" refers to a straight or branched hydrocarbon group containing one or more double bonds and generally having a length of 1 to 20 carbon atoms. Alkenyl is preferably C1-C6 alkenyl, more preferably C1-C4 alkenyl or C2-C4 alkenyl. Alkenyl can be a group that directly forms a double bond with a carbon atom on a cycloalkyl or heterocycloalkyl group, such as a methylene group (e.g. ). Alkenyl groups include, but are not limited to, for example, methanyl (e.g. ), vinyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, etc. In the present invention, alkenyl includes substituted alkenyl. In the present invention, alkenyl also includes substituted alkenyl, and the substituent may be halogenated (such as ), hydroxyl, cyano, nitro, etc.

[0133] The term "alkynyl" refers to a straight or branched hydrocarbon group containing one or more triple bonds and typically having a length of 2 to 20 carbon atoms. Alkynyl groups are preferably C2-C6 alkynyl groups, more preferably C2-C4 alkynyl groups. Alkynyl groups include, but are not limited to, ethynyl, propynyl, and similar groups. In the present invention, alkynyl groups also include substituted alkynyl groups, and the substituents may be halo, hydroxyl, cyano, nitro, and the like.

[0134] In the present invention, the term "cycloalkyl" refers to a fully saturated cyclic hydrocarbon compound group, including 1-4 rings, each containing 3-8 carbon atoms. 20" refers to a cycloalkyl group containing 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms. The cycloalkyl group is preferably C3-C 14 Cycloalkyl, more preferably C3-C 10 Cycloalkyl, more preferably C3-C6 monocyclic cycloalkyl, C7-C 10 Bicyclic or tricyclic cycloalkyl. "Substituted cycloalkyl" means that one or more positions in the cycloalkyl are substituted, especially 1-4 substituents, which can be substituted at any position. In the present invention, "cycloalkyl" includes substituted cycloalkyl, and typical substitutions include but are not limited to one or more of the following groups: such as hydrogen, deuterium, halogen (for example, a monohalogen substituent or a polyhalogen substituent, the latter such as trifluoromethyl or an alkyl containing Cl3), nitrile, nitro, oxygen (such as =O), trifluoromethyl, trifluoromethoxy, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aromatic ring, OR a SR a 、S(=O)R e 、S(=O)2R e 、P(=O)2R e 、S(=O)2OR e 、P(=O)2OR e NR b R c NR b S(=O)2R e NR b P(=O)2R e 、S(=O)2NR b R c 、P(=O)2NR b R c 、C(=O)OR d 、C(=O)R a 、C(=O)NR b R c 、OC(=O)R a 、OC(=O)NR b R c NR b C(=O)OR e NR d C(=O)NR b R c NR d S(=O)2NR b R c NR d P(=O)2NR b R c NR b C(=O)R a , or NRb P(=O)2R e , where R appears here a R may independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocyclyl, aryl or heteroaryl. b 、R c and R d can independently represent hydrogen, deuterium, alkyl, cycloalkyl, heterocyclic or aromatic ring, or R b and R c Together with the N atom, it can form a heterocyclic ring; R e Can independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocyclic radical, aryl or heteroaryl.Above-mentioned typical substituents can be optionally substituted.Typical substitution also includes spirocycle, pyrimidocyclic or fused ring substituents, especially spirocyclic alkyl, spirocyclic alkenyl, spirocyclic heterocycle (excluding heteroaromatic ring), pyrimidocyclic alkyl, pyrimidocyclic alkenyl, pyrimidocyclic heterocycle (excluding heteroaromatic ring), fused cycloalkyl, fused cycloalkenyl, fused ring heterocyclic radical or fused ring aromatic ring radical, above-mentioned cycloalkyl, cycloalkenyl, heterocyclic radical and heteroaryl can be optionally substituted.The example of cycloalkyl includes but is not limited to: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl etc.

[0135] The term "C3-C20 cycloalkylene" refers to a group formed by removing two hydrogen atoms from a cycloalkyl group. The cycloalkylene group is preferably C3-C 14 Cycloalkylene, more preferably C3-C 10 Cycloalkylene, more preferably C3-C6 monocyclic cycloalkylene, C7-C 10 Bicyclic or tricyclic cycloalkylene. For example: The cycloalkylene group may be optionally further substituted.

[0136] As used herein, the term "heterocyclyl" refers to a fully saturated or partially unsaturated cyclic group (including but not limited to a 3-7 membered monocyclic, 4-7 membered monocyclic, 6-11 membered bicyclic, or 8-16 membered tricyclic or polycyclic ring system) wherein at least one heteroatom is present in the ring containing at least one carbon atom. The term "4-20 membered heterocyclyl" refers to a heterocyclyl group containing 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 ring atoms. "Heterocyclyl" has the same meaning as "saturated or unsaturated heterocyclyl." "Heterocyclyl" is preferably a 4-14 membered heterocyclyl (including but not limited to a 4-6 membered monocyclic, 7-10 membered bicyclic or 8-14 membered tricyclic or polycyclic ring system), more preferably a 4-12 membered heterocyclyl, more preferably a 4-10 membered heterocyclyl, such as a 4-6 membered monocyclic heterocyclyl, a 7-11 membered bicyclic or tricyclic heterocyclyl, more preferably a 4-8 membered heterocyclyl, more preferably a 4-6 membered heterocyclyl. Each heterocyclic ring containing a heteroatom may have 1, 2, 3 or 4 heteroatoms, each of which is independently selected from a nitrogen atom, an oxygen atom or a sulfur atom, wherein the nitrogen atom or sulfur atom may be oxidized and the nitrogen atom may be quaternized. The heterocyclic group may be attached to the residue of any heteroatom or carbon atom of the ring or ring system, preferably to an N or C atom of the ring or ring system. Typical monocyclic heterocycles include, but are not limited to, azetidinyl, pyrrolidinyl, oxetanyl, pyrazolinyl, imidazolinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, hexahydroazepinyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dioxanyl, and tetrahydro-1,1-dioxythiophene, and the like. Polycyclic heterocyclic groups include spirocyclic, fused and bridged heterocyclic groups; wherein the spirocyclic, fused and bridged heterocyclic groups are optionally connected to other groups through single bonds, or further connected to other cycloalkyl, heterocyclic, aryl and heteroaryl groups through any two or more atoms on the ring; the heterocyclic group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more groups independently selected from alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, alkylthio, alkylamino, halogen, amino, nitro, hydroxyl, thiol, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkylthio, oxo, carboxyl and carboxylate.

[0137] The term "4-20 membered heterocyclylene" refers to a group formed by removing two hydrogen atoms from a heterocyclyl group. The "heterocyclylene" is preferably a 4-14 membered heterocyclylene (including but not limited to a 4-6 membered monocyclic, 7-10 membered bicyclic or 8-14 membered tricyclic or polycyclic system), more preferably a 4-12 membered heterocyclylene, more preferably a 4-10 membered heterocyclylene, such as a 4-6 membered monocyclic heterocyclylene, a 7-11 membered bicyclic or tricyclic heterocyclylene, more preferably a 4-8 membered heterocyclylene, more preferably a 4-6 membered heterocyclylene or a 4-5 membered heterocyclylene. For example: The heterocyclylene group may be optionally further substituted.

[0138] In the present invention, the term "aryl" refers to an aromatic cyclic hydrocarbon group having 1-5 rings, especially a monocyclic and bicyclic group. 14 "Aryl" refers to an aromatic cyclic hydrocarbon compound group containing 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring carbon atoms. Aryl is preferably C6-C 10 Aryl. Aryl includes phenyl, biphenyl or naphthyl. Where there are two or more aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group can be connected by a single bond (such as biphenyl) or fused (such as naphthalene, anthracene, etc.). "Substituted aryl" means that one or more positions in the aryl group are substituted, especially 1-3 substituents, which can be substituted at any position. Typical substitutions include, but are not limited to, one or more of the following groups: such as hydrogen, deuterium, halogen (for example, a monohalogen substituent or a polyhalogen substituent, the latter such as trifluoromethyl or an alkyl group containing Cl3), cyano, nitro, oxo (such as =O), trifluoromethyl, trifluoromethoxy, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocyclyl, aryl, heteroaryl, OR a SR a 、S(=O)R e 、S(=O)2R e 、P(=O)2R e 、S(=O)2OR e 、P(=O)2OR e NR b R c NR b S(=O)2R e NR b P(=O)2R e 、S(=O)2NR b R c 、P(=O)2NR b R c 、C(=O)OR d 、C(=O)R a 、C(=O)NR b R c 、OC(=O)Ra 、OC(=O)NR b R c NR b C(=O)OR e NR d C(=O)NR b R c NR d S(=O)2NR b R c NR d P(=O)2NR b R c NR b C(=O)R a , or NR b P(=O)2R e , where R appears here a R may independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocyclic or aryl. b 、R c and R d can independently represent hydrogen, deuterium, alkyl, cycloalkyl, heterocyclic or aromatic ring, or R b and R c Together with the N atom, it can form a heterocyclic ring; R e The alkyl radicals may independently represent hydrogen, deuterium, an alkyl radical, a cycloalkyl radical, an alkenyl radical, a cycloalkenyl radical, an alkynyl radical, a heterocyclic radical, or an aryl radical. The aforementioned typical substituents may optionally be substituted. Typical substitutions also include fused ring substituents, particularly fused ring alkyl radicals, fused ring alkenyl radicals, fused ring heterocyclic radicals, or fused ring aromatic radicals, wherein the aforementioned cycloalkyl radicals, cycloalkenyl radicals, heterocyclic radicals, and heterocyclic aromatic radicals may optionally be substituted.

[0139] The term "heteroaryl" refers to an aromatic cyclic hydrocarbon group containing 1-4 heteroatoms, wherein the heteroatoms are selected from oxygen, nitrogen and sulfur. Among them, "5-14 membered heteroaryl" refers to a heteroaromatic system containing 1-4 heteroatoms and 5-14 ring atoms. The heteroaryl group is preferably a 5- to 10-membered ring, more preferably a 5- or 6-membered ring, such as pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl and tetrazolyl. "Heteroaryl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more groups independently selected from alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, alkylthio, alkylamino, halogen, amino, nitro, hydroxy, mercapto, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylthio, oxo, carboxyl and carboxylate.

[0140] In the present invention, the term "alkoxy" refers to a linear or branched alkoxy group, including alkyl-O-, alkyl-O-alkyl, wherein "C1-C 18 "Alkoxy" refers to a straight or branched chain alkoxy group having 1 to 18 carbon atoms, including C1-C 18 Alkyl-O-, -C1-C6 alkyl-O-C1-C6 alkyl, including but not limited to methoxy, ethoxy, propoxy, isopropoxy and butoxy, etc. Preferably it is C1-C8 alkoxy, more preferably C1-C6 alkoxy.

[0141] In the present invention, the term "cycloalkyloxy" refers to cycloalkyl-O-, wherein "C3-C 20 "Cycloalkyloxy" refers to C3-C 20 Cycloalkyl-O-, wherein C3-C 20 Cycloalkyl is as defined above.

[0142] In the present invention, the term "heterocyclyloxy" refers to heterocyclyl-O-, wherein "4-20 membered heterocyclyloxy" refers to 4-20 membered heterocyclyl-O-, wherein the definition of 4-20 membered heterocyclyl is as described above.

[0143] In the present invention, the term "C1-C 18 "Alkyleneoxy" refers to "C1-C 18 Alkoxy is a group formed by removing a hydrogen atom.

[0144] In the present invention, the term "halogen" or "halo" refers to chlorine, bromine, fluorine, and iodine.

[0145] In the present invention, the term "halogenated" means substituted with halogen.

[0146] In the present invention, the term "deuterated" means substituted with deuterium.

[0147] In the present invention, the term "hydroxyl" refers to a group with the structure OH.

[0148] In the present invention, the term "nitro" refers to a group having the structure NO2.

[0149] In the present invention, the term "cyano" refers to a group having the structure CN.

[0150] In the present invention, the term "ester group" refers to a group with the structure -COOR, wherein R represents hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heterocycle or substituted heterocycle. The ester group is preferably -COOC1-C6 alkyl.

[0151] The term "amine group" refers to a group having the structure -NRR', wherein R and R' can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heterocycle or substituted heterocycle, as defined above. R and R' can be the same or different in the dialkylamine moiety. The amine group is preferably NH2, NHC1-C6 alkyl, or N(C1-C6 alkyl)2.

[0152] The term "amido" refers to a group having the structure -CONRR', where R and R' can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heterocycle or substituted heterocycle, as defined above. R and R' can be the same or different in the dialkylamine moiety. The amide group is preferably CONH2, NHCO(C1-C6 alkyl), or NHCO(C3-C6 cycloalkyl).

[0153] The term "sulfone group" refers to a group having the structure -SO2R, wherein R can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, heterocyclyl or substituted heterocyclyl, as defined above. The sulfone group is preferably -SO2C1-C6 alkyl.

[0154] The term "sulfonamido" refers to a group having the structure -SO2NRR', wherein R can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, heterocyclyl or substituted heterocyclyl, as defined above. Sulfonamido is preferably -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2NH(C3-C6 cycloalkyl).

[0155] The term "urea group" refers to a group having the structure -NRCONR'R", wherein R, R' and R" can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, heterocyclyl or substituted heterocyclyl, as defined above. R, R' and R" can be the same or different in the dialkylamine fragment. The urea group is preferably -NHCONH2, -NHCONH(C1-C6 alkyl).

[0156] The term "alkylaminoalkyl" refers to a group having the structure -RNHR', where R and R' independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, or heterocyclyl or substituted heterocyclyl, as defined above. R and R' may be the same or different. Alkylaminoalkyl is preferably -C1-C6 alkylene or NHC1-C6 alkyl.

[0157] The term "dialkylaminoalkyl" refers to a group having the structure -RNHR'R", wherein R, R' and R" can independently represent alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, heterocyclyl or substituted heterocyclyl, as defined above. R, R' and R" can be the same or different in the dialkylamino moiety. The dialkylaminoalkyl group is preferably -C1-C6 alkylene N(C1-C6 alkyl)2.

[0158] The term "heterocyclylalkyl" refers to a group having the structure -RR', wherein R can independently represent alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl; and R' represents a heterocycle or a substituted heterocycle.

[0159] In the present invention, the term "substituted" refers to the replacement of one or more hydrogen atoms on a specific group with a specific substituent. The specific substituent is the substituent described above or the substituent appearing in the examples. Unless otherwise specified, a substituted group may have a substituent selected from the specific group at any substitutable position of the group, and the substituent may be the same or different at each position. It will be understood by those skilled in the art that the combinations of substituents contemplated by the present invention are those that are stable or chemically feasible. The substituents include, but are not limited to, halogen, hydroxyl, cyano, carboxyl (-COOH), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 12-membered heterocyclic group, aryl, heteroaryl, C1-C8 aldehyde, C2-C10 acyl, C2-C10 ester, amino (-NH2, -NH(C1-C6 alkyl) or -NH(C1-C6 alkyl)2), C1-C6 alkoxy, C1-C10 sulfonyl, and C1-C6 urea, etc.

[0160] Unless otherwise stated, any heteroatom with insufficient valence is assumed to have sufficient hydrogen atoms to complete the valence.

[0161] When a substituent is non-terminal, it is a substituent of the corresponding group, for example, alkyl for alkylene, cycloalkyl for cycloalkylene, heterocyclyl for heterocyclylene, alkoxy for alkyleneoxy, and the like.

[0162] In the present invention, a plurality refers to 2, 3, 4, or 5.

[0163] Active ingredient

[0164] As used herein, "compounds of the present invention" refers to compounds represented by formula I0, and also includes stereoisomers or optical isomers, pharmaceutically acceptable salts, prodrugs or solvates of the compounds of formula I0.

[0165] The salts that may be formed by the compounds of the present invention also fall within the scope of the present invention. Unless otherwise indicated, the compounds of the present invention are understood to include their salts. The term "salt" as used herein refers to acidic or basic salts formed with inorganic or organic acids and bases. In addition, when the compound of the present invention contains a basic fragment, it includes but is not limited to pyridine or imidazole, and contains an acidic fragment, including but not limited to carboxylic acid, the zwitterions ("inner salts") that may be formed are included within the scope of the term "salt". Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful, for example, in separation or purification steps during the preparation process. The compounds of the present invention may form salts, for example, compound I reacts with a certain amount, such as an equivalent amount, of an acid or base, salts out in a medium, or is obtained by freeze-drying in an aqueous solution.

[0166] The compounds of the present invention contain basic moieties, including but not limited to amines or pyridine or imidazole rings, which may form salts with organic or inorganic acids. Typical acids that can form salts include acetates (e.g., acetic acid or trihaloacetic acid, such as trifluoroacetic acid), adipates, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphor, camphorsulfonate, cyclopentanepropionate, diglycolate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide,

[0014] Examples of the present invention include, for example, hydroxyethylsulfonates, lactates, maleates, methanesulfonates, naphthalenesulfonates (e.g., 2-naphthalenesulfonate), nicotinates, nitrates, oxalates, pectinates, persulfates, phenylpropionates (e.g., 3-phenylpropionate), phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (e.g., with sulfuric acid), sulfonates, tartrates, thiocyanates, toluenesulfonates such as p-toluenesulfonate, dodecanoates, and the like.

[0167] Certain compounds of the present invention may contain acidic moieties, including but not limited to carboxylic acids, which may form salts with various organic or inorganic bases. Typical base-forming salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, and salts formed with organic bases (e.g., organic amines), such as benzathine, dicyclohexylamine, hepamine (salt formed with N,N-di(dehydroabietyl)ethylenediamine), N-methyl-D-glucamine, N-methyl-D-glucamide, tert-butylamine, and salts formed with amino acids such as arginine, lysine, and the like. Basic nitrogen-containing groups can react with halide quaternary ammonium salts, such as small molecular alkyl halides (such as chlorides, bromides and iodides of methyl, ethyl, propyl and butyl), dialkyl sulfates (such as dimethyl sulfate, diethyl sulfate, dibutyl sulfate and dipentyl sulfate), long chain halides (such as chlorides, bromides and iodides of decyl, dodecyl, tetradecyl and tetradecyl), aralkyl halides (such as benzyl and phenyl bromide), etc.

[0168] Prodrugs and solvates of the compounds of the present invention are also encompassed. The term "prodrug" herein refers to a compound that undergoes chemical transformation via metabolic or chemical processes to produce a compound, salt, or solvate of the present invention when used to treat a relevant disease. The compounds of the present invention include solvates, such as hydrates.

[0169] The compounds, salts or solvates of the present invention may exist in tautomeric forms (such as amides and imino ethers). All such tautomers are part of the present invention.

[0170] All stereoisomers of the compounds (e.g., those that may exist due to asymmetric carbon atoms for various substitutions), including enantiomeric and diastereomeric forms, are contemplated by the present invention. Individual stereoisomers of the compounds of the present invention may not exist with other isomers (e.g., as a pure or substantially pure optical isomer having a particular activity), or may be mixtures, such as racemates, or mixtures with all other stereoisomers or portions thereof. The chiral centers of the present invention have either S or R configurations, as defined by the 1974 recommendations of the International Union of Pure and Applied Chemistry (IUPAC). Racemic forms can be resolved by physical methods, such as fractional crystallization, or by crystallization of diastereomers derived from them, or by separation by chiral column chromatography. Individual optical isomers can be obtained from the racemate by suitable methods, including but not limited to conventional methods, such as salt formation with an optically active acid followed by recrystallization.

[0171] The compounds of the present invention, obtained by sequential preparation, isolation, and purification, are described in the text to a concentration of 90% or greater by weight, for example, 95% or greater, or 99% or greater ("very pure" compounds). Such "very pure" compounds of the present invention are also considered part of the present invention.

[0172] All configurational isomers of the compounds of the present invention are encompassed, whether in mixture, pure or very pure form. The definition of the compounds of the present invention includes both cis (Z) and trans (E) olefin isomers, as well as cis and trans isomers of carbocyclic and heterocyclic rings.

[0173] Throughout the specification, groups and substituents may be chosen to provide stable fragments and compounds.

[0174] Specific functional groups and chemical term definitions are detailed below. For the purposes of this invention, chemical elements are referred to as Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 th The definitions of specific functional groups are consistent with those in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito, 1999, which is incorporated by reference in its entirety.

[0175] Certain compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention encompasses all compounds, including their cis and trans isomers, R and S enantiomers, diastereomers, (D) isomers, (L) isomers, racemic mixtures, and other mixtures. Additionally, asymmetric carbon atoms may represent substituents, such as alkyl groups. All isomers and mixtures thereof are encompassed by the present invention.

[0176] According to the present invention, mixtures of isomers can contain various ratios of isomers. For example, mixtures containing only two isomers can have the following ratios: 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0. All ratios of isomers are within the scope of the present invention. Similar ratios, as well as ratios for more complex mixtures of isomers, are readily understood by those skilled in the art and are also within the scope of the present invention.

[0177] The present invention also includes isotopically labeled compounds that are equivalent to the original compounds disclosed herein. However, in practice, it is common for one or more atoms to be replaced by atoms having a different atomic mass or mass number. Examples of isotopes of the compounds of the present invention include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine isotopes, such as 2 H. 3 H. 13 C. 11 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 The compounds of the present invention, or enantiomers, diastereomers, isomers, or pharmaceutically acceptable salts or solvates thereof, which contain isotopes or other isotopic atoms of the above compounds are within the scope of the present invention. Certain isotopically labeled compounds of the present invention, such as 3 H and 14 Radioisotopes of C are also included and are useful in tissue distribution experiments of drugs and substrates. 3 H and carbon-14, i.e. 14 C, their preparation and detection are relatively easy. It is the first choice among isotopes. In addition, heavier isotope substitutions such as deuterium, i.e. 2 H, due to its excellent metabolic stability, has advantages in certain therapeutics, such as increasing half-life in vivo or reducing dosage, and therefore, may be preferred in some cases. Isotopically labeled compounds can be prepared using conventional methods by replacing readily available isotopically labeled reagents with non-isotopic reagents using the protocols disclosed in the examples.

[0178] If a synthesis of a specific enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, followed by separation of the resulting diastereomeric mixture and removal of the chiral auxiliary to obtain the pure enantiomer. Alternatively, if the molecule contains a basic functional group, such as an amino acid, or an acidic functional group, such as a carboxyl group, diastereomeric salts can be formed with a suitable optically active acid or base, followed by separation by conventional means such as fractional crystallization or chromatography to obtain the pure enantiomer.

[0179] As described herein, the compounds of the present invention may be substituted with any number of substituents or functional groups to broaden their scope. Generally, the term "substituted," whether preceded or followed by the term "optionally," in formulas of the present invention including substituents, refers to the replacement of a hydrogen radical with a substituent of the specified structure. When multiple positions in a particular structure are substituted with multiple substituents of the specified structure, the substituents may be the same or different at each position. As used herein, the term "substituted" includes all permissible substitutions in organic compounds. Broadly speaking, permissible substituents include acyclic, cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic organic compounds. For example, heteroatoms such as nitrogen may be substituted with hydrogen or any of the permissible organic compounds described above to supplement their valences. Furthermore, the present invention is not intended to limit the permissible substitutions in any way to organic compounds. The present invention recognizes that combinations of substituents and variables are advantageous for providing stable compounds for the treatment of diseases, such as infectious or proliferative diseases. As used herein, the term "stable" refers to compounds that are stable and maintain the structural integrity of the compound over a period of time sufficient to be detected, preferably over a period of time sufficient to be effective, as used herein for the purposes described above.

[0180] The metabolites of the compounds and pharmaceutically acceptable salts thereof involved in the present application, as well as prodrugs that can be converted into the structures of the compounds and pharmaceutically acceptable salts involved in the present application and in vivo, are also included in the claims of the present application.

[0181] Preparation method

[0182] The preparation method of the compound of formula (I) of the present invention is described in more detail below, but these specific methods do not constitute any limitation to the present invention. The compounds of the present invention can also be optionally combined with various synthetic methods described in this specification or known in the art and easily prepared, and such combination can be easily carried out by those skilled in the art.

[0183] Typically, the preparation process of the compound of the present invention is as follows, wherein the raw materials and reagents used can be purchased through commercial channels unless otherwise specified.

[0184] Preferably, the compounds of the present invention are prepared by the following method

[0185] (i) reacting a compound of formula XI with a compound of formula X-II in an inert solvent in the presence of a base, with or without a Pd catalyst, and with or without a condensing agent to obtain a compound of formula X-III;

[0186] (ii) reacting the compound of formula X-III with the compound of formula X-IV in an inert solvent in the presence of a base and Pd or other metal catalyst to obtain a compound of formula XV;

[0187] (iii) reacting a compound of formula XV with a compound of formula X-VI in an inert solvent in the presence of a base with or without a Pd catalyst to obtain a compound of formula I;

[0188] LG1, LG2, LG 3、 LG4 and LG5 are leaving groups, each independently selected from: H, OH, halogen, OTf, OTs, OMs, -B(OH)2, -B(KBF3), -Sn( n Bu)3, wait;

[0189] The Pd catalyst is selected from: Pd(OAc)2, Pd(dba)2, Pd2(dba)3, XPhos PdG2, RuPhos PdG2, XantPhos-Pd-G2, cataCXium A-Pd-G2, XPhos PdG3, RuPhos PdG3, PdG3, SPhos PdG3, tBuXPhos-Pd-G3, XantPhos-Pd-G4, BrettPhos PG4, SPhos Pd G4, cataCXium A-Pd-G4, Rockphos PdG4, etc.;

[0190] R 1a 、R 1b 、R 1c 、R 2 、R 3 , Ring A, Ring B, X, Y, Z, and m are as defined above.

[0191] Pharmaceutical compositions and methods of administration

[0192] The pharmaceutical composition of the present invention is used to prevent and / or treat the following diseases: inflammation, cancer, cardiovascular disease, infection, immune disease, and metabolic disease.

[0193] The compounds of general formula (I) can be used in combination with other drugs known to treat or improve similar conditions. When administered in combination, the original drug's administration method and dosage can remain unchanged, while the compound of formula I is taken simultaneously or subsequently. When the compound of formula I is taken simultaneously with one or more other drugs, a pharmaceutical composition containing one or more known drugs and the compound of formula I can be preferably used. Drug combination also includes taking the compound of formula I and one or more other known drugs during overlapping time periods. When the compound of formula I is used in combination with one or more other drugs, the dosage of the compound of formula I or the known drug may be lower than the dosage of each drug taken alone.

[0194] The drugs or active ingredients that can be used in combination with the compounds of general formula (I) include but are not limited to: PD-1 inhibitors (such as nivolumab, pembrolizumab, pidilizumab, cemiplimab, JS-001, SHR-120, BGB-A317, IBI-308, GLS-010, GB-226, STW204, HX008, HLX10, BAT 1306, AK105, LZM 009 or biosimilars of the above drugs, etc.), PD-L1 inhibitors (such as durvalumab, atezolizumab, avelumab, CS1001, KN035, HLX20, SHR-1316, BGB-A333, JS003, CS1003, KL-A167, F 520, GR1405, MSB2311 or biosimilars of the above drugs, etc.), CD20 antibodies (such as rituximab, obinutuzumab, ofatumumab, veltuzumab, tositumomab, 131I-tositumomab, ibritumomab, 90Y-ibritumomab, 90In-ibritumomab, ibritumomab tiuxetan, etc.), CD47 antibodies (such as Hu5F9-G4, CC-90002, TTI-621, TTI-622, OSE-172, SRF-231, ALX-148, NI-1701, SHR-1603, IBI188, IMM01), ALK inhibitors (such as Ceritinib, Alectinib, Brigatinib, Lorlatinib, Ocatinib), PI3K inhibitors (such as Idelalisib, Duvelisib, Dactolisib, Taselisib), ib, Bimiralisib, Omipalisib, Buparlisib, etc.), BTK inhibitors (such as Ibrutinib, Tirabrutinib, Acalabrutinib, Zanubrutinib, Vecabrutinib, etc.), EGFR inhibitors (such as Afatinib, Gefitinib, Erlotinib, Lapatinib, Dacomitinib, Icotinib, Canertinib, Sapitinib, Naquotinib,Pyrotinib, Rociletinib, Osimertinib, etc.), VEGFR inhibitors (such as Sorafenib, Pazopanib, Regorafenib, Sitravatinib, Ningetinib, Cabozantinib, Sunitinib, Donafenib, etc.), HDAC inhibitors (such as Givinostat, Tucidinostat, Vorinostat, Fimepinostat, Droxinostat, Entinostat, Dacinostat, Quisinostat, Tacedinaline, etc.), CDK inhibitors (such as Palbociclib, Ribociclib, Abemaciclib, Milciclib, Trilaciclib, Lerociclib, etc.), MEK inhibitors (such as Selumetinib (AZD6244), Trametinib (GSK1120212), PD0325901, U0126, Pimasertib (AS-703026), PD184352 (CI-1040), etc.), mTOR inhibitors (such as Visusertib, etc.), SHP2 inhibitors (such as RMC-4630, JAB-3068, TNO155, etc.), or combinations thereof. The dosage forms of the pharmaceutical composition of the present invention include (but are not limited to): injection, tablet, capsule, aerosol, suppository, film, pill, external use ointment, controlled release or sustained release, or nanoformulation.

[0195] The pharmaceutical composition of the present invention comprises a safe and effective amount of a compound of the present invention or a pharmacologically acceptable salt thereof, and a pharmacologically acceptable excipient or carrier. "Safe and effective amount" means an amount of the compound sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, more preferably 10-1000 mg of the compound of the present invention per dose. Preferably, "one dose" is one capsule or tablet.

[0196] "Pharmaceutically acceptable carriers" refer to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0197] There is no particular limitation on the administration of the compound or pharmaceutical composition of the present invention. Representative administration routes include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.

[0198] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

[0199] Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifying agents, and the release of the active compound or compounds in such compositions can be delayed in a certain portion of the digestive tract. Examples of useful encapsulating components are polymeric substances and waxes. If desired, the active compound can also be microencapsulated with one or more of the above-mentioned excipients.

[0200] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, or mixtures thereof.

[0201] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0202] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances.

[0203] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0204] Dosage forms for topical administration of the compounds of this invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.

[0205] The treatment method of the present invention can be used alone or in combination with other treatment methods or therapeutic drugs.

[0206] When using a pharmaceutical composition, a safe and effective amount of the compound of the present invention is administered to a mammal (e.g., a human) in need of treatment, wherein the dosage is a pharmaceutically effective dosage. For a 60 kg human, the daily dosage is generally 1 to 2000 mg, preferably 50 to 1000 mg. Of course, the specific dosage will also take into account factors such as the route of administration and the patient's health condition, all of which are within the skill of a skilled physician.

[0207] The present invention also provides a method for preparing a pharmaceutical composition, comprising the steps of: mixing a pharmaceutically acceptable carrier with the compounds of general formula (IA) and formula (IB) of the present invention or their crystal forms, pharmaceutically acceptable salts, hydrates or solvates, thereby forming a pharmaceutical composition.

[0208] The present invention also provides a treatment method, which comprises the steps of administering to a subject in need of treatment the compound of formula (I) of the present invention, or a crystalline form, pharmaceutically acceptable salt, hydrate or solvate thereof, or administering the pharmaceutical composition of the present invention, for inhibiting KRAS mutation.

[0209] Compared with the prior art, the present invention has the following main advantages:

[0210] (1) The compound has a good inhibitory effect on KRAS mutation;

[0211] (2) The compound has better pharmacodynamics and pharmacokinetic properties and lower toxic side effects.

[0212] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, were generally performed under conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0213] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those familiar to those skilled in the art. Furthermore, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred embodiments and materials described herein are for illustrative purposes only.

[0214] The structures of the compounds of the present invention are confirmed by nuclear magnetic resonance (NMR) and liquid chromatography-mass spectrometry (LC-MS).

[0215] NMR was measured using a Bruker AVANCE-400 nuclear magnetic spectrometer. The measurement solvents included deuterated dimethyl sulfoxide (DMSO-d6), deuterated acetone (CD3COCD3), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD). Tetramethylsilane (TMS) was used as the internal standard, and chemical shifts were measured in parts per million (ppm).

[0216] Liquid chromatography-mass spectrometry (LC-MS) was performed using a Waters SQD2 mass spectrometer, and HPLC was performed using an Agilent 1100 high pressure chromatograph (Microsorb 5micron C18 100 x 3.0 mm column).

[0217] TLC silica gel plates used were Qingdao GF254 silica gel plates, with a diameter of 0.15-0.20 mm for TLC and 0.4-0.5 mm for preparative thin layer chromatography. Column chromatography generally used Qingdao 200-300 mesh silica gel as a carrier.

[0218] The starting materials in the examples of the present invention are all known and commercially available, or can be synthesized using or according to literature data reported in the art.

[0219] Unless otherwise specified, all reactions of the present invention are carried out under the protection of dry inert gas (such as nitrogen or argon) with continuous magnetic stirring, and the reaction temperatures are all degrees Celsius.

[0220] Example

[0221] Preparation of Intermediate 1-1 3-(1-aminoethyl)-N,N-bis(4-methoxybenzyl)pyridin-2-amine hydrochloride

[0222] Step 1: Preparation of 1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethan-1-one

[0223] To a solution of 1-(2-chloropyridin-3-yl)ethan-1-one (28.4 g, 182 mmol, 1.00 eq) in dioxane (300 mL) were added DIEA (117 g, 912 mmol, 159 mL, 5.00 eq) and 1-(4-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]methanamine (70.5 g, 273 mmol, 1.50 eq). The mixture was reacted at 110°C for 16 h, diluted with ice water (100 mL), and extracted with EtOAc (250 mL x 2). The combined organic phases were washed with saturated brine (250 mL x 2), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was isolated by silica gel column chromatography to obtain the desired product (24.3 g, 61.3 mmol, 33.6% yield).

[0224] 1 H NMR (400MHz, DMSO-d6) δ8.27(dd,J=4.69,1.81Hz,1H),7.84(dd,J=7.57,1.81Hz,1H ),7.04(d,J=8.63Hz,4H),6.71-6.93(m,5H),4.42(s,4H),3.71(s,6H)2.42(s,3H).

[0225] Step 2: Preparation of (R)-N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)vinyl)-2-methylpropane-2-sulfenamide

[0226] To a solution of 1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethan-1-one (24.3 g, 64.6 mmol, 1.00 eq) in THF (300 mL) were added Ti(OEt)4 (58.9 g, 258 mmol, 53.5 mL, 4.00 eq) and (R)-2-methylpropane-2-sulfenamide (11.7 g, 96.8 mmol, 1.50 eq). The mixture was reacted at 180°C for 16 h, diluted with ice water (100 mL), and extracted with EtOAc (250 mL x 2). The combined organic phases were washed with saturated brine (250 mL x 2), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was isolated by silica gel column chromatography to yield the desired product (11.0 g, 19.2 mmol, 30.8% yield).

[0227] 1 H NMR (400MHz, DMSO-d6) δ8.24(dd,J=4.58,1.53Hz,1H),7.63(dd,J=7.40,1.53Hz,1H),7.04(br d,J=8.44Hz,4H),6.94(dd,J=7.40,4.83Hz,1H),6.84(d,J=8.56Hz,4H),4.22 -4.48(m,4H),3.71(s,6H),2.51(dt,J=3.48,1.68Hz,3H),1.11-1.25(m,9H).

[0228] Step 3: Preparation of (R)-N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide

[0229] Under nitrogen, NaBH4 (670 mg, 17.7 mmol, 2.50 eq) was added to a solution of (R)-N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)vinyl)-2-methylpropane-2-sulfenamide (11.0 g, 21.5 mmol, 1.00 eq) in THF (100 mL) and H2O (16 mL) at 0°C. The mixture was reacted at 25°C for 5 h, then quenched with saturated aqueous ammonium chloride (50 mL) at 0°C and extracted with EtOAc (100 mL x 2). The combined organic phases were washed with saturated brine (60 mL x 2), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was isolated by silica gel column chromatography to yield the desired product (3.40 g, 7.06 mmol, 32.8% yield).

[0230] 1H NMR (400MHz, DMSO-d6) δ8.13-8.26(m,1H),7.75-7.96(m,1H),7.18(dd,J=11.62,8.68Hz,4H),7.04-7.12(m,1H),6.83(d,J =8.56Hz,4H),5.36-5.55(m,1H),4.90-5.14(m,1H),3.99-4.23(m,4H),3.70(s,6H),1.21-1.40(m,3H),0.99-1.13(m,9H).

[0231] Step 4: Preparation of 3-(1-aminoethyl)-N,N-bis(4-methoxybenzyl)pyridin-2-amine hydrochloride

[0232] To a solution of (R)-N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide (3.40 g, 7.06 mmol, 1.00 eq) in EtOAc (40 mL) was added HCl / EtOAc (4 M, 5.29 mL, 3.00 eq). The mixture was reacted at 0°C for 5 h and then concentrated under reduced pressure. The residue was isolated by silica gel column chromatography to obtain the desired product (2.20 g, 5.83 mmol, 82.6% yield).

[0233] LC-MS: m / z 378 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δ8.80(br d,J=2.32Hz,3H),8.20-8.44(m,2H),7.29(dd,J=7.64,4.95Hz,1H),7.15(d,J=8.68 Hz, 4H), 6.86 (d, J = 8.68Hz, 4H), 4.08-4.24 (m, 4H), 3.72 (s, 6H), 1.28-1.41 (m, 3H).

[0234] The following compounds were synthesized using the same synthetic method as intermediate 1-1 with different starting materials:

[0235] Intermediate 1-2 N,N-bis(4-methoxybenzyl)-3-(1-(methylamino)ethyl)pyridin-2-amine hydrochloride

[0236] LC-MS: m / z 392 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.17(dd,J=4.62,1.98Hz,1H),7.78(dd,J=7.59,1.87Hz,1H),7.17(d,J=8.58Hz,4H),7.05(dd,J=7.59 ,4.73Hz,1H),6.84(d,J=8.58Hz,4H),4.13-4.21(m,1H),4.05-4.12(m,4H),3.70(s,6H),1.96(s,3H),1.14(d,J=6.60Hz,3H).

[0237] Intermediate 1-2 was subjected to SFC chiral separation (chiral column: DAICEL CHIRALPAK IG (250 mm*50 mm, 10 um); mobile phase: CO2-EtOH (0.1% NH3H2O); B%: 30%-100%, 200 min) to give isomers 1-2A and 1-2B.

[0238] Intermediate 1-2A (S) -N,N-bis (4-methoxybenzyl) -3- (1- (methylamino) ethyl) pyridin-2-amine hydrochloride

[0239] RT: 3.568min. LC-MS: m / z 392(M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.17(dd,J=4.63,1.88Hz,1H),7.79(dd,J=7.63,1.75Hz,1H),7.17(d,J=8.63Hz,4H),7.0 5(dd,J=7.57,4.69Hz,1H),6.84(d,J=8.50Hz,4H),4.12(m,5H),3.70(s,6H),1.97(s,3H),1.14(d,J=6.38Hz,3H).

[0240] Intermediate 1-2B (R)-N,N-bis(4-methoxybenzyl)-3-(1-(methylamino)ethyl)pyridin-2-amine hydrochloride

[0241] RT: 3.870min. LC-MS: m / z 392(M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.21(dd,J=4.63,1.88Hz,1H),7.83(dd,J=7.63,1.75Hz,1H),7.16(d,J=8.63Hz,4H),7.09(dd,J=7.6 3,4.75Hz,1H),6.84(d,J=8.63Hz,4H),4.25(q,J=6.46Hz,1H),4.10(m,4H),3.70(s,6H),1.99(s,3H),1.17(d,J=6.50Hz,3H).

[0242] Intermediate 1-3 N,N-bis(4-methoxybenzyl)-5-(1-(methylamino)ethyl)pyrimidin-4-amine hydrochloride

[0243] LC-MS: m / z 393 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.51(d,J=6.11Hz,2H),7.14(d,J=8.68Hz,4H),6.89(d,J=8.68Hz,4H )4.41-4.63(m,4H),3.77(d,J=6.48Hz,1H),3.73(s,6H),2.00(s,3H),1.28(d,J=6.60Hz,3H).

[0244] Intermediate 1-4 3-(1-(ethylamino)ethyl)-N,N-bis(4-methoxybenzyl)pyridin-2-amine hydrochloride

[0245] LC-MS: m / z 406 (M+H) + .

[0246] Preparation of Intermediate 2-1 N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-chloro-8-fluoro-2-(2,2,2-trifluoroethoxy)pyridin[4,3-d]pyrimidin-4-amine

[0247] Step 1: Preparation of N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-amine

[0248] To a solution of 2,4,7-trichloro-8-fluoropyrido[4,3-d]pyrimidine (400 mg, 1.58 mmol, 1.00 eq) in DCM (10 mL) at -40°C were added 3-(1-aminoethyl)-N,N-bis(4-methoxybenzyl)pyridin-2-amine (668 mg, 1.62 mmol, 1.02 eq, hydrochloride) and DIEA (614 mg, 4.75 mmol, 827 μL, 3.00 eq). The mixture was reacted at 25°C for 2 h, then quenched with H₂O (50 mL) and extracted with EtOAc (100 mL x 2). The combined organic phases were washed with saturated brine (60 mL x 2), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was isolated by silica gel column chromatography to yield the desired product (0.750 g, 1.26 mmol, 79.7% yield).

[0249] 1 H NMR(400MHz,DMSO-d6)δ9.61(br d,J=6.97Hz,1H),9.34-9.47(m,1H),8.24(dd,J=4.77,1.71Hz,1H),7.82(dd,J=7.64,1.77Hz ,1H),7.25(d,J=8.68Hz,4H),7.08(dd,J=7.58,4.77Hz,1H),6.80(d,J=8.68Hz,4H),5.89(br t,J=6.79Hz,1H),4.21-4.42(m,4H),3.60-3.78(m,6H),1.45(d,J=6.85Hz,3H).

[0250] Step 2: Preparation of N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-chloro-8-fluoro-2-(2,2,2-trifluoroethoxy)pyridin[4,3-d]pyrimidin-4-amine

[0251] To a solution of N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-amine (0.750 g, 1.26 mmol, 1.00 eq) in CF3CH2OH (10 mL) was added DIEA (489 mg, 3.79 mmol, 660 μL, 3.00 eq). The reaction mixture was stirred at 70°C for 3 h and then concentrated under reduced pressure. The residue was added with H2O (30 mL) and extracted with EtOAc (25 mL x 2). The combined organic phases were washed with saturated brine (25 mL x 2), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was isolated by silica gel column chromatography to obtain the desired product (0.770 g, 1.17 mmol, 92.7% yield).

[0252] LC-MS: m / z 657 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ9.37-9.55(m,2H),8.24(dd,J=4.71,1.77Hz,1H),7.86-7.97(m,1H),7.25(d,J=8.56Hz,3H) ,7.08(dd,J=7.58,4.77Hz,1H),6.69-6.86(m,4H),4.89-5.10(m,2H),4.15-4.45(m,3H),3.62-3.76(m,6H),1.47(br d,J=6.72Hz,3H).

[0253] The following compounds were synthesized using the same synthetic method as intermediate 2-1 with different starting materials:

[0254] Preparation of Intermediate 2-2 N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-chloro-8-fluoro-N-methyl-2-(2,2,2-trifluoroethoxy)pyridin[4,3-d]pyrimidin-4-amine

[0255] LC-MS: m / z 671 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.82(s,1H),8.48–8.34(m,1H),8.00(d,J=7.6Hz,1H),7.24(dd,J=7.6,4.8Hz,1H),6.95(d,J=8.3Hz,4H),6.60( t,J=9.1Hz,4H),6.44(d,J=6.9Hz,1H),5.26–4.98(m,2H),4.15–3.99(m,4H),3.66(s,6H),3.10(d,J=10.0Hz,3H),1.51(d,J=6.8Hz,3H).

[0256] Preparation of Intermediate 2-2A (S)-N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-chloro-8-fluoro-N-methyl-2-(2,2,2-trifluoroethoxy)pyridin[4,3-d]pyrimidin-4-amine

[0257] LC-MS: m / z 671 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.81(s,1H),8.41(dd,J=4.7,1.6Hz,1H),8.00(dd,J=7.7,1.4Hz,1H),7.24(dd,J=7.7,4.7Hz,1H),6.95(d,J=8.4H z,4H),6.58(d,J=8.6Hz,4H),6.43(q,J=6.7Hz,1H),5.24–5.01(m,2H),4.13–3.98(m,4H),3.66(s,6H),3.08(s,3H),1.51(d,J=6.9Hz,3H).

[0258] Preparation of Intermediate 2-2B (R)-N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-chloro-8-fluoro-N-methyl-2-(2,2,2-trifluoroethoxy)pyridin[4,3-d]pyrimidin-4-amine

[0259] LC-MS: m / z 671 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.81(s,1H),8.41(dd,J=4.7,1.7Hz,1H),8.00(dd,J=7.7,1.5Hz,1H),7.24(dd,J=7.7,4.7Hz,1H),6.95(d,J=8. 5Hz,4H),6.58(d,J=8.6Hz,4H),6.43(d,J=6.9Hz,1H),5.26–4.95(m,2H),4.06(s,4H),3.66(s,6H),3.08(s,3H),1.51(d,J=6.9Hz,3H).

[0260] Preparation of Intermediate 2-3 N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-chloro-N-ethyl-8-fluoro-2-(2,2,2-trifluoroethoxy)pyridin[4,3-d]pyrimidin-4-amine

[0261] LC-MS: m / z 685 (M+H) + . 1H NMR(400MHz, DMSO-d6)δ8.79(s,1H),8.38-8.48(m,1H),8.01-8.13(m,1H),7.25(dd,J=7.63,4.75Hz,1H),6.75-6.93(m, 4H),6.47-6.65(m,5H),4.94-5.25(m,2H),3.83-4.15(m,5H),3.66(s,7H),3.52-3.61(m,2H),1.40-1.58(m,3H),0.51(br t,J=6.69Hz,3H).

[0262] Preparation of Intermediate 2-4 N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)propyl)-7-chloro-8-fluoro-N-methyl 2-(2,2,2-trifluoroethoxy)pyridin[4,3-d]pyrimidin-4-amine

[0263] LC-MS: m / z 685 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.72-8.91(m,1H),8.76(s,1H),8.43(dd,J=4.51,1.43Hz,1H),7.91-8.04(m,1H),7.99(br d,J=6.60Hz,1H),7.21-7.30(m,1H),7.17-7.35(m,1H),7.26(dd,J=7.59,4. 73Hz,1H),6.87-7.04(m,4H),6.49-6.65(m,4H),6.15-6.39(m,1H),5.06(br d,J=3.52Hz,2H),4.02(q,J=14.38Hz,4H),3.60-3.68(m,6H),3.03-3.19(m,3H),1.99(s,2H),1.81-1.83(m,1H),0.42-0.75(m,3H).

[0264] Preparation of Intermediate 2-5 N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-chloro-N-cyclopropyl-8-fluoro-2-(2,2,2-trifluoroethoxy)pyridin[4,3-d]pyrimidin-4-amine

[0265] LC-MS: m / z 697 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ9.04(s,1H),8.47-8.35(m,1H),8.10(br d,J=7.5Hz,1H),7.31-7.18(m,1H),6.96(br d,J=8.6Hz,4H),6.58(d,J=8.6Hz,4H),6.28-6.12(m,1H),5.20-5.02(m,2H),4.17-3.97(m,4H),3.65(s,6H),2.69(br s,1H),1.61(br d,J=7.3Hz,3H),1.27-1.16(m,1H),0.97-0.86(m,1H),0.78-0.68(m,1H),0.38-0.27(m,1H).

[0266] Preparation of Intermediate 2-6 N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-chloro-N-(2-fluoroethyl)-8-fluoro-2-(2,2,2-trifluoroethoxy)pyridin[4,3-d]pyrimidin-4-amine

[0267] LC-MS: m / z 703 (M+H) + . 1 H NMR(400MHz, DMSO-d6)δ8.93(s,1H)8.56(br dd,J=4.69,1.69Hz,1H)7.82(br d,J=6.25Hz,1H)7.22(dd,J=7.75,4.75Hz,1H)6.67(m,8H)6.26(br d,J=6.88Hz,1H)4.85(q,J=8.42Hz,2H)4.25(m,1H)3.92(m,5H)3.78(m,6H)3.62(m,2H)1.51(br d,J=7.00Hz,3H).

[0268] Preparation of Intermediate 2-7 N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-chloro-N-(2-fluoroethyl)-8-fluoro-2-(2,2,2-trifluoroethoxy)pyridin[4,3-d]pyrimidin-4-amine

[0269] LC-MS: m / z 715 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.7-8.8(m,1H),8.4-8.5(m,1H),7.71(dd,1H,J=1.4,7.7Hz ),7.08(dd,1H,J=4.8,7.6Hz),6.7-6.8(m,4H),6.5-6.5(m,4H),6.3-6.4(m,1H),4. 7-4.9(m,2H),4.03(d,2H,J=13.3Hz),3.83(d,2H,J=13.4Hz),3.6-3.7(m,6H),3.4- 3.5(m,2H),3.0-3.1(m,3H),2.7-2.9(m,1H),2.3-2.4(m,1H),1.36(d,3H,J=6.8Hz).

[0270] Preparation of Intermediate 3-1 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-2,6-dichloro-8-fluoroquinazolin-4(3H)-one

[0271] Step 1: Preparation of methyl 2-amino-3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate

[0272] Under nitrogen, to a solution of methyl 2-amino-4-bromo-3-fluorobenzoate (198 g, 798 mmol, 1.00 eq) in dioxane (2000 mL) was added pinacol borane (304 g, 1.20 mol, 1.50 eq), KOAc (235 g, 2.39 mol, 3.00 eq), and Pd(dppf)Cl2 (40.8 g, 55.8 mmol, 0.07 eq) at room temperature. The mixture was reacted at 90°C under nitrogen for 16 h, then cooled to room temperature and filtered. The filter cake was washed with EtOAc (2 L). The combined filtrates were diluted with H2O (2 L) and extracted with EtOAc (2 x 1.5 L). The combined organic phases were washed with saturated brine (2 L), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography to obtain the desired product (250 g, 762 mmol, 95.5% yield).

[0273] LC-MS: m / z 296 (M+H) + .

[0274] Step 2: Preparation of methyl 2-amino-4-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-3-fluorobenzoate

[0275] Under nitrogen, 6-chloro-N,N-bis(4-methoxybenzyl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine (47.3 g, 105 mmol, 1.00 eq), Pd-118 (6.85 g, 10.5 mmol, 0.10 eq), and KF (18.3 g, 315 mmol, 3.00 eq) were added to a solution of methyl 2-amino-3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (31.0 g, 105 mmol, 1.00 eq) in dioxane (400 mL) and water (40 mL) at room temperature. The mixture was reacted at 100°C under nitrogen for 1 h, then cooled to room temperature and filtered. The filtrate was diluted with H2O (500 mL) and extracted with EtOAc (3 x 500 mL). The combined organic phases were washed with saturated brine (300 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography to obtain the desired product (44.0 g, 75.4 mmol, 71.78% yield).

[0276] LC-MS: m / z 584 (M+H) + .

[0277] Step 3: Preparation of methyl 2-amino-4-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-5-chloro-3-fluorobenzoate

[0278] To a solution of methyl 2-amino-4-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-3-fluorobenzoate (44.0 g, 75.4 mmol, 1.00 eq) in NMP (500 mL) was added NCS (12.5 g, 94.2 mmol, 1.25 eq). The mixture was reacted at 70°C for 3 h, then cooled to 0°C, diluted with H2O (500 mL), and extracted with EtOAc (3 x 200 mL). The combined organic phases were washed with saturated brine (300 mL), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography to obtain the desired product (17.5 g, 28.3 mmol, 37.5% yield).

[0279] LC-MS: m / z 618 (M+H) + .

[0280] Step 4: Preparation of 2-amino-4-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-5-chloro-3-fluorobenzoic acid

[0281] To a solution of methyl 2-amino-4-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-5-chloro-3-fluorobenzoate (17.5 g, 28.3 mmol, 1.00 eq) in MeOH (180 mL), THF (60 mL), and H₂O (60 mL) was added NaOH (16.9 g, 424 mmol, 15.0 eq). The mixture was reacted at 50°C for 3 h, then cooled to room temperature and concentrated under reduced pressure. The residue was diluted with H₂O (300 mL) and extracted with EtOAc (3 x 200 mL). The combined organic phases were washed with saturated brine (200 mL), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was used directly in the next reaction without purification (20.0 g, crude product).

[0282] LC-MS: m / z 604 (M+H) + .

[0283] Step 5: Preparation of 2-amino-4-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-5-chloro-3-fluorobenzamide

[0284] To a solution of 2-amino-4-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-5-chloro-3-fluorobenzoic acid (9.00 ± 14.9 mmol, 1.00 eq) in DMF (80 mL) at 0°C were added NH4Cl (2.39 g, 44.7 mmol, 3.00 eq), DIEA (5.78 g, 44.7 mmol, 7.79 mL, 3.00 eq), and HATU (11.3 g, 29.8 mmol, 2.00 eq). The mixture was reacted at 25°C for 2 h, then cooled to room temperature and concentrated under reduced pressure. The residue was diluted with H2O (300 mL) at 0°C and extracted with EtOAc (3 x 200 mL). The combined organic phases were washed with saturated brine (200 mL), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography to obtain the desired product (9.00 g, 11.0 mmol, 74.1% yield).

[0285] LC-MS: m / z 603 (M+H) + .

[0286] Step 6: Preparation of 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-2,6-dichloro-8-fluoroquinazolin-4(3H)-one

[0287] To a solution of 2-amino-4-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-5-chloro-3-fluorobenzamide (9.00 g, 14.9 mmol, 1.00 eq) in dioxane (80 mL) was added CSCl₂ (3.43 g, 29.8 mmol, 2.29 mL, 2.00 eq). The mixture was reacted at 100°C for 1 h, then cooled to room temperature and concentrated under reduced pressure. The residue was diluted with H₂O (300 mL) and the pH was adjusted to 7 with NaHCO₃. The mixture was extracted with EtOAc (3 x 200 mL). The combined organic phases were washed with saturated brine (200 mL), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography to obtain the desired product (4.60 g, 5.68 mmol, 38.0% yield).

[0288] LC-MS: m / z 647 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ13.34-13.92(m,1H),8.00(d,J=0.98Hz,1H),7.16(d,J=8.56Hz,4H),6.88(br d,J=8.31Hz,4H),6.84(s,1H),4.54-4.82(m,4H),3.73(s,6H),2.40(br d,J=1.10Hz,3H).

[0289] Intermediate 3-1 was subjected to SFC chiral separation (chiral column: DAICEL CHIRALPAK AD (250 mm*50 mm, 10 um); mobile phase: [CO2-EtOH (0.1% NH3H2O)]; B%: 40%, isocratic elution mode) to obtain intermediate 3-1A and intermediate 3-1B.

[0290] Intermediate 3-1A (S)-7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-2,6-dichloro-8-fluoroquinazolin-4(3H)-one

[0291] RT: 0.891min. LC-MS: m / z 647(M+H) + . 1H NMR (400MHz, DMSO-d6) δ7.99 (s, 1H), 7.16 (d, J = 8.56Hz, 4H), 6.88 (br d, J = 8.31Hz, 4H), 6.84 (s, 1H), 4.58-4.82 (m, 4H), 3.73 (s, 6H), 2.40 (br d,J=1.10Hz,3H).

[0292] Intermediate 3-1B (R)-7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-2,6-dichloro-8-fluoroquinazolin-4(3H)-one

[0293] RT: 1.168min. LC-MS: m / z 647(M+H) + . 1 H NMR (400MHz, DMSO-d6) δ7.99 (s, 1H), 7.16 (d, J = 8.56Hz, 4H), 6.88 (br d, J = 8.31Hz, 4H), 6.84 (s, 1H), 4.58-4.82 (m, 4H), 3.73 (s, 6H), 2.40 (br d,J=1.10Hz,3H).

[0294] The following compounds were synthesized using the same synthetic method as intermediate 3-1 with different starting materials:

[0295] Intermediate 3-2 2,6-dichloro-8-fluoro-7-(7-fluoro-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)quinazolin-4(3H)-one

[0296] LC-MS: m / z 557 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ14.08-13.58(m,1H),8.31-8.17(m,2H),7.94(s,1H),7.77-7.59(m,2H),7.51(br d,J=7.0Hz,1H),0.98-0.82(m,18H),0.71-0.61(m,3H).

[0297] Intermediate 3-tert-Butyl (3-cyano-4-(2,6-dichloro-8-fluoro-4-oxo-3,4-dihydroquinazolin-7-yl)-7-fluorobenzo[b]thiophen-2-yl)carboxylate

[0298] LC-MS: m / z 523 (M+H) + .1 H NMR (400MHz, DMSO-d6) δ11.86 (br s, 1H), 8.05 (d, 1H, J = 1.1Hz), 7.4-7.5 (m, 2H), 1.52 (s, 9H).

[0299] Intermediate 3-4 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-2-chloro-6,8-difluoroquinazolin-4(3H)-one

[0300] LC-MS: m / z 631 (M+H) + .

[0301] Intermediate 3-4 was subjected to SFC chiral separation (chiral column: DAICEL CHIRALPAK AD (250 mm * 50 mm, 10 μm); mobile phase: [CO2-EtOH (0.1% NH3H2O)]; B%: 40%, isocratic elution mode) to obtain intermediate 3-4A and intermediate 3-4B.

[0302] Intermediate 3-4A (R) -7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-2-chloro-6,8-difluoroquinazolin-4(3H)-one

[0303] RT: 1.507min. LC-MS: m / z 631(M+H) + . 1 H NMR(400MHz, CDCl3)δ10.88(br d,J=11.00Hz,1H),7.81(dd,J=8.03,1.43Hz,1H),7.14(d,J=8.58Hz,4H),6.86(d,J=8 .58Hz, 4H), 6.42 (s, 1H), 4.66 (q, J = 16.07Hz, 4H), 3.81 (s, 6H), 2.42 (d, J = 1.76Hz, 3H).

[0304] Intermediate 3-4B (S) -7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-2-chloro-6,8-difluoroquinazolin-4(3H)-one

[0305] RT: 1.784min. LC-MS: m / z 631(M+H) + . 1H NMR (400MHz, CDCl3) δ10.22-10.79(m,1H)7.81(d,J=7.92Hz,1H)7.14(d,J=8.36Hz,4H) 6.86(d,J=8.36Hz,4H)6.42(s,1H)4.53-4.82(m,4H)3.81(s,6H)2.41(d,J=1.54Hz,3H).

[0306] Preparation of Intermediate 4-1 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-2,6-dichloro-8-fluoro-N-methylquinazolin-4-amine

[0307] To a solution of 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-2,6-dichloro-8-fluoroquinazolin-4(3H)-one (120 mg, 185 μmol, 1.00 eq) in DCM (3 mL) were added N,N-bis(4-methoxybenzyl)-3-(1-(methylamino)ethyl)pyridin-2-amine (72.5 mg, 185 μmol, 1.00 eq), DIEA (239 mg, 1.85 mmol, 322 μL, 10.0 eq), and Bop-Cl (188 mg, 741 μmol, 4.00 eq). The mixture was reacted at 25°C for 16 h, then quenched by the addition of water (30 mL) and extracted with DCM (30 mL*3). The combined organic phases were washed with saturated brine (100 mL), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the desired product (105 mg, 47.0% yield).

[0308] LC-MS: m / z 1020 (M+H) + . 1 H NMR(400MHz, DMSO-d6)δ8.29-8.39(m,1H)7.97-8.11(m,1H)7.84-7.95(m,1H)7.19(s,1H)7.13-7.18(m,4H)6.92(br s,4H)6.85-6.89(m,4H)6.60-6.67(m,4H)6.23-6.44(m,1H)4.52-4.86(m,4H)3 .99-4.12(m,4H)3.71-3.73(m,6H)3.58-3.67(m,6H)3.10-3.19(m,3H)2.39(br s,3H)1.43-1.57(m,1H)1.43-1.56(m,3H).

[0309] The following compounds were synthesized using the same synthetic method as intermediate 4-1 with different starting materials:

[0310] Intermediate 4-2 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-2,6-dichloro-8-fluoro-N-methylquinazolin-4-amine

[0311] LC-MS: m / z 1020 (M+H) + .

[0312] Intermediate 4-2A (S)-7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-2,6-dichloro-8-fluoro-N-methylquinazolin-4-amine

[0313] LC-MS: m / z 1020 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δ8.36-8.34(m,1H),8.03(s,1H),7.92-7.90(m,1H) ),7.20-7.15(m,5H),7.00-6.98(m,4H),6.89-6.83(m,5H),6.64-6.62(m ,4H),6.36-6.31(m,1H),4.81(s,2H),4.61(d,J=16Hz,2H),4.10(s,4H), 3.73(s,6H),3.61(s,6H),3.17(s,3H),2.40(s,3H),1.54(d,J=8Hz,3H).

[0314] Intermediate 4-2B (R)-7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-2,6-dichloro-8-fluoro-N-methylquinazolin-4-amine

[0315] LC-MS: m / z 1020 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.36 (dd, J=4.7, 1.8Hz,

[0316] 1H),8.05(d,J=1.6Hz,1H),7.94(dd,J=7.7,1.8Hz,1H),7.21–7.12(m,5H) ,6.95(d,J=8.2Hz,4H),6.89–6.81(m,5H),6.68–6.62(m,4H),6.42–6.34( m,1H),4.88–4.66(m,2H),4.63–4.50(m,2H),4.12–4.03(m,4H),3.71(s,6 H), 3.66 (s, 6H), 3.12 (s, 3H), 2.40 (d, J = 2.0Hz, 3H), 1.47 (d, J = 6.9Hz, 3H).

[0317] Intermediate 4-3 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-2,6-dichloro-N-ethyl-8-fluoroquinazolin-4-amine

[0318] LC-MS: m / z 1034 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.41 (ddd, J=9.74, 4.68, 1.65Hz, 1H) 8.00-8.08 (m, 1H) 7.93 (br s,1H)7.20-7.26(m,1H)7.13-7.19(m,4H)6.74-6.91(m,9H)6.58-6.67(m,4H)6.39-6.51(m,1H)4.45-4.92(m ,4H)3.84-4.07(m,4H)3.77-3.84(m,1H)3.67-3.77(m,6H)3.65-3.67(m,2H)3.63(d,J=15.19Hz,6H)2.41(br d,J=2.20Hz,3H)1.44-1.56(m,3H)0.49-0.66(m,3H)

[0319] Intermediate 4-tert-Butyl 4-(4-(4-(((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)(methyl)amino)-2,6-dichloro-8-fluoroquinazolin-7-yl)-3-cyano-7-fluorobenzo[b]thiophen-2-yl)carboxylate

[0320] LC-MS: m / z 896 (M+H) + .

[0321] Intermediate 4-5(tert-Butyl 4-(4-(((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)(ethyl)amino)-2,6-dichloro-8-fluoroquinazolin-7-yl)-3-cyano-7-fluorobenzo[b]thiophen-2-yl)carboxylate

[0322] LC-MS: m / z 910 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ11.89(br s,1H),8.4-8.5(m,1H),8.05(br d,1H,J=6.9Hz),7.92(s,1H),7.4-7.5(m,2H),6.96(br d,4H,J=8.4Hz),6.71(d,4H,J=8.6Hz),6.5-6.6(m,1H),6.52(br d,1H,J=6.6Hz),4.13(br d,2H,J=13.5Hz),3.9-3.9(m,2H),3.7-3.7(m,6H),3.5-3.6(m,3H),1.36(s, 9H), 1.20 (d, 1H, J = 6.8Hz), 1.2-1.2 (m, 3H), 0.8-0.9 (m, 1H), 0.8-0.9 (m, 3H).

[0323] Intermediate 4-6A (R)-7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-2-chloro-6,8-difluoro-N-methylquinazolin-4-amine

[0324] LC-MS: m / z 524 (M+H) + .

[0325] Intermediate 4-6B (S)-7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-2-chloro-6,8-difluoro-N-methylquinazolin-4-amine

[0326] LC-MS: m / z 524 (M+H) + .

[0327] Intermediate 5-1 Preparation of 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-2,4,6-trichloro-8-fluoroquinoline-3-carbonitrile

[0328] Step 1: Preparation of methyl 4-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-5-chloro-2-(2-cyanoacetyl)-3-fluorobenzoate

[0329] To a solution of methyl 2-amino-4-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-5-chloro-3-fluorobenzoate (5.80 g, 9.38 mmol, 1.00 eq) and 2-cyanoacetic acid (1.60 g, 18.7 mmol, 2.00 eq) in DCM (50 mL) was added methyl 2-amino-4-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-5-chloro-3-fluorobenzoate (3.60 g, 18.7 mmol, 2.00 eq). The resulting mixture was reacted at 25°C for 16 h, then quenched by the addition of H2O (200 mL) at 0°C and extracted with DCM (100 mL x 3). The combined organic phases were washed with saturated brine (300 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was isolated by silica gel column chromatography to yield the desired product (3.77 g, 5.50 mmol, 58.6% yield).

[0330] LC-MS: m / z 685 (M+H) + .

[0331] Step 2: Preparation of 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2,4-dihydroquinoline-3-carbonitrile

[0332] To a solution of methyl 4-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-5-chloro-2-(2-cyanoacetyl)-3-fluorobenzoate (3.77 g, 5.50 mmol, 1.00 eq) in MeOH (40 mL) was added MeONa / MeOH (1.49 g, 8.25 mmol, 30% wt, 1.50 eq). The reaction mixture was allowed to react at 0°C for 1 h, followed by dropwise addition of HCl (10% wt) to adjust the pH to 2-3. The resulting mixture was filtered, and the filter cake was collected and dried under vacuum to afford the desired product (3.20 g, 4.90 mmol, 89.0% yield). This product was used directly in the next step without further purification.

[0333] LC-MS: m / z 653 (M+H) + .

[0334] Step 3: Preparation of 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-2,4,6-trichloro-8-fluoroquinoline-3-carbonitrile

[0335] To a mixture of 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2,4-dihydroquinoline-3-carbonitrile (2.00 g, 3.06 mmol, 1.00 eq) and POCl (1.41 g, 9.19 mmol, 856 μL, 3.00 eq) in a volume of 1% (20 mL) was added DIEA (1.98 g, 15.3 mmol, 2.67 mL, 5.00 eq) at 0°C. The resulting mixture was reacted at 110°C for 16 h and then concentrated under reduced pressure. The residue was poured into ice water and extracted with DCM (100 mL x 3). The combined organic phases were washed with saturated brine (300 mL), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography to obtain the target product (0.52 g, 753 μmol, 24.6% yield).

[0336] LC-MS: m / z 689 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.18 (s, 1H), 7.15 (br d, J = 8.4Hz, 4H), 6.87 (br d,J=8.4Hz,4H),6.48(s,1H),4.81-4.68(m,2H),4.66-4.55(m,2H),3.82(s,6H),2.46(br s,3H).

[0337] Example A1 Preparation of 4-(4-((1-(2-aminopyridin-3-yl)ethyl)amino)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoropyridin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0338] Step 1: Preparation of N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-(2,2,2-trifluoroethoxy)pyridin[4,3-d]pyrimidin-4-amine

[0339] Under nitrogen protection, N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-chloro-8-fluoro-2-(2,2,2-trifluoroethoxy)pyridin[4,3-d]pyrimidin-4-amine (630 mg, 958 μmol, 1.00 eq), 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-1-naphthyl]ethynyl-triisopropylsilane (589 mg, 1.15 mmol, 1.20 eq), Cs2CO3 (937 mg, 2.88 mmol, 3.00 eq) and CataxciAmPd A mixture of G2 (64.1 mg, 95.9 μmol, 0.100 eq) in dioxane (10 mL) and H₂O (2 mL) was reacted at 100°C for 3 h, then diluted with water (30 mL) and extracted with EtOAc (25 mL x 2). The combined organic phases were washed with saturated brine (25 mL x 2), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was isolated by silica gel column chromatography to yield the desired product (0.66 g, 655 μmol, 68.3% yield).

[0340] LC-MS: m / z 1007 (M+H) + . 1 H NMR(400MHz, CDCl3)δ8.63-9.04(m,1H)8.29-8.56(m,1H)7.76-7.90(m,1H)7.64-7. 73(m,1H)7.47-7.59(m,1H)7.29-7.41(m,3H)6.98-7.20(m,4H)6.84(d,J=8.56Hz,1H )6.67(d,J=8.68Hz,3H)5.89-6.07(m,1H)5.23-5.44(m,2H)4.26-4.49(m,4H)3.65-3 .85(m,6H)1.41-1.56(m,3H)0.83-0.99(m,15H)0.71-0.82(m,5H)0.45-0.65(m,4H).

[0341] Step 2: Preparation of N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyridin[4,3-d]pyrimidin-4-amine

[0342] To a solution of ((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methanol (30 mg, 0.149 mmol) in toluene (1 mL) was added sodium hydride (12 mg, 60% wt, 0.297 mmol). The mixture was stirred at room temperature for 2 minutes, followed by the addition of N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-(2,2,2-trifluoroethoxy)pyridin[4,3-d]pyrimidin-4-amine (100 mg, 0.099 mmol). The resulting mixture was reacted at 110°C for 2 hours, then diluted with water and extracted with EtOAc. The combined organic phases were washed with saturated brine (25 mL x 2), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography to obtain the desired product (35 mg, 21.2% yield).

[0343] LC-MS: m / z 1110 (M+H) + .

[0344] Step 3: Preparation of 4-(4-((1-(2-aminopyridin-3-yl)ethyl)amino)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoropyridin-7-yl)-6-fluoro-5-((triisopropylsilyl)ethynyl)naphthalen-2-ol

[0345] A solution of N-(1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-amine (35 mg, 0.03 mmol) in trifluoroacetic acid (1 mL) was stirred at room temperature for 16 h and then concentrated under reduced pressure (25 mg crude product). It was used directly in the next reaction without further purification.

[0346] LC-MS: m / z 826 (M+H) + .

[0347] Step 4: Preparation of 4-(4-((1-(2-aminopyridin-3-yl)ethyl)amino)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoropyridin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0348] 4-(4-((1-(2-aminopyridin-3-yl)ethyl)amino)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoropyridin[4,3-d]pyrimidin-7-yl)-6-fluoro-5-((triisopropylsilyl)ethynyl)naphthalen-2-ol (25 mg) obtained in the previous step was dissolved in DMF (1 mL) and cesium fluoride (167 mg, 1.1 mmol) was added. The mixture was stirred at room temperature for 16 h and then separated by preparative liquid phase to obtain the desired product (3.2 mg, 16% yield over two steps).

[0349] LC-MS: m / z 670 (M+H) + .

[0350] The following examples were synthesized using different starting materials according to the method of Example A1:

[0351] Example A2 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylpyridin-4-amine

[0352] LC-MS: m / z 693 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ9.21(s,1H),7.97(d,J=3.7Hz,1H),7.64(d,J=7.3Hz,1H),6.88(s,1H),6.66( dd,J=7.3,5.0Hz,1H),6.46(s,1H),6.34(s,2H),6.16(s,1H),5.81(s,2H),4.23(t,J=11.9Hz,2H),3.2 4(s,3H),3.14–3.06(m,1H),3.01(s,1H),2.72(d,J=11.8Hz,1H),2.54(s,1H),2.06(dd,J=20.5,16.4H z,2H),1.90(d,J=13.2Hz,1H),1.78(d,J=18.4Hz,2H),1.67–1.53(m,5H),1.48(dd,J=8.6,3.8Hz,1H).

[0353] Example A2 was subjected to SFC chiral separation (equipment: SFC-150 (Waters); chiral column: OD 25*250 mm, 10 μm (Daicel); column temperature: 35° C.; mobile phase: CO 2 / MEOH [0.2% NH 3 (7 M in MeOH) = 50 / 50] to give Examples A2-A and A2-B:

[0354] Example A2-A: 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(1-((R)-2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylpyridin[4,3-d]pyrimidin-4-amine

[0355] RT: 1.782min. LCMS:m / z 693(M+H) + . 1H NMR (400MHz, DMSO-d6) δ9.22 (s, 1H), 7.99 (d, J = 8Hz, 1H), 7.67 (d, J = 8Hz, 1H), 6.90 (s, 1H), 6.69-6. 66(m,1H),6.47(s,1H),6.33(s,2H),6.20-6.15(m,1H),5.81(s,2H),4.31-4.20(m,2H),3.25(s,3H ),3.14-3.10(m,1H),3.05-3.01(m,1H),2.76(d,J=12Hz,1H),2.59-2.55(m,1H),2.12-2.07(m,1H) ,2.05-1.99(m,1H),1.94(d,J=16Hz,1H),1.84-1.75(m,2H),1.67-1.54(m,5H),1.52-1.45(m,1H).

[0356] Example A2-B: 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(1-((S)-2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylpyridin[4,3-d]pyrimidin-4-amine

[0357] RT: 2.303min. LCMS:m / z 693(M+H) + . 1 H NMR(400MHz,DMSO-d6)δ9.22(s,1H),7.99(d,J=8Hz,1H),7.67(d,J=8Hz,1H),6.90(s,1H),6.69- 6.66(m,1H),6.47(s,1H),6.33(s,2H),6.20-6.15(m,1H),5.81(s,2H),4.25(s,2H),3.25(s,3H), 3.14-3.10(m,1H),3.05-3.01(m,1H),2.76(d,J=12Hz,1H),2.59-2.55(m,1H),2.12-2.07(m,1H), 2.05-1.99(m,1H),1.94(d,J=16Hz,1H),1.84-1.75(m,2H),1.67-1.54(m,5H),1.52-1.45(m,1H).

[0358] Example A3 4-(4-((1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoropyridin[4,3-d]pyrimidin-7-yl)-5-ethyl-6-fluoronaphthalen-2-ol

[0359] LCMS: m / z 688 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ9.96(s,1H),9.28(d,J=11.6Hz,1H),7.98(d,J=4.9Hz,1H),7.77(dd,J=9.1,6.0Hz,1H),7.66(d, J=7.4Hz,1H),7.35(dd,J=13.2,5.9Hz,2H),7.01(s,1H),6.19(s,1H),5.93(d,J=13.2Hz,1H),5.78(d,J=8.3Hz,1H),4.28 (d,J=11.6Hz,2H),3.28(d,J=2.0Hz,3H),3.12(s,1H),3.03(s,1H),2.75(s,1H),2.36(d,J=15.7Hz,1H),2.11(d,J=12.9H z, 2H), 2.02 (s, 1H), 1.92 (d, J = 13.0Hz, 1H), 1.79 (d, J = 24.4Hz, 2H), 1.61 (dd, J = 36.9, 33.8Hz, 6H), 0.75 (t, J = 6.8Hz, 3H).

[0360] Example A4 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(1-(2-aminopyridin-3-yl)ethyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)-N-methylpyridin[4,3-d]pyrimidin-4-amine

[0361] LCMS: m / z 649 (M+H) + . 1H NMR(400MHz,DMSO-d6)δ9.22(s,1H),7.99(d,J=8Hz,1H),7.66(d,J=8Hz,1H),6 .89(m,1H),6.69-6.66(m,1H),6.47(s,1H),6.32(m,2H),6.19-6.14(m,1H),5.8 0(s,2H),5.38-5.25(m,1H),4.22-4.10(m,2H),3.26(s,3H),3.14(m,2H),3.06 (m,1H),2.87(m,1H),2.18-2.03(m,3H),1.89-1.81(m,3H),1.63(d,J=8Hz,3H).

[0362] Example A5 4-(4-((1-(2-2-aminopyridin-3-yl)ethyl)(methyl)amino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)pyridin[4,3-d]pyrimidin-7-yl)-5-ethyl-6-fluoronaphthalen-2-ol

[0363] LCMS: m / z 644 (M+H) + .

[0364] Example A6 4-(4-((1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)pyridin[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0365] LCMS: m / z 640 (M+H) + .

[0366] Example A7 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(1-(2-aminopyridin-3-yl)ethyl)-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoro-N-methylpyrido[4,3-d]pyrimidin-4-amine

[0367] LCMS: m / z 619 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ9.22 (s, 1H), 7.98 (d, J = 4Hz, 1H), 7.65 (d, J = 8Hz, 1 H),6.88(s,1H),6.68-6.65(m,1H),6.46(s,1H),6.32(s,2H),6.18-6.13(m ,1H),5.79(s,2H),4.39(s,1H),4.21(s,1H),3.52-3.41(m,1H),3.25(s,3 H),3.16(s,1H),1.62(d,J=8Hz,3H),1.24-1.17(m,6H),0.72-0.55(m,4H).

[0368] Example A8 2-((1-(((1R,4R)-2-oxo-5-azabicyclo[2.2.1]heptane-5-yl)methyl)cyclopropyl)methoxy)-7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(1-(2-aminopyridin-3-yl)ethyl)-8-fluoro-N-methylpyrido[4,3-d]pyrimidin-4-amine

[0369] LCMS: m / z 673 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ9.19 (s, 1H), 7.97 (d, J = 8Hz, 1H), 7.64 (d, J = 12Hz, 1H), 6.88 (s, 1H),6.67-6.64(m,1H),6.46(m,1H),6.31(s,2H),6.12(s,1H),5.77-5.75(m,2H),4.43 -4.18(m,3H),3.79-3.77(m,1H),3.48-3.46(m,2H),3.24(s,3H),2.86-2.84(m,1H),2. 69-2.56(m,2H),2.41-2.38(m,1H),1.67-1.51(m,5H),0.588(s,2H),0.49-0.40(m,2H).

[0370] Example A9 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(1-(2-aminopyridin-3-yl)ethyl)-8-fluoro-N-methyl-2-((1-methylpiperidin-4-yl)oxy)pyridin[4,3-d]pyrimidin-4-amine trifluoroacetate

[0371] LCMS: m / z 605 (M+H) + . 1H NMR(400MHz,DMSO-d6)δ9.83-9.73(m,1H),9.28(s,1H),8.05-7.97(m,2H),7.69-7.55(m,2H),6.90(s,2H),6.46-6.38(m,3H),6.04-6 .01(m,1H),5.39(s,1H),5.20(s,1H),3.38-3.18(m,4H),2.87-2.82(m,3H),2.34-2.03(m,4H),1.91-1.82(m,1H),1.68-1.66(m,3H).

[0372] Example A10 Example A11 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoropyridin[4,3-d]pyrimidin-4-amine

[0373] LCMS: m / z 679 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ9.44(s,1H), 9.13(m,1H), 7.85(m,1H), 7.51(m,1H), 6.88(d,J=2.20Hz,1H), 6.55(m,1H), 6.46(d,J=2.2 4Hz,1H), 6.33(s,2H), 5.93(s,2H), 5.51(m,1H), 4.56(m,3H), 4.18(s,2H), 3.04(m,2H), 2.67(m,1H), 1.91(m,5H), 1.59(m,4H).

[0374] Example A11 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)pyridin[4,3-d]pyrimidin-4-amine

[0375] LCMS: m / z 635 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ9.43 (s, 1H), 9.19 (d, J = 6.84Hz, 1H), 7.85 (d, d, J = 1.80H) z, J=4.92Hz, 1H), 7.52 (m, 1H), 6.56 (d, d, J=4.88Hz, J=7.40Hz, 1H), 6.45 (s, 1H), 6.33(s,1H), 5.97(s,2H), 5.47(m,1H), 5.40(br,0.5H), 5.27(br,0.5H), 4.20(m, 3H), 3.48(m,1H), 3.42(m,1H), 2.94(m,1H), 2.03(m,1H), 1.56(d,J=6.84Hz,3H).

[0376] Example A12 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-pyridin[4,3-d]pyrimidin-4-amine

[0377] LCMS: m / z 679 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ 9.45 (s, 1H), 9.19 (m, 1H), 7.85 (m, 1H), 7.51 (m, 1H), 6.88 (d, J = 2.20Hz, 1H), 6.55 (m, 1H), 6.46 (m, 1H), 6.34(s,2H), 5.94(s,2H), 5.47(m,1H), 4.55(m,3H), 4.23(s,2H), 3.05(m,2H), 2.78(m,1H), 1.91(m,5H), 1.59(m,4H).

[0378] Example A13 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)pyridin[4,3-d]pyrimidin-4-amine

[0379] LCMS: m / z 635 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ 9.42 (s, 1H), 9.12 (d, J = 7.20Hz, 1H), 7.85 (m, 1H), 7.50 (m, 1H), 6.88 (m, 1H), 6.45 (m, 1H), 6.32 (s, 1H), 5.93 (s, 2H), 5.46 (m,1H), 5.29(br,0.5H), 5.16(br,0.5H), 4.56(m,2H), 4.07(s,2H), 3.0 6(m,2H), 2.80(m,1H), 1.95(m,2H), 1.77(m,3H), 1.56(d,J=6.84Hz,3H).

[0380] Example A14 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-8-fluoro-N-methyl-2-((S)-1-methylpyrrolidin-2-yl)methoxy)pyridin[4,3-d]pyrimidin-4-amine

[0381] LCMS: m / z 605 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ9.21 (s, 1H), 7.99 (d, J = 4Hz, 1H), 7.67 (d, J = 8Hz, 1H), 6.9 0(s,1H),6.70-6.67(m,1H),6.48(s,1H),6.33(s,2H),6.19-6.15(m,1H),5.76(d, J=12Hz,2H),4.43(s,1H),4.28(s,1H),3.24(s,3H),2.99(s,1H),2.68(s,1H),2. 40(s,3H),2.24(s,1H),2.01-1.96(m,1H),1.74-1.69(m,3H),1.63(d,J=4Hz,3H).

[0382] Example A15 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-8-fluoro-N-methyl-2-((S)-1-methylpyrrolidin-2-yl)ethoxy)pyridin[4,3-d]pyrimidin-4-amine

[0383] LCMS: m / z 619 (M+H) + . 1H NMR(400MHz,DMSO-d6)δ9.20(d,J=16Hz,1H),7.96(t,J=4Hz 1H),7.62(t,J=8Hz,1H),6.88(s,1H),6.68-6.63(m,1H),6.46(s,1H),6.31 (s,2H),6.16-6.05(m,1H),5.72(d,J=20Hz,2H),5.28(s,1H),3.25(d,J=16H z,3H),2.95(s,1H),2.63(s,1H),2.36(s,3H),2.17(s,1H),1.80-1.74(m,2H ),1.67(m,2H),1.61(d,J=4Hz,3H),1.29(d,J=4Hz,2H),1.21(d,J=4Hz,1H).

[0384] Example A16 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-8-fluoro-N-methylpyrido[4,3-d]pyrimidin-4-amine

[0385] LCMS: m / z 605 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δ9.22(m,1H),7.99(d,J=4Hz,1H),7.67(d,J=8Hz,1H),6.90 (s,1H),6.69-6.66(m,1H),6.48(s,1H),6.33(s,2H),6.18-6.15(m,1H),5.78(d,J =8Hz,2H),5.28-5.14(m,1H),4.51-4.33(m,2H),3.52-3.41(m,2H),3.24(s,3H),2 .99(s,1H),2.43(s,3H),2.22-2.10(m,1H),2.03-1.84(m,1H),1.63(d,J=4Hz,3H).

[0386] Example A17 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((3R,6S)-1,1-difluoro-5-methyl-5-azaspiro[2.4]heptane-6-yl)methoxy)-8-fluoro-N-methylpyrido[4,3-d]pyrimidin-4-amine

[0387] LCMS: m / z 667 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ9.22(d,J=4Hz,1H),7.99(d,J=4Hz,1H),7.67(d,J=8Hz,1H),6.90(s, 1H),6.69-6.66(m,1H),6.47(s,1H),6.34(s,2H),6.18-6.14(m,1H),5.75(d,J=8Hz,2H),4.5 1(s,1H),4.35(s,1H),3.24(s,3H),2.99(d,J=12Hz,1H),2.92-2.90(m,1H),2.47-2.45(m,1H ),2.39(s,3H),2.09-2.03(m,1H),1.96-1.89(m,1H),1.63(d,J=4Hz,3H),1.53-1.42(m,2H).

[0388] Example A18 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((3S,6S)-1,1-difluoro-5-methyl-5-azaspiro[2.4]heptane-6-yl)methoxy)-8-fluoro-N-methylpyrido[4,3-d]pyrimidin-4-amine

[0389] LCMS: m / z 667 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ9.23(d,J=4Hz,1H),7.99(d,J=4Hz,1H),7.67(d,J=8Hz,1H),6.90(s,1H ),6.69-6.66(m,1H),6.47(s,1H),6.34(s,2H),6.18-6.14(m,1H),5.79(d,J=16Hz,2H),4.50(s, 1H),4.42(s,1H),3.25(s,3H),2.93(d,J=8Hz,1H),2.84(m,1H),2.61-2.58(m,1H),2.39(s,3H), 2.27-2.22(m,1H),1.84-1.76(m,1H),1.63(d,J=4Hz,3H),1.58-1.55(m,1H),1.51-1.45(m,1H).

[0390] Example A19 2-((1-(((1S,4S)-2-oxo-5-azabicyclo[2.2.1]heptane-5-yl)methyl)cyclopropyl)methoxy)-7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(1-(2-aminopyridin-3-yl)ethyl)-8-fluoro-N-methylpyrido[4,3-d]pyrimidin-4-amine

[0391] LCMS: m / z 605 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ9.19 (s, 1H), 7.97 (d, J = 8Hz, 1H), 7.64 (d, J = 12Hz, 1H), 6.88 (s, 1H),6.67-6.64(m,1H),6.46(m,1H),6.31(s,2H),6.12(s,1H),5.77-5.75(m,2H),4.43 -4.18(m,3H),3.79-3.77(m,1H),3.48-3.46(m,2H),3.24(s,3H),2.86-2.84(m,1H),2. 69-2.55(m,2H),2.40-2.38(m,1H),1.67-1.51(m,5H),0.58(s,2H),0.49-0.40(m,2H).

[0392] Example A20 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(1-(2-aminopyridin-3-yl)ethyl)-8-fluoro-N-methyl-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridin[4,3-d]pyrimidin-4-amine trifluoroacetate

[0393] LCMS: m / z 692 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ9.30 (s, 1H), 8.04-8.02 (m, 3H), 6.95 (t, J = 8Hz, 1H), 6.90 (s, 1H), 6.46 (s, 1H), 6.01-5.96 (m, 1H), 5. 20-5.15(m,1H),3.90-3.80(m,6H),3.54-3.42(m,5H),2.05-2.01(m,1H),1.80(s,1H),1.74-1.67(m,3H),1.63-1.54(m,1H).

[0394] Example A21 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-N-ethyl-8-fluoro-pyridin[4,3-d]pyrimidin-4-amine

[0395] LCMS: m / z 707 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ9.11 (s, 1H), 8.01 (d, J = 5.0Hz, 1H), 7.74 (d, J = 7.5Hz, 1H), 6.91 (d, J = 2. 2Hz,1H),6.72(dd,J=7.6,5.0Hz,1H),6.49(d,J=2.4Hz,1H),6.39–6.23(m,2H),5.71(s,2H),4. 65–4.42(m,2H),3.92–3.66(m,2H),3.07–2.85(m,2H),2.43–2.26(m,1H),2.25–2.11(m,2H),2. 10–1.91(m,3H),1.89–1.70(m,3H),1.65(d,J=6.8Hz,3H),1.31–1.18(m,3H),1.05–0.94(m,2H).

[0396] Example A22 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(1-(2-aminopyridin-3-yl)ethyl-N-ethyl-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)pyridin[4,3-d]pyrimidin-4-amine

[0397] LCMS: m / z 663 (M+H) + . 1H NMR(400MHz, DMSO-d6)δ9.05(s,1H),8.00(d,J=4.8Hz,1H),7.71(d,J=7.4Hz,1H),6.96–6.85(m,1H),6.70 (m,1H),6.50(d,J=9.7Hz,1H),6.31(m,3H),5.64(s,1H),5.30(m,1H),4.25–3.96(m,3H),3.71(m,2H),3.18 –2.95(m,3H),2.89–2.76(m,1H),2.10(m,3H),1.81(m,2H),1.63(d,J=6.7Hz,3H),1.30(m,1H),1.02(m,3H).

[0398] Example A22 was chirally separated by SFC to give Examples A22-A and A22-B:

[0399] Example A22-A

[0400] LCMS: m / z 663 (M+H) + .

[0401] Example A22-B

[0402] LCMS: m / z 663 (M+H) + .

[0403] Example A23 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-(2-methoxyethyl)pyridin[4,3-d]pyrimidin-4-amine trifluoroacetate

[0404] LCMS: m / z 737 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ10.96 (s, 1H), 9.28 (d, J = 8Hz, 1H), 8.17 (d, J = 8Hz, 1H) , 8.05 (d, J = 8Hz, 1H), 7.79 (s, 2H), 6.97-6.91 (m, 2H), 6.49-6.35 (m, 2H), 6.06 -6.05(m,1H),4.68-4.54(m,2H),4.13-4.01(m,3H),3.78-3.44(m,6H),3.18( s,1H),3.13(s,3H),2.34-2.17(m,3H),2.12-1.88(m,4H),1.71(d,J=8Hz,3H).

[0405] Example A24 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(1-(2-aminopyridin-3-yl)ethyl)-N-cyclopropyl-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoropyridin[4,3-d]pyrimidin-4-amine trifluoroacetate

[0406] LCMS: m / z 719 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δ11.04(s,1H),9.63(s,1H),8.27(m,1H),8.13-8.04(m,2H),,6.96 -6.91(m,2H),6.52(m,1H),6.36(s,1H),5.74(s,1H),4.65-4.63(m,1H),4.54-4.48(m,1H) ,3.78-3.65(m,3H),3.47-3.43(m,3H),3.15-3.09(m,1H),2.46-2.41(m,1H),2.28-2.15( m,3H),2.10-1.94(m,2H),1.91-1.85(m,5H),0.94-0.93(m,2H),0.64(m,1H),0.26(m,1H).

[0407] Example A25 7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-(1-(2-aminopyridin-3-yl)propyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylpyrido[4,3-d]pyrimidin-4-amine trifluoroacetate

[0408] LCMS: m / z 707 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δ0.96(s,1H),9.46(s,1H),8.28-8.18(m,3H),8.10( d,J=8Hz,1H),6.99(t,J=8Hz,1H),6.92(m,1H),6.51-6.45(m,1H),5.99(s, 1H),4.74-4.61(m,2H),3.83-3.66(m,5H),3.49-3.43(m,4H),3.18-3.11(m ,1H),2.47-2.45(m,1H),2.34-2.17(m,4H),2.11-1.89(m,5H),0.98(s,3H).

[0409] Example A26 4-(4-((1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoropyridin[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0410] LCMS: m / z 684 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ10.29(s,1H),9.60(s,1H),8.64(s,1H),8.29(s,1H),8.07–7.95(m,1H),7.65–7. 35(m,3H),7.21(d,J=3.3Hz,1H),4.56(m,3H),4.00(m,1H),2.22–1.74(m,8H),1.67(m,4H),1.25(s,3H).

[0411] Example A27 2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-7-yl))-7-fluorophenylpropyl[b]thiophene-3-carbonitrile

[0412] LCMS: m / z 690 (M+H)+ . 1 H NMR (400MHz, DMSO-d6) δ9.25 (s, 1H), 8.09 (s, 2H), 7.98 (d, J = 8Hz 1H), 7.66 (d, J = 8Hz 1H), 7.40-7.37 (m, 1H), 7.15 (t, J = 8Hz 1H),6.68-6.65(m,1H),6.19-6.14(m,1H),5.81(s,2H),4.31-4.20(m,2H),3.24(s,3H),3.14-3.04(m,2H),2.75-2.68(m ,1H),2.58-2.55(m,1H),2.13-2.00(m,2H),1.93-1.90(m,1H),1.81-1.76(m,1H),1.65-1.55(m,6H),1.51-1.45(m,1H).

[0413] Example A28 2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)pyridin[4,3-d]pyrimidin-7-yl)-7-fluorophenylpropyl[b]thiophene-3-carbonitrile

[0414] LCMS: m / z 605 (M+H) + .

[0415] Example A29 N-((R)-1-(2-aminopyridin-3-yl)ethyl)-7-(8-ethynyl-7-fluoronaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)-N-methylpyridin[4,3-d]pyrimidin-4-amine

[0416] LCMS: m / z 624 (M+H) + . 1H NMR(400MHz, DMSO-d6)δ9.36(d,J=7.2Hz,1H),8.43(d,J=4.7Hz,1H),8.31–8.17 (m,2H),7.96(m,1H),7.74–7.58(m,3H),7.37(m,1H),5.24(d,J=54.1Hz,1H),4. 08(m,3H),3.89–3.80(m,1H),3.05(m,2H),2.98(m,1H),2.86–2.75(m,1H),2.21 (d,J=11.9Hz,3H),2.02(m,3H),1.85–1.63(m,3H),1.33(dd,J=15.6,6.6Hz,3H).

[0417] Example A30 N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-7-(8-ethynyl-7-fluoronaphthalen-1-yl)-8-fluoro-N-methylpyridin-4-amine

[0418] LCMS: m / z 668 (M+H) + . 1 H NMR(400MHz, DMSO-d6)δ9.35(d,J=6.8Hz,1H),8.47–8.36(m,1H),8.23(m,2H),7.99–7.90(m,1H),7.77–7.57(m,3H),7.35(m,1H),4.16 (m,3H),3.82(m,1H),3.09–2.91(m,2H),2.68(d,J=11.5Hz,1H),2.19(d,J=10.7Hz,3H),2.04–1.88(m,2H),1.87–1.63(m,3H),1.49(m,m 3H),1.31(m,3H).

[0419] Example A31 4-(4-((1-(2-aminopyridin-3-yl)ethyl)(ethyl)amino)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)pyridin[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol trifluoroacetate

[0420] LCMS: m / z 654 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ11.24(s,1H),10.83(s,1H),10.27(s,1H),9.61(d,J=8Hz,1H),9.12-8.93(m ,2H),8.65(m,1H),8.28(m,1H),8.04-8.01(m,1H),7.68(s,1H),7.51(t,J=8Hz,1H),7.44(m,1H),7.2 6-7.13(m,1H),5.58-5.45(m,1H),4.64-4.48(m,4H),4.00-3.84(m,5H),3.28(s,2H),2.90(s,1H),2 .75-2.68(m,1H),2.43(m,1H),2.26-2.13(m,4H),1.96(s,1H),1.69-1.60(m,3H),1.25-1.15(m,4H).

[0421] Example A32 N-(1-(2-aminopyridin-3-yl)ethyl)-N-ethyl-7-(8-ethynyl-7-fluoronaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)pyridin[4,3-d]pyrimidin-4-amine trifluoroacetate

[0422] LCMS: m / z 638 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ11.24(s,1H),10.83(s,1H),9.63(d,J=12Hz,1H),9.09(s,1H ),8.94(m,1H),8.65(m,1H),8.30-8.24(m,3H),7.74(t,J=4Hz,1H),7.69-7.63(m,3H ),5.58-5.45(m,1H),4.54-4.48(m,4H),4.09-4.02(m,2H),3.27(s,2H),2.88(s,1H) ,2.43(m,1H),2.28-2.15(m,4H),1.97(s,1H),1.69-1.60(m,3H),1.25-1.15(m,4H).

[0423] Example A32 was chirally separated by SFC to give Examples A32-A and A32-B: N-((R)1-(2-aminopyridin-3-yl)ethyl)-N-ethyl-7-(8-ethynyl-7-fluoronaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)pyridin[4,3-d]pyrimidin-4-amine and N-((S)1-(2-aminopyridin-3-yl)ethyl)-N-ethyl-7-(8-ethynyl-7-fluoronaphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)pyridin[4,3-d]pyrimidin-4-amine

[0424] Example A32-A:

[0425] LCMS: m / z 638 (M+H) + .

[0426] Example A32-B:

[0427] LCMS: m / z 638 (M+H) + .

[0428] Example A33 2-amino-4-(4-((1-(2-aminopyridin-3-yl)ethyl)(ethyl)amino-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)pyridin[4,3-d]pyrimidin-7-yl)-7-fluorophenylpropano[b]thiophene-3-carbonitrile trifluoroacetate

[0429] LCMS: m / z 660 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ10.83(s,1H),9.27(s,1H),8.10-8.15(m,3H),7.42-7. 39(m,1H),7.20-7.11(m,1H),6.94-6.91(m,1H),6.24-6.19(m,1H),5.66-5.53( m,1H),4.67-4.50(m,2H),4.05-3.99(m,1H),3.92-3.73(m,6H),3.35-3.29(m,2 H),2.36-2.33(m,1H),2.19-1.88(m,4H),1.69-1.61(m,3H),1.13-1.08(m,3H).

[0430] Example A33 was chirally separated by SFC to give Examples A33-A and A33-B: 2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(ethyl)amino-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fusedpyrrolidin-7a(5H)-yl)methoxy)pyridin[4,3-d]pyrimidin-7-yl)- 7-Fluorophenylpropyl[b]thiophene-3-carbonitrile and 2-amino-4-(4-(((S)-1-(2-aminopyridin-3-yl)ethyl)(ethyl)amino-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)pyridin[4,3-d]pyrimidin-7-yl)-7-fluorophenylpropyl[b]thiophene-3-carbonitrile

[0431] Example A33-A:

[0432] LCMS: m / z 660 (M+H) + .

[0433] Example A33-B:

[0434] LCMS: m / z 660 (M+H) + .

[0435] Example B1 Preparation of (S)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0436] Step 1: Preparation of (S)-7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0437] To a solution of ((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methanol in tetrahydrofuran (5 mL) was added sodium tert-butoxide (198 mg, 2.06 mmol). The mixture was reacted at room temperature for 10 minutes, followed by the addition of (S)-7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-2,6-dichloro-8-fluoro-N-methylquinazolin-4-amine (700 mg, 0.68 mmol). The resulting mixture was reacted at room temperature for 5 hours, quenched by the addition of water, and extracted with ethyl acetate. The combined organic phases were concentrated under reduced pressure, and the residue was separated by silica gel column chromatography to obtain the target product (650 mg, yield: 80%).

[0438] LCMS: m / z 1187 (M+H) + .

[0439] Step 2: Preparation of (S)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0440] A solution of (S)-7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine (650 mg, 0.55 mmol) in trifluoroacetic acid (5 mL) was reacted at 55°C for 7 hours and then concentrated under reduced pressure. The residue was basified with aqueous sodium bicarbonate and extracted with ethyl acetate. The combined organic phases were concentrated under reduced pressure, and the residue was separated by preparative liquid chromatography to give the desired product (203 mg, 51% yield).

[0441] LCMS: m / z 707 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.00 (s, 1H), 7.96-7.94 (m, 1H), 7.63 (d, J = 8Hz, 1H), 6.85 (s, 2H), 6.66-6.63(m,1H),6.48(s,1H),6.01-5.98(m,3H),4.24-4.12(m,2H),3.18(s,3H),3.12- 3.07(m,1H),3.04-2.99(m,1H),2.73-2.67(m,1H),2.56-2.54(m,1H),2.37(s,3H),2.10- 1.97(m,2H),1.92-1.88(m,1H),1.83-1.73(m,2H),1.65-1.53(m,5H),1.50-1.44(m,1H).

[0442] The following examples were synthesized using different starting materials according to the method of Example B1:

[0443] Example B2: (S)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)-N-methylquinazolin-4-amine

[0444] LCMS: m / z 663 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δ8.00(s,1H),7.96-7.95(m,1H),7.63-7.61(s,1H),6.84 (s,2H),6.66-6.63(m,1H),6.49(s,1H),6.07-5.97(m,3H),5.36-5.22(m,1H),4 .08(s,2H),3.18(s,3H),3.15-3.11(m,2H),3.04(s,1H),2.85(s,1H),2.37(m,3 H),2.20-2.14(m,1H),2.07-2.03(m,2H),1.87-1.80(m,3H),1.61-1.59(m,3H).

[0445] Example B3: (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0446] LCMS: m / z 707 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.01(d,J=1.5Hz,1H),7.97(dd,J=4.9,1.7Hz,1H),7.63(dd,J=7.6,1.7Hz,1 H),6.87(s,2H),6.66(dd,J=7.5,4.9Hz,1H),6.50(s,1H),6.03–5.95(m,1H),5.80(s,2H),4.19(q,J= 10.5Hz,2H),3.15(s,3H),3.13–3.07(m,1H),3.06–2.99(m,1H),2.76–2.70(m,1H),2.38(d,J=2.2Hz ,3H),2.13–2.06(m,1H),2.05–1.97(m,1H),1.95–1.88(m,1H),1.86–1.71(m,2H),1.68–1.44(m,6H).

[0447] Example B4: (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)-N-methylquinazolin-4-amine

[0448] LCMS: m / z 663 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.00 (d, J=1.6Hz, 1H), 7.96 (dd, J=4.9, 1.7Hz, 1H), 7.62 (dd, J= 7.7,1.8Hz,1H),6.85(s,2H),6.65(dd,J=7.5,4.9Hz,1H),6.49(s,1H),6.02–5.93(m,1H ),5.77(s,2H),5.36–5.22(m,1H),4.19–3.97(m,2H),3.19–3.01(m,7H),2.90–2.79(m, 1H),2.37(d,J=2.2Hz,3H),2.23–1.97(m,3H),1.91–1.75(m,3H),1.61(d,J=6.7Hz,3H).

[0449] Example B5: 7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-(1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-N-ethyl-8-fluoroquinazolin-4-amine

[0450] LCMS: m / z 721 (M+H) + .

[0451] Example B5 was subjected to preparative liquid phase separation to obtain Examples B5-A and B5-B:

[0452] Example B5-A:

[0453] LCMS: m / z 721 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ11.16–10.68(m,1H),8.19(d,J=7.4Hz,1H),8.13–7.96(m,3H ),7.03–6.79(m,3H),6.56–6.52(m,1H),6.00–5.89(m,1H),4.68–4.61(m,2H),4.56– 4.48(m,2H),3.89–3.84(m,2H),3.82–3.74(m,1H),3.71–3.63(m,1H),3.48–3.40(m, 1H),3.18–3.07(m,1H),2.47–1.87(m,13H),1.70–1.64(m,3H),1.09(t,J=6.9Hz,3H).

[0454] Example B5-B:

[0455] LCMS: m / z 721 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ11.16–10.79(m,1H),8.21–8.03(m,4H),7.03–6.80(m,3H),6.52(s,1H),5.99–5.91(m,1H),4.67–4.53(m,3H),4 .03–3.95(m,1H),3.81–3.65(m,3H),3.49–3.43(m,1H),3.18–3.09(m,1H),2.49–1.87(m,12H),1.67(d,J=6.8Hz,3H),1.17–1.05(m,3H).

[0456] Example B6: 7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-(1-(2-aminopyridin-3-yl)ethyl)-6-chloro-N-ethyl-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)quinazolin-4-amine

[0457] LCMS: m / z 677 (M+H) + .

[0458] Example B6 was subjected to preparative liquid phase separation to obtain Examples B6-A and B6-B:

[0459] Example B6-A:

[0460] LCMS: m / z 677 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ11.16–10.72(m,2H),8.68–8.55(m,1H),8.21–8.15(m,1H),8.13–7.97(m,3H),7.02–6.77(m,3H),6.56–6.49(m,1H) ,5.98–5.87(m,1H),5.69–5.51(m,1H),4.64–4.37(m,3H),3.92–3.82 (m,3H),2.44–2.00(m,11H),1.66(d,J=6.7Hz,3H),1.12–1.04(m,3H).

[0461] Example B6-B:

[0462] LCMS: m / z 677 (M+H)+ . 1 H NMR (400MHz, DMSO-d6) δ10.82(s,1H),8.13(m,1H),8.07–7.82(m,3H),7.02–6.78(m,3H),6.53–6.49(m,1H),5.99–5.87(m, 1H),5.93–5.54(m,1H),4.67–4.37(m,3H),3.97–3.78(m,4H),2.40–2.05(m,12H),1.66(d,J=6.7Hz,3H),1.12–1.03(m,3H).

[0463] Example B7: (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-6,8-difluoro-N-methylquinazolin-4-amine

[0464] LCMS: m / z 691 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ7.95 (dd, J=4.9, 1.7Hz, 1H), 7.81 (dd, J=11.1, 1.7Hz, 1H), 7.63 (dd, J=7.5, 1.8Hz,1H),6.87(s,2H),6.65(dd,J=7.5,4.9Hz,1H),6.51(s,1H),6.06–5.95(m,1H),5.79(s,2H), 4.27–4.10(m,2H),3.18–3.02(m,5H),2.73(d,J=11.9Hz,1H),2.60–2.52(m,1H),2.37(d,J=2.3Hz, 3H),2.13–2.05(m,1H),2.04–1.97(m,1H),1.94–1.87(m,1H),1.85–1.72(m,2H),1.62–1.45(m,5H).

[0465] Example B8: (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)-N-methylquinazolin-4-amine

[0466] LCMS: m / z 647 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ7.97(dd,J=4.9,1.7Hz,1H),7.83(dd,J=11.2Hz,1.7Hz,1H),7.64(dd,J=7.5Hz,1.7Hz,1H),6.89(s,2H),6.67(dd,J=7.5,4. 9Hz,1H),6.52(s,1H),6.05–5.97(m,1H),5.79(s,2H),5.38(s,0.5H),5.2 5(s,0.5H),4.21–4.02(m,2H),3.22–3.02(m,6H),2.93–2.82(m,1H),2.38 (d,J=2.2Hz,3H),2.25–2.01(m,3H),1.93–1.75(m,3H),1.62(d,J=6.8Hz,3H).

[0467] Example B9: (S)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-6,8-difluoro-N-methylquinazolin-4-amine

[0468] LCMS: m / z 691 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ7.95 (dd, J=4.9, 1.7Hz, 1H), 7.82 (dd, J=11.1, 1.7Hz, 1H), 7.63 (dd ,J=7.5,1.8Hz,1H),6.87(s,2H),6.65(dd,J=7.5,4.9Hz,1H),6.50(s,1H),6.06–5.93(m,3H ),4.28–4.08(m,2H),3.21–3.06(m,5H),2.74(d,J=11.9Hz,1H),2.60–2.52(m,1H),2.37(d ,J=2.2Hz,3H),2.13–1.97(m,2H),1.95–1.88(m,1H),1.85–1.74(m,2H),1.63–1.46(m,6H).

[0469] Example B10: (S)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6,8-difluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)-N-methylquinazolin-4-amine

[0470] LCMS: m / z 647 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ7.97 (dd, J=5.0, 1.7Hz, 1H), 7.83 (dd, J=11.2Hz, 1.7Hz, 1H), 7.6 4(dd,J=7.6,1.7Hz,1H),6.89(s,2H),6.66(dd,J=7.5,4.9Hz,1H),6.52(s,1H),6.07–5. 93(m,3H),5.38(s,0.5H),5.25(s,0.5H),4.10(s,2H),3.22–3.02(m,6H),2.93–2.82(m, 1H),2.38(d,J=2.4Hz,3H),2.25–2.01(m,3H),1.95–1.77(m,3H),1.61(d,J=6.7Hz,3H).

[0471] Example B11A: (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((S)-1-(2-amino-5-fluoropyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0472] LCMS: m / z 725 (M+H) + . 1H NMR(400MHz, DMSO-d6)δ8.02(s,1H),7.95–7.94(d,J=2.8Hz,1H),7.61–7.58(dd,J=9.7,2.9Hz,1H),6.87(s,2H),6.50(s,1H),6.02–5.84( m,3H),4.28–4.07(m,2H),3.23(s,3H),3.18–3.00(m,2H),2.81–2.67(m,1H),2.38(d,J=2.2Hz,3H),2.13–1.73(m,5H),1.71–1.46(m,6H).

[0473] Example B11B: (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-amino-5-fluoropyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0474] LCMS: m / z 725 (M+H) + . 1 H NMR(400MHz, DMSO-d6)δ8.02(d,J=1.5Hz,1H),7.95–7.94(d,J=2.8Hz,1H),7.63–7.60(dd,J=9.5,2.9Hz,1H),6.88(s,2H),6.50(s,1H),5.98–5 .88(m,1H),5.75(s,2H),4.30–4.08(m,2H),3.25–2.92(m,5H),2.83–2. 68(m,1H),2.38(d,J=2.2Hz,3H),2.15–1.72(m,5H),1.70–1.44(m,6H).

[0475] Example B12A: (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(3-amino-pyrazin-2-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0476] LCMS: m / z 708 (M+H) + . 1H NMR(400MHz, DMSO-d6)δ8.10–8.04(m,1H),7.95(d,J=2.7Hz,1H),7.79(d, J=2.5Hz,1H),6.88(s,2H),6.50(s,1H),6.46(s,2H),6.07–5.99(m,1H),4 .27–4.06(m,2H),3.35(s,3H),3.19–2.99(m,2H),2.83–2.67(m,1H),2.62 –2.53(m,1H),2.38(d,J=2.3Hz,3H),2.13–1.72(m,5H),1.68–1.46(m,6H).

[0477] Example B12B: (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((S)-1-(3-amino-pyrazin-2-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0478] LCMS: m / z 708 (M+H) + . 1 H NMR(400MHz, DMSO-d6)δ8.08(s,1H),7.95(d,J=2.7Hz,1H),7.79(d,J=2.7Hz,1H),6.89(s,2H),6.61(s,2H),6.50(s,1H),6.05–5.97(m,1H),4.39 –4.05(m,2H),3.41(s,3H),3.26–3.02(m,2H),2.89–2.71(m,1H),2.69–2 .55(m,1H),2.38(d,J=2.2Hz,3H),2.19–1.74(m,5H),1.70–1.45(m,6H).

[0479] Example B13A and Example B13B: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b ]thiophene-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0480] Example B13A

[0481] LCMS: m / z 723 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δ8.11(s,2H),8.03(s,1H),7.97-7.95(m,1H),7.64-7.61(m,1H),7.24-7.21(m,1H ),7.17-7.12(m,1H),6.67-6.64(m,1H),6.01-5.96(m,1H),5.83(s,2H),4.25-4.14(m,2H),3.17(s,3H), 3.12-3.08(m,1H),3.04-2.99(m,1H),2.74-2.66(m,1H),2.56-2.52(m,1H),2.11-2.06(m,1H),.03-1.98 (m,1H),1.92-1.88(m,1H),1.83-1.72(m,2H),1.64(d,J=8Hz,3H),1.60-1.54(m,2H),1.50-1.43(m,1H).

[0482] Example B13B

[0483] LCMS: m / z 723 (M+H) + . 1H NMR(400MHz,DMSO-d6)δ8.10(s,3H),7.97-7.95(m,1H),7.65-7.63(m,1H),7.25-7.22(m,1H),7. 17-7.13(m,1H),6.67-6.64(m,1H),6.11-6.06(m,1H),5.93(s,2H),4.24-4.14(m,2H),3.17(s,3 H),3.13-3.09(m,1H),3.03-3.01(m,1H),2.74-2.67(m,1H),2.56-2.52(m,1H),2.12-2.07(m,1H ),2.04-1.98(m,1H),1.92-1.89(m,1H),1.83-1.72(m,2H),1.66-1.54(m,5H),1.49-1.43(m,1H).

[0484] Example B14A and Example B14B: (R)-7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methyl Quinazolin-4-amine and (S)-7-(5-amino-3-chloro-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0485] Example B14A

[0486] LCMS: m / z 726 (M+H) + . 11H NMR (400 MHz, DMSO-d6) δ 8.05 (s, 1H), 7.97 (d, J = 4 Hz, 1H), 7.64 (d, J = 8 Hz, 1H), 6.90 (s, 1H), 6.68 - 6.65 (m, 1H), 6.36 - 6.33 (m, 3H), 6.04 - 5.99 (m, 1H), 5.85 (s, 2H), 4.24 - 4.15 (m, 2H), 3.17 (s, 3H), 3.14 - 3.08 (m, 1H), 3.06 - 3.00 (m, 1H), 2.75 - 2.68 (m, 1H), 2.57 - 2.55 (m, 1H), 2.11 - 2.06 (m, 1H), 2.04 - 1.98 (m, 1H), 1.93 - 1.89 (m, 1H), 1.84 - 1.72 (m, 2H), 1.66 - 1.44 (m, 6H).

[0487] Example B14B

[0488] LCMS: m / z 726 (M + H) + 。 1 1H NMR (400 MHz, DMSO-d6) δ 8.05 (s, 1H), 7.97 (d, J = 4 Hz, 1H), 7.64 (d, J = 8 Hz, 1H), 6.90 (s, 1H), 6.68 - 6.65 (m, 1H), 6.36 - 6.33 (m, 3H), 6.05 - 6.00 (m, 1H), 5.92 (s, 2H), 4.25 - 4.13 (m, 2H), 3.19 (s, 3H), 3.13 - 3.08 (m, 1H), 3.05 - 3.00 (m, 1H), 2.74 - 2.68 (m, 1H), 2.57 - 2.55 (m, 1H), 2.10 - 2.06 (m, 1H), 2.04 - 1.98 (m, 1H), 1.93 - 1.89 (m, 1H), 1.85 - 1.72 (m, 2H), 1.66 - 1.45 (m, 6H).

[0489] Example B15A and Example B15B: (R)-7-(3-amino-2-fluoro-5-methyl-6-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methyl Quinazolin-4-amine and (S)-7-(3-amino-2-fluoro-5-methyl-6-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0490] Example B15A

[0491] LCMS: m / z 724 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.11 (s, 1H), 7.97 (d, J = 4Hz, 1H), 7.64 (d, J = 8Hz, 1H), 6.86-6.83 (m, 1H), 6.68-6.65(m,1H),6.07-6.02(m,3H),5.89(s,2H),4.25-4.15(m,2H),3.19(s,3H),3.14-3.09(m, 1H),3.06-3.00(m,1H),2.75-2.68(m,1H),2.57-2.55(m,1H),2.37-2.34(m,3H),2.11-2.06(m,1H ),2.04-1.98(m,1H),1.93-1.89(m,1H),1.85-1.73(m,2H),1.66-1.54(m,5H),1.51-1.45(m,1H).

[0492] Example B15B

[0493] LCMS: m / z 724 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.08 (s, 1H), 7.98 (d, J = 4Hz, 1H), 7.65 (d, J = 8Hz, 1H), 6.86-6.8 4(m,1H),6.68-6.65(m,1H),6.05-6.00(m,3H),5.86(s,2H),4.27-4.16(m,2H),3.20(s, 3H),3.14-3.04(m,2H),2.77-2.69(m,1H),2.59-2.56(m,1H),2.37-2.33(m,3H),2.12-2 .00(m,2H),1.94-1.90(m,1H),1.83-1.74(m,2H),1.67-1.55(m,5H),1.52-1.46(m,1H).

[0494] Example B16A and Example B16B: 7-((R)-3-amino-8-ethynyl-7-fluoronaphthalen-1-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methyl Quinazolin-4-amine and 7-((S)-3-amino-8-ethynyl-7-fluoronaphthalen-1-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0495] Example B16A

[0496] LCMS: m / z 718 (M+H) + .

[0497] Example B16B

[0498] LCMS: m / z 718 (M+H) + .

[0499] Example B17A and Example B17B: 7-((R)-3-amino-8-ethynyl-7-fluoronaphthalen-1-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-6,8-difluoro-N-methyl Quinazolin-4-amine and 7-((S)-3-amino-8-ethynyl-7-fluoronaphthalen-1-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-6,8-difluoro-N-methylquinazolin-4-amine

[0500] Example B17A

[0501] LCMS: m / z 702 (M+H) + .

[0502] Example B17B

[0503] LCMS: m / z 702 (M+H) + .

[0504] Example B18A and Example B18B: (S)-7-(6-amino-4-(prop-1-yn-1-yl)-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-6,8-difluoro-N-methyl Quinazolin-4-amine and (R)-7-(6-amino-4-(prop-1-yn-1-yl)-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-6,8-difluoro-N-methylquinazolin-4-amine

[0505] Example B18A

[0506] LCMS: m / z 731 (M+H) + . 11H NMR (400 MHz, DMSO-d6) δ 8.02 (s, 1H), 7.97 (d, J = 8 Hz, 1H), 7.64 (d, J = 8 Hz, 1H), 7.07 (s, 2H), 6.67 - 6.65 (m, 2H), 6.00 - 5.96 (m, 1H), 5.80 (s, 2H), 4.23 - 4.16 (m, 2H), 3.15 (s, 3H), 3.10 (m, 1H), 3.03 (m, 1H), 2.74 - 2.68 (m, 1H), 2.57 - 2.55 (m, 1H), 2.12 (s, 3H), 2.10 - 2.07 (m, 1H), 2.04 - 1.98 (m, 1H), 1.93 - 1.89 (m, 1H), 1.84 - 1.70 (m, 2H) 1.63 - 1.54 (m, 5H), 1.51 - 1.45 (m, 1H).

[0507] Example B18B

[0508] LCMS: m / z 731 (M + H) + 。 1 1H NMR (400 MHz, DMSO-d6) δ 1 1H NMR (400 MHz, DMSO-d6) δ 8.02 (s, 1H), 7.97 (d, J = 8 Hz, 1H), 7.64 (d, J = 8 Hz, 1H), 7.07 (s, 2H), 6.67 - 6.64 (m, 2H), 6.02 - 5.97 (m, 3H), 4.27 - 4.14 (m, 2H), 3.19 (s, 3H), 3.12 - 3.02 (m, 1H), 2.78 - 2.68 (m, 1H), 2.59 - 2.55 (m, 1H), 2.12 (s, 3H), 2.10 - 2.07 (m, 1H), 2.05 - 1.99 (m, 1H), 1.94 - 1.91 (m, 1H), 1.87 - 1.75 (m, 2H), 1.68 - 1.46 (m, 7H).

[0509] Example B19A and Example B19B: (S)-7-(3-amino-2-fluoro-5-(prop-1-yn-1-yl)-6-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-6,8-difluoro-N-methyl Quinazolin-4-amine and (R)-7-(3-amino-2-fluoro-5-(prop-1-yn-1-yl)-6-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-6,8-difluoro-N-methylquinazolin-4-amine

[0510] Example B19A

[0511] LCMS: m / z 748 (M+H) + .

[0512] Example B19B

[0513] LCMS: m / z 748 (M+H) + .

[0514] Example B20A and Example B20B: (R)-7-(5-amino-4-fluoro-3-(prop-1-yn-1-yl)-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-6,8-difluoro-N-methyl Quinazolin-4-amine and (S)-7-(5-amino-4-fluoro-3-(prop-1-yn-1-yl)-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-6,8-difluoro-N-methylquinazolin-4-amine

[0515] Example B20A

[0516] LCMS: m / z 748 (M+H) + .

[0517] Example B20B

[0518] LCMS: m / z 748 (M+H) + .

[0519] Example B21A and Example B21B: (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methyl-N-((S)-1-(2-(methylamino)pyridin-3-yl)ethyl )quinazolin-4-amine and (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methyl-N-((R)-1-(2-(methylamino)pyridin-3-yl)ethyl)quinazolin-4-amine

[0520] Example B21A

[0521] LCMS: m / z 721 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.05(d,J=4Hz,1H),8.02(s,1H),7.61(d,J=8Hz,1H),6.85(s,2H),6.67-6.6 4(m,1H),6.62-6.59(m,1H),6.49(s,1H),6.00-5.95(m,1H),4.25-4.23(m,1H),4.13-4.11(m,1H),3. 19(s,3H),3.13-3.08(m,1H),3.04-2.99(m,1H),2.83(d,J=4Hz,3H),2.74-2.67(m,1H),2.57-2.55(m ,1H),2.37-2.33(m,3H),2.11-1.99(m,2H),1.92-1.88(m,1H),1.83-1.71(m,2H),1.65-1.44(m,6H).

[0522] Example B21B

[0523] LCMS: m / z 721 (M+H) + . 1H NMR(400MHz,DMSO-d6)δ8.05(d,J=4Hz,1H),8.01(s,1H),7.63(d,J=8Hz,1H),6.99-6.96(m,1H) ,6.85(s,2H),6.62-6.59(m,1H),6.49(s,1H),5.96-5.91(m,1H),4.25-4.14(m,2H),3.22(s,3H) ,3.14-3.03(m,2H),2.85(d,J=4Hz,3H),2.75-2.67(m,1H),2.58-2.54(m,1H),2.37-2.33(m,3H) ,2.14-2.10(m,1H),2.04-1.99(m,1H),1.94-1.91(m,1H),1.83-1.76(m,2H),1.61-1.47(m,6H).

[0524] Example B22 7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazoline-6-carbonitrile

[0525] LCMS: m / z 698 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.53–8.46(m,1H),8.00–7.93(m,1H),7.67–7.60(m,1H),6.94(s ,2H),6.69–6.62(m,1H),6.53(s,1H),6.13–5.99(m,1H),5.89(s,1H),5.75(s,1H),4.29– 4.09(m,2H),3.25–3.16(m,3H),3.13–2.96(m,2H),2.77–2.69(m,1H),2.54(dd,J=8.9,6. 2Hz,1H),2.39(q,J=2.1Hz,3H),2.11–1.94(m,2H),1.92–1.70(m,3H),1.66–1.42(m,6H).

[0526] Examples B23A and B23B: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-trimethylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-trimethylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0527] Example B23A

[0528] LCMS: m / z 634 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.11(s,2H),7.95(d,J=4.5Hz,2H),7.60(d,J=7.3Hz,1H),7.21(dd,J=8.3,5.4Hz,1H),7.14(t,J=8.9Hz,1H ),6.64(dd,J=7.3,5.0Hz,1H),6.04(m,3H),3.94(m,2H),3.79(m,2H),3.11(s,3H),2.21(s,6H),1.60(d,J=6.7Hz,3H),1.32(s,3H).

[0529] Example B23B

[0530] LCMS: m / z 634 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.11(s,2H),7.94(dd,J=4.8,1.4Hz,1H),7.89(s,1H),7.59(d,J=7.3Hz,1H),7.26–7.06(m,2H),6.64(dd,J=7 .4,5.0Hz,1H),5.96(d,J=10.3Hz,3H),3.92(m,2H),3.76(m,2H),3.12(s,3H),2.17(s,6H),1.61(d,J=6.8Hz,3H),1.38–1.26(m,3H).

[0531] Examples B24A, B24B, B24C and B24D: (R)-2-amino-4-(4-(((S)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl )-7-fluorobenzo[b]thiophene-3-carbonitrile, (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzene benzo[b]thiophene-3-carbonitrile, (S)-2-amino-4-(4-(((S)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene -3-carbonitrile, and (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0532] Example B24A

[0533] LCMS: m / z 724 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.12 (s, 2H), 8.08 (s, 1H), 7.94 (d, J = 4Hz, 1H), 7.77 (d, J = 4Hz, 1H),7.24-7.21(m,1H),7.17-7.13(m,1H),6.49(s,2H),6.02-5.97(m,1H),4.17-4.08( m,2H),3.40(s,3H),3.13-3.00(m,2H),2.73-2.68(m,1H),2.58-2.55(m,1H),2.09-2. 04(m,1H),1.99-1.95(m,1H),1.91-1.87(m,1H),1.81-1.72(m,2H),1.65-1.42(m,6H).

[0534] Example B24B

[0535] LCMS: m / z 724 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.15(s,1H),8.12(s,2H),7.93(d,J=4Hz,1H),7.77(d,J=4Hz,1H),7.27-7.23(m,1H),7.18-7.13(m,1H),6.57(s,2H), 6.05-6.00(m,1H),4.18-4.06(m,2H),3.40(s,3H),3.06-3.03(m,2H),2.73-2.67( m,1H),2.58-2.53(m,1H),2.08-1.95(m,2H),1.90-1.75(m,3H),1.65-1.45(m,6H).

[0536] Example B24C

[0537] LCMS: m / z 724 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.12(s,2H),8.08(s,1H),7.94(d,J=4Hz,1H),7.78(d,J= 4Hz,1H),7.24-7.21(m,1H),7.17-7.13(m,1H),6.51(s,2H),6.04-5.99(m,1H),4. 21-4.05(m,2H),3.39(s,3H),3.11-3.00(m,2H),2.73-2.67(m,1H),2.57-2.54(m ,1H),2.08-1.95(m,2H),1.89-1.86(m,1H),1.80-1.74(m,2H),1.65-1.42(m,6H).

[0538] Example B24D

[0539] LCMS: m / z 724 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.15(s,1H),8.12(s,2H),7.93(d,J=4Hz,1H),7.77(d,J=4Hz,1H),7.27-7.23(m,1H),7.18-7.13(m,1H),6.53(s,2H),6. 04-5.99(m,1H),4.16-4.06(m,2H),3.41(s,3H),3.12-3.00(m,2H),2.7 3-2.67(m,1H),2.56-2.53(m,1H),2.07-1.72(m,5H),1.65-1.44(m,6H).

[0540] Examples B25A and B25B: (R)-7-(5-amino-4-fluoro-3-methyl-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinone Quinazolin-4-amine and (S)-7-(5-amino-4-fluoro-3-methyl-2-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0541] Example B25A

[0542] LCMS: m / z 724 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.06 (s, 1H), 7.98-7.97 (m, 1H), 7.65 (d, J = 8Hz, 1H), 6.69-6.66 (m ,1H),6.44(d,J=8Hz,1H),6.10(s,2H),6.05-6.00(m,1H),5.88(s,2H),4.26-4.16(m,2H), 3.18(s,3H),3.16-3.04(m,2H),2.76-2.70(m,1H),2.59-2.57(m,1H),2.36(s,3H),2.12-1 .99(m,2H),1.94(d,J=12Hz,1H),1.85-1.75(m,2H),1.64-1.62(m,3H),1.59-1.48(m,3H).

[0543] Example B25B

[0544] LCMS: m / z 724 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.03 (s, 1H), 7.96 (d, J = 4Hz, 1H), 7.63 (d, J = 8Hz, 1H), 6.66-6. 63(m,1H),6.41(d,J=8Hz,1H),6.08(s,2H),6.03-5.98(m,1H),5.93(s,2H),4.23-4.1 2(m,2H),3.18(s,3H),3.12-3.00(m,2H),2.74-2.67(m,1H),2.56-2.54(m,1H),2.33( s,3H),2.10-1.97(m,2H),1.92(d,J=12Hz,1H),1.81-1.71(m,2H),1.65-1.45(m,6H).

[0545] Example B26: Preparation of (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(4-methylpiperazin-1-yl)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0546] LCMS: m / z 620 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ10.32(s,1H),8.22–7.86(m,7H),7.17(m,2H),7.01–6.87(m,1H),5.91–5. 79(m,1H),4.75(m,2H),3.48(m,2H),3.31(m,5H),3.04(m,2H),2.82(s,3H),1.66(d,J=6.7Hz,3H).

[0547] Example B27: Preparation of (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S)-1-methylpyrrolin-2-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0548] LCMS: m / z 635 (M+H) + . 1H NMR(400MHz,DMSO-d6)δ9.98(s,1H),8.10(m,7H),7.25–7.16(m,1H),7.00– 6.94(m,1H),5.89(m,1H),4.75(m,1H),4.48(m,1H),3.83(m,1H),3.62(m,1 H),3.38(s,3H),3.15(m,1H),2.97(s,3H),2.80(m,1H),2.27(m,1H),2.07( d,J=13.8Hz,1H),1.93(m,2H),1.70(d,J=6.8Hz,3H),1.51(d,J=6.6Hz,1H).

[0549] Example B28: Preparation of (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-((1-((dimethylamino)methyl)cyclopropyl)methoxy)-8-fluoroquinazolin-7-yl)-fluorobenzo[b]thiophene-3-carbonitrile

[0550] LCMS: m / z 649 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.15(s,2H),8.04(s,1H),7.96(d,J=4.1Hz,1H),7.62(d,J=7.0Hz,1H),7.27–7.09(m,2H),6.66(dd,J=7.3,4.9Hz,1H),5.9 8(d,J=6.5Hz,1H),5.84(s,2H),4.33(d,J=11.4Hz,1H),4.21(d,J=11.4Hz ,1H),3.18(s,3H),1.63(d,J=6.6Hz,3H),1.40–1.05(m,5H),0.80(m,4H).

[0551] Example B29: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)azetidin-1-yl)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0552] LCMS: m / z 620 (M+H) + . 1H NMR(400MHz, DMSO-d6)δ8.14(s,2H),7.95(dd,J=4.9,1.4Hz,1H),7.91(d,J=1.1Hz,1H),7.61(d,J=6.6Hz,1H),7.24–7.06(m,2H), 6.65(dd,J=7.4,5.0Hz,1H),6.11–5.90(m,3H),4.23–4.10(m,2H),4.07–3.89(m,2H),3.12(s,3H),2.30(s,6H),1.61(d,J=6.8Hz,3H).

[0553] Example B30: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-pyrrolin-1-yl)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile trifluoroacetate

[0554] LCMS: m / z 634 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ10.51(s,1H),8.02(m,7H),7.37(s,1H),7.23–7.11(m,1H),6.94(m,1H),5.88–5.75(m,1H),3.95(m,2 H),3.77–3.63(m,2H),3.34(s,3H),2.84(s,6H),2.38(s,1H),2.25–2.08(m,1H),1.67(d,J=6.7Hz,3H),1.52(t,J=8.7Hz,1H).

[0555] Example B31: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-piperidin-1-yl)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0556] LCMS: m / z 620 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.12(s,2H),8.00–7.94(m,1H),7.87–7.83(m,1H),7.60(dd,J=12.6, 7.4Hz,1H),7.26–7.11(m,2H),6.73–6.64(m,1H),5.98–5.88(m,1H),5.69(s,2H),4.89–4.71 (m,1H),4.57–4.40(m,1H),3.11(d,J=12.2Hz,3H),2.70–2.55(m,2H),2.08–1.96(m,2H),1.8 8–1.74(m,1H),1.63(d,J=6.7Hz,3H),1.55–1.38(m,2H),1.25(s,6H),0.87(t,J=6.6Hz,1H).

[0557] Example B32: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(4-(dimethylamino)-piperidin-1-yl)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile trifluoroacetate

[0558] LCMS: m / z 620 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ9.88(s,1H),8.39–7.89(m,6H),7.29–7.08(m,2H),6.95(t,J=6.8Hz,1H),5.78(q,J=6.7Hz,1H),4.85(d,J=12.5Hz ,2H),3.48(m,1H),3.34(s,3H),2.88(m,2H),2.81–2.60(m,6H),2.09–1.91(m,2H),1.67(d,J=6.8Hz,3H),1.52(m,1H),1.43–1.23(m,1H).

[0559] Example B33: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(6-methyl-1,6-diazaspiro[3.3]hept-1-yl)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0560] LCMS: m / z 632 (M+H) + .

[0561] Example B34: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(1-methyl-1,6-diazaspiro[3.3]hept-6-yl)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile trifluoroacetate

[0562] LCMS: m / z 632 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ10.69(s,1H),8.32–7.94(m,7H),7.24–7.10(m,2H),7.05–6.94(m,1H),5.80(d,J=6 .6Hz,1H),4.53(m,4H),4.29(m,2H),3.28(s,3H),2.92(s,3H),2.75(t,J=8.3Hz,2H),1.69(d,J=6.7Hz,3H).

[0563] Example B35: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-methylazetidin-3-yl)oxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile trifluoroacetate

[0564] LCMS: m / z 607 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ10.44(s,1H),8.26–8.05(m,5H),7.81(s,2H),7.20(m,2H),7.05–6.94(m,1H),5.85( s,1H),5.43(m,1H),4.68(s,1H),4.41(s,2H),4.20(s,1H),3.26(s,3H),2.94(s,3H),1.69(d,J=6.6Hz,3H).

[0565] Example B36: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-methylazetidin-3-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile trifluoroacetate

[0566] LCMS: m / z 621 (M+H) + .1 H NMR (400MHz, DMSO-d6) δ10.17(s,1H),8.39–7.91(m,7H),7.29–7.09(m,2H),6.97(t,J=6.7Hz,1H),5.91(d,J=6.6Hz,1H),4 .52(m,2H),4.31(m,1H),4.18(m,1H),4.05(m,1H),3.92(m,1H),3.26(m,4H),2.86(d,J=9.3Hz,3H),1.69(d,J=6.6Hz,3H).

[0567] Example B37: (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoro-N-methylquinazolin-4-amine

[0568] LCMS: m / z 618 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ7.94(dd,J=4.8,1.4Hz,1H),7.86(s,1H),7.58(d,J=7.2Hz,1H),6.84(s,2H),6.63(dd,J=7.4,4.9Hz,1H),6.47 (s,1H),6.01–5.83(m,3H),3.97–3.78(m,2H),3.72(m,2H),3.09(s,3H),2.36(s,3H),2.12(s,6H),1.58(d,J=6.8Hz,3H),1.25(s,3H).

[0569] Example B38: (4R)-4-(4-((1-(1H-pyrazol-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile trifluoroacetate

[0570] LCMS: m / z 697 (M+H) + . 1H NMR(400MHz,DMSO-d6)δ11.00(s,1H),8.33–8.10(m,3H),7.76–7.70(m,1H),7.32(s,1H),7. 30–7.23(m,1H),7.22–7.14(m,2H),7.06(s,1H),6.42–6.34(m,1H),6.11–5.99(m,1H),4.67– 4.64(m,1H),3.81–3.75(m,1H),3.71–3.64(m,1H),3.48–3.43(m,1H),3.21–3.07(m,4H),2. 31–2.12(m,3H),2.09–2.02(m,1H),1.99–1.93(m,1H),1.91–1.82(m,2H),1.69–1.60(m,3H).

[0571] Example B39A and 39B: (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-6-fluoro-8-(prop-1-yn-1-yl)quinazolin-7-yl)-7-fluorobenzo[b]thiazole Thiophene-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-6-fluoro-8-(prop-1-yn-1-yl)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0572] Example B39A

[0573] LCMS: m / z 728 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.06 (s, 2H), 7.94 (d, J = 4Hz, 1H), 7.90 (d, J = 12Hz, 1H), 7 .79(d,J=4Hz,1H),7.25-7.22(m,1H),7.14(t,J=8Hz,1H),6.50(s,2H),6.03-5.9 9(m,1H),4.29-4.14(m,2H),3.11-3.04(m,3H),2.74-2.68(m,1H),2.57-2.55(m, 1H),2.12-2.07(m,1H),2.04-1.98(m,1H),1.91-1.75(m,7H),1.65-1.45(m,7H).

[0574] Example B39B:

[0575] LCMS: m / z 728 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.06 (s, 2H), 7.97 (d, J = 8Hz, 1H), 7.93 (d, J = 4Hz, 1H), 7. 78(d,J=4Hz,1H),7.29-7.25(m,1H),7.14(t,J=8Hz,1H),6.60(s,2H),6.05-5.99 (m,1H),4.24-4.14(m,2H),3.12-3.02(m,3H),2.74-2.68(m,1H),2.57-2.55(m, 1H),2.09-2.04(m,1H),2.00-1.96(m,1H),1.90-1.73(m,7H),1.65-1.45(m,7H).

[0576] Examples B40A and B40B: (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-6,8-difluoroquinazolin-7-yl)-7-fluorobenzo[b]thiol Thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-6,8-difluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0577] Example B40A:

[0578] LCMS: m / z 708 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.17 (s, 2H), 7.95 (d, J = 4Hz, 1H), 7.90 (d, J = 12Hz, 1H), 7.79 (d, J = 4Hz, 1H),7.35-7.31(m,1H),7.17(t,J=8Hz,1H),6.53(s,2H),6.08-6.03(m,1H),4.21-4.06(m,2H) ,3.38(s,3H),3.12-3.02(m,2H),2.73-2.70(m,1H),2.57-2.55(m,1H),2.09-2.04(m,1H),2.0 2-1.96(m,1H),1.91(d,J=12Hz,1H),1.83-1.71(m,2H),1.66(d,J=8Hz,3H),1.60-1.45(m,3H).

[0579] Example B40B:

[0580] LCMS: m / z 708 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.17 (s, 2H), 7.95-7.92 (m, 2H), 7.79 (d, J = 4Hz, 1H) 7.36-7.33 (m ,1H),7.17(t,J=8Hz,1H),6.59(s,2H),6.09-6.04(m,1H),4.19-4.04(m,2H),3.39(s,3H ),3.12-3.02(m,2H),2.72-2.69(m,1H),2.57-2.55(m,1H),2.08-2.03(m,1H),2.00-1.9 4(m,1H),1.89(d,J=12Hz,1H),1.83-1.71(m,2H),1.65(d,J=8Hz,3H),1.60-1.45(m,3H).

[0581] Example B41: 2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile trifluoroacetate

[0582] LCMS: m / z 689 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ10.89 (s, 1H), 8.12-8.09 (m, 3H), 7.95-7.93 (m, 1H), 7.79 (t, J = 4Hz, 1H), 7.27-7.23 (m, 2H), 7.17-7.12 (m,1H),6.66(s,1H),6.55(s,1H),6.13-6.06(m,1H),4.37(s,3H),3.45(d,J=20Hz,4H),2.22-1.89(m,6H),1.67-1.65(m,5H).

[0583] Example B42: (R)-2-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0584] LCMS: m / z 632 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.10(s,2H),7.93(dd,J=23.4,8.5Hz,2H),7.73(d,J=1.9Hz,1H),7.20(dd,J=8.4,5.4Hz,1H),7.13(t ,J=8.9Hz,1H),6.54(d,J=20.0Hz,2H),5.89(s,1H),3.99–3.56(m,4H),2.11(s,6H),1.61(d,J=6.8Hz,3H),1.33–1.18(m,6H).

[0585] Examples B43A and B43B: (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-8-(prop-1-yn-1-yl)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((S)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-8-(prop-1-yn-1-yl)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0586] Example B43A

[0587] LCMS: m / z 639 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.02 (s, 2H), 7.90 (d, J = 4Hz, 1H), 7.75-7.73 (m, 2H), 7.22-7.19 (m, 1H), 7.12 (t, J = 12Hz, 1H), 6.55 (s, 2 H),5.93-5.87(m,1H),3.86(s,1H),3.71-3.62(m,3H),3.31(s,3H),2.11(s,6H),1.82(s,3H),1.62(d,J=8Hz,3H),1.25(s,3H).

[0588] Example B43B:

[0589] LCMS: m / z 639 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.02(s,2H),7.89(d,J=4Hz,1H),7.73-7.72(m,1H),7.26-7.23(m,1H),7.13(t,J=12Hz,2H),6.64(s,2 H),5.87(s,1H),3.85-3.80(m,1H),3.68-3.56(m,3H),3.38(s,3H),2.10(s,6H),1.83(s,3H),1.61(d,J=8Hz,3H),1.23(s,3H).

[0590] Example B44: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S)-1-methylpyrrolidin-3-yl)oxy)quinazolin-7-yl)-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile trifluoroacetate

[0591] LCMS: m / z 621 (M+H) + . 1H NMR(400MHz,DMSO-d6)δ10.31(s,1H),8.11(m, 5H),7.78(m,1H),7.31–7.08(m,2H),7.01–6.92(m,1H),5.87(d,J=6.6Hz,1H),5.65(m,1H),3.25(m ,4H),3.20–3.10(m,2H),2.89(s,3H),2.68(m,1H),2.28(m,2H),1.70(d,J=6.6Hz,3H),1.47(m,1H).

[0592] Example B45: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((R)-1-methylpyrrolidin-3-yl)oxy)quinazolin-7-yl)-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile trifluoroacetate

[0593] LCMS: m / z 621 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ10.47(s,1H),8.12(m,7H),7.29–7.12(m,3H),6.98(t,J=6.7Hz,1H),5.8 9(s,1H),5.64(s,1H),3.30(m,5H),3.17(m,1H),2.90(m,4H),2.25(m,2H),1.70(d,J=6.6Hz,3H).

[0594] Example B46: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((trans)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0595] LCMS: m / z 651 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.15(s,2H),8.02(s,1H),7.98(d,J=4.9Hz,1H),7.62(d,J=7.7Hz,1H),7.24(d d,J=8.5,5.2Hz,1H),7.16(t,J=8.9Hz,1H),6.68(dd,J=7.6,4.8Hz,1H),5.96–5.89(m,1H),5.72(s,2H ),5.45–5.39(m,1H),4.11(dd,J=10.5,5.4Hz,1H),4.02(dd,J=9.4,6.7Hz,1H),3.85(dd,J=10.6,2.5H z,1H),3.62(dd,J=9.4,6.2Hz,1H),3.19(s,3H),3.12–3.04(m,1H),2.25(s,6H),1.64(d,J=5.9Hz,3H).

[0596] Example B46 was subjected to chiral separation to provide the isomers Example B46A and Example B46B: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0597] Example B46A

[0598] LCMS: m / z 651 (M+H) + .

[0599] Example B46B

[0600] LCMS: m / z 651 (M+H) + .

[0601] Example B47: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((cis)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0602] LCMS: m / z 651 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.15(s,2H),8.02(s,1H),7.98(dd,J=4.9,1.8Hz,1H),7.61(dd,J=7.7,1.7Hz,1H), 7.24(dd,J=8.4,5.3Hz,1H),7.16(t,J=8.9Hz,1H),6.67(dd,J=7.5,4.8Hz,1H),5.96–5.89(m,1H),5.72(s,2 H),5.40(dd,J=5.4,2.7Hz,1H),4.10(dd,J=10.7,5.5Hz,1H),4.01(dd,J=9.2,6.6Hz,1H),3.85(dd,J=10.4, 2.5Hz,1H),3.61(dd,J=9.2,6.2Hz,1H),3.19(s,3H),3.07–3.01(m,1H),2.23(s,6H),1.63(d,J=6.5Hz,3H).

[0603] Example B47 was subjected to chiral resolution to provide the isomers Example B47A and Example B47B: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0604] Example B47A

[0605] LCMS: m / z 651 (M+H) + .

[0606] Example B47B

[0607] LCMS: m / z 651 (M+H) + .

[0608] Example B48: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-methylpiperidin-4-yl)oxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile trifluoroacetate

[0609] LCMS: m / z 635 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δ9.95(s,1H),8.14(m,3H),8.05(m,3H),7.30(m,1H),7.26–7.11(m,3H),7.05(m,1H),6.92(m ,1H),5.89(m,1H),5.34(m,1H),3.33(m,3H),3.19(m,4H),2.84(m,3H),2.34~2.20(m,4H),1.88(m,1H),1.69(s,3H).

[0610] Example B49: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-(methoxyethyl)piperidin-4-yl)oxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile trifluoroacetate

[0611] LCMS: m / z 679 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δ9.59(s,1H),8.24–7.85(m,6H),7.19(m,2H),6.92(m,1H),5.88(m ,1H),5.23(m,1H),3.68(m,3H),3.33(m,7H),3.15(m,3H),2.39–1.83(m,6H),1.68(s,3H).

[0612] Example B50: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0613] LCMS: m / z 653 (M+H) + . 1H NMR(400MHz, DMSO-d6)δ8.11(s,2H),7.96(d,J=4.0Hz,1H),7.89(s,1H),7.61(d,J=7.1Hz,1H),7.26–7.03(m,2H),6.65(dd,J=7.4,5.0Hz,1H), 5.96(s,3H),4.16–3.90(m,4H),3.71(s,1H),3.11(s,3H),2.78(s,2H), 2.56(m,2H),2.31(s,3H),2.11(t,J=6.9Hz,2H),1.61(d,J=6.8Hz,3H).

[0614] Example B51: (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0615] LCMS: m / z 654 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δ8.51(d,J=7.4Hz,2H),8.28(s,1H),8.15(s,2H),7.27(dd,J=8 .3,5.3Hz,1H),7.17(t,J=8.9Hz,1H),5.14(d,J=57.1Hz,1H),4.34(dd,J=11.1,4.3Hz, 1H),4.26(dd,J=11.0,5.5Hz,1H),4.17(s,1H),3.51–3.42(m,2H),2.86(m,1H),2.45( m,1H),2.43–2.23(m,7H),2.17–1.97(m,1H),1.95–1.75(m,1H),1.41(t,J=7.9Hz,3H).

[0616] Example B52: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0617] LCMS: m / z 649 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.14(s,2H),7.98(d,J=6.0Hz,2H),7.63(d,J=6.5Hz,1H),7 .24(dd,J=8.4,5.3Hz,1H),7.15(t,J=8.9Hz,1H),6.68(dd,J=7.4,4.9Hz,1H),5.91 (q,J=6.5Hz,1H),5.71(s,2H),5.25(dd,J=12.1,6.1Hz,1H),3.15(s,3H),2.98(s,1 H),2.68(s,1H),2.40(s,3H),2.23(s,1H),1.87–1.57(m,7H),1.29(d,J=6.3Hz,3H).

[0618] Example B53: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((S)-1-((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)ethoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0619] LCMS: m / z 667 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.12 (s, 2H), 8.00–7.94 (m, 2H), 7.61 (dd, J = 7.5, 1.8Hz, 1H), 7. 23(dd,J=8.4,5.3Hz,1H),7.15(t,J=8.9Hz,1H),6.66(dd,J=7.5,4.9Hz,1H),5.93–5.84 (m,1H),5.70(s,2H),5.30–5.04(m,2H),3.46–3.36(m,1H),3.15(s,3H),3.00–2.91(m, 1H),2.48–2.35(m,4H),2.08–1.83(m,2H),1.63(d,J=6.7Hz,3H),1.26(d,J=6.3Hz,3H).

[0620] Example B54: (4R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0621] LCMS: m / z 649 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.12(s,2H),8.02(d,J=1.6Hz,1H),7.96(dd,J=4.9,1.7Hz,1H),7.6 1(dd,J=7.5,1.8Hz,1H),7.22(dd,J=8.4,5.3Hz,1H),7.15(t,J=8.9Hz,1H),6.65(dd,J=7.5 ,4.9Hz,1H),6.00–5.91(m,1H),5.83(s,2H),4.19(d,J=11.0Hz,2H),3.19(s,3H),2.92–2.8 0(m,1H),2.65–2.55(m,1H),2.30(s,3H),1.98–1.87(m,1H),1.74–1.56(m,6H),1.05(s,3H).

[0622] Example B55: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0623] LCMS: m / z 671 (M+H) + .

[0624] Example B56: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((S)-4-(difluoromethylenyl)-1-methylpyrrolidin-2-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0625] LCMS: m / z 683 (M+H) + .

[0626] Example B57: (4R)-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((S)-4-(difluoromethyl)-1-methylpyrrolidin-2-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0627] LCMS: m / z 685 (M+H) + .

[0628] Example B58: (4R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((2S)-6,6-difluoro-3-methyl-3-azabicyclo[3.1.0]ethane-2-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0629] LCMS: m / z 683 (M+H) + .

[0630] Example B59: (4R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((6S)-1,1-difluoro-5-methyl-5-azaspiro[2.4]heptan-6-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0631] LCMS: m / z 697 (M+H) + .

[0632] Examples B60A and B60B: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-4-(difluoromethyl)-1-methylpiperidin-3-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-4-(difluoromethyl)-1-methylpiperidin-3-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0633] Example B60A

[0634] LCMS: m / z 699 (M+H) + .

[0635] Example B60B

[0636] LCMS: m / z 699 (M+H) + .

[0637] Examples B61A and B61B: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-4-(difluoromethyl)-1,3-dimethylpiperidin-3-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-4-(difluoromethyl)-1,3-dimethylpiperidin-3-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0638] Example B61A

[0639] LCMS: m / z 713 (M+H) + .

[0640] Example B61B

[0641] LCMS: m / z 713 (M+H) + .

[0642] Examples B62A and B62B: (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-4-(difluoromethyl)-1,3-dimethylpiperidin-3-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-4-(difluoromethyl)-1,3-dimethylpiperidin-3-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0643] Example B62A

[0644] LCMS: m / z 714 (M+H) + . 1H NMR(400MHz, DMSO-d6)δ8.13(s,2H),8.09–8.06(m,1H),7.95(d,J=2.6Hz,1H),7.80(d,J=2.7Hz,1H),7.25–7.19(m,1H),7.18–7.11(m,1H),6.5 1(s,2H),6.04–5.90(m,1H),4.50–4.37(m,1H),4.36–4.25(m,1H),3.40 (s,3H),2.92–2.70(m,2H),2.11(s,3H),1.95–1.39(m,9H),1.11(s,3H).

[0645] Example B62B

[0646] LCMS: m / z 714 (M+H) + .

[0647] Examples B63A, B63B, B63C and B63D:

[0648] (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-1,1-difluoro-6-methyl-6-azaspiro[2.5]octan-4-yl))methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0649] (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4R)-1,1-difluoro-6-methyl-6-azaspiro[2.5]octan-4-yl))methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0650] (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4S)-1,1-difluoro-6-methyl-6-azaspiro[2.5]octan-4-yl))methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0651] and (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-1,1-difluoro-6-methyl-6-azaspiro[2.5]octan-4-yl))methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0652] Example B63A

[0653] LCMS: m / z 711 (M+H) + .

[0654] Example B63B

[0655] LCMS: m / z 711 (M+H) + .

[0656] Example B63C

[0657] LCMS: m / z 711 (M+H) + .

[0658] Example B63D

[0659] LCMS: m / z 711 (M+H) + .

[0660] Examples B64A, B64B, B64C and B64D:

[0661] (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-1,1-difluoro-6-methyl-6-azaspiro[2.5]octan-4-yl))methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0662] (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4R)-1,1-difluoro-6-methyl-6-azaspiro[2.5]octan-4-yl))methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0663] (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4S)-1,1-difluoro-6-methyl-6-azaspiro[2.5]octan-4-yl))methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0664] and (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-1,1-difluoro-6-methyl-6-azaspiro[2.5]octan-4-yl))methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0665] Example B64A

[0666] LCMS: m / z 712 (M+H) + .

[0667] Example B64B

[0668] LCMS: m / z 712 (M+H) + .

[0669] Example B64C

[0670] LCMS: m / z 712 (M+H) + .

[0671] Example B64D

[0672] LCMS: m / z 712 (M+H) + .

[0673] Examples B65A, B65B, B65C and B65D:

[0674] (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3S,6S,8aS)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0675] (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3S,6S,8aR)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0676] (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3S,6R,8aS)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0677] and (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3S,6R,8aR)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0678] Example B65A

[0679] LCMS: m / z 691 (M+H) + .

[0680] Example B65B

[0681] LCMS: m / z 691 (M+H) + .

[0682] Example B65C

[0683] LCMS: m / z 691 (M+H) + .

[0684] Example B65D

[0685] LCMS: m / z 691 (M+H) + .

[0686] Examples B66A, B66B, B66C and B66D:

[0687] (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3R,6S,8aS)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0688] (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3R,6S,8aR)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0689] (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3R,6R,8aS)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0690] and (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3R,6R,8aR)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0691] Example B66A

[0692] LCMS: m / z 691 (M+H) + .

[0693] Example B66B

[0694] LCMS: m / z 691 (M+H) + .

[0695] Example B66C

[0696] LCMS: m / z 691 (M+H) + .

[0697] Example B66D

[0698] LCMS: m / z 691 (M+H) + .

[0699] Example B67: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(6-methyl-2,6-diazaspiro[3.3]heptane-2-yl)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile trifluoroacetate

[0700] LCMS: m / z 632 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ10.03(s,1H),8.28–7.85(m,7H),7.23–7.10(m,2H),7.03–6.93(m,1H),5.81(d,J=6 .8Hz,1H),4.42(m,2H),4.27(m,4H),4.15(m,2H),3.26(s,3H),2.83(d,J=2.9Hz,3H),1.68(d,J=6.8Hz,3H).

[0701] Example B68: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(6-methyl-2,6-diazaspiro[3.4]octan-2-yl)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0702] LCMS: m / z 646 (M+H) + . 1 H NMR(400MHz, DMSO-d6)δ8.11(s,2H),7.96(d,J=4.0Hz,1H),7.89(s,1H),7.61(d,J=7.1Hz,1H),7.26–7.03(m,2H),6.65(dd,J=7.4,5.0Hz,1H), 5.96(s,3H),4.16–3.90(m,4H),3.71(s,1H),3.11(s,3H),2.78(s,2H), 2.56(m,2H),2.31(s,3H),2.11(t,J=6.9Hz,2H),1.61(d,J=6.8Hz,3H).

[0703] Example B69: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(2-methyl-2,6-diazaspiro[3.4]octan-6-yl)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile trifluoroacetate

[0704] LCMS: m / z 646 (M+H) + . 1H NMR(400MHz,DMSO-d6)δ10.29(s,1H),8.03(m,7H),7.24–7.09(m,2H),6.97(s,1H),5.85(s,1H),4.34– 3.92(m,6H),3.47–3.35(m,2H),3.27(s,3H),2.88(d,J=4.4Hz,3H),2.25(s,2H),1.68(d,J=5.9Hz,3H).

[0705] Example B70: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-((4-(fluoromethylenyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0706] LCMS: m / z 719 (M+H) + .

[0707] Example B71: (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-((4-(fluoromethylenyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0708] LCMS: m / z 720 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.14(s,2H),8.08(s,1H),7.94(d,J=2.8Hz,1H),7.77(d,J=2 .7Hz,1H),7.25–7.21(m,1H),7.16(t,J=8.9Hz,1H),6.49(s,2H),6.01–5.94(m,1H), 4.29–4.24(m,1H),4.12–4.05(m,1H),3.41(s,3H),2.49–2.30(m,5H),2.31–2.16(m, 3H),2.08–1.94(m,2H),1.64(d,J=6.8Hz,3H),0.69–0.54(m,2H),0.45–0.29(m,2H).

[0709] Example B72: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-((4-(difluoromethyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0710] LCMS: m / z 737 (M+H) + .

[0711] Example B73: (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-((4-(difluoromethyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0712] LCMS: m / z 738 (M+H) + .

[0713] Example B74: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-((4-(difluoromethyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0714] LCMS: m / z 739 (M+H) + .

[0715] Example B75: (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-((4-(difluoromethyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0716] LCMS: m / z 740 (M+H) + .

[0717] Example B76: (4R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-((6-fluoro-3-azabicyclo[3.1.0]hexan-3-yl)methyl)cyclopropyl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0718] LCMS: m / z 705 (M+H) + .

[0719] Example B77: (4R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-((1-((6,6-difluoro-3-azabicyclo[3.1.0]hexan-3-yl)methyl)cyclopropyl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0720] LCMS: m / z 723 (M+H) + .

[0721] Example B78: (4R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-((1-((1,1-difluoro-5-azaspiro[2.4]heptan-5-yl)methyl)cyclopropyl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0722] LCMS: m / z 737 (M+H) + .

[0723] Example B79: (4R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-((1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0724] LCMS: m / z 685 (M+H) + .

[0725] Example B80: (4R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-((1-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0726] LCMS: m / z 686 (M+H) + .

[0727] Example B81: (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-((S)-2-(dimethylamino)propyl)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0728] LCMS: m / z 623 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ10.21(s,1H),8.49–7.94(m,7H),7.35–7.10(m,2H),6.96(t,J=6.8Hz,1H),5.90(d,J=6.7Hz ,1H),4.64(m,1H),4.52(m,1H),3.85(m,1H),3.36(s,3H),2.82(s,6H),1.70(d,J=6.6Hz,3H),1.35(d,J=6.8Hz,3H).

[0729] Example B82: (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-((S)-1-(dimethylamino-2-yl)propyl)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0730] LCMS: m / z 623 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.13(s,2H),8.00(d,J=1.6Hz,1H),7.96(dd,J=4.9,1.7Hz,1H),7. 61(dd,J=7.6,1.8Hz,1H),7.22(dd,J=8.4,5.3Hz,1H),7.15(t,J=8.9Hz,1H),6.66(dd,J=7 .5,4.8Hz,1H),5.98–5.88(m,1H),5.73(s,2H),5.44–5.33(m,1H),3.78–3.63(m,2H),3.17 (s,3H),2.39–2.25(m,5H),1.62(d,J=6.8Hz,3H),1.51–1.42(m,1H),1.33(d,J=6.2Hz,3H).

[0731] Example B83: N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-N-methylquinazolin-4-amine

[0732] LCMS: m / z 681 (M+H) + .

[0733] Example B84: N-((R)-1-(3-aminopyrazin-2-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-N-methylquinazolin-4-amine

[0734] LCMS: m / z 682 (M+H) + .

[0735] Example B84 was subjected to chiral separation to provide Examples B84A and B84B: N-((R)-1-(3-aminopyrazin-2-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-7-((S)-6-fluoro-5-methyl-1H-indazol-4-yl )-N-methylquinazolin-4-amine and N-((R)-1-(3-aminopyrazin-2-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-7-((R)-6-fluoro-5-methyl-1H-indazol-4-yl)-N-methylquinazolin-4-amine

[0736] Example B84A

[0737] LCMS: m / z 682 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ13.26(s,1H),8.22(s,1H),7.95(d,J=2.8Hz,1H),7.79(d,J=2.7Hz,1H),7.48(d,J=9.8Hz,1H),7.20(s,1H), 6.66(s,1H),6.53(s,2H),6.09(d,J=6.7Hz,1H),4.25–4.04(m,2H),3.05–2.98(m,2 H),2.09–1.99(m,6H),1.64(d,J=6.7Hz,3H),1.51–1.39(m,7H),0.90–0.81(m,2H).

[0738] Example B84B

[0739] LCMS: m / z 682 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ13.27(s,1H),8.21(s,1H),7.95(d,J=2.6Hz,1H),7.79(d,J=2.6Hz,1H),7.59(s,1H),7.49(d,J=10.2Hz,1H),6.66(s,1H),6 .53(s,2H),6.11–6.03(m,1H),4.21–4.05(m,2H),3.04–2.96(m,2H),2.10 –2.02(m,6H),1.65(d,J=6.8Hz,3H),1.51–1.41(m,7H),0.88–0.82(m,2H).

[0740] Example B85: 2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[0741] LCMS: m / z 741 (M+H) + .

[0742] Example B85 was subjected to chiral separation to provide Examples B85A and B85B: (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-5,7-dihydro- Fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[0743] Example B85A

[0744] LCMS: m / z 741 (M+H) + .

[0745] Example B85B

[0746] LCMS: m / z 741 (M+H) + .

[0747] Example B86: 2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[0748] LCMS: m / z 742 (M+H) + .

[0749] Example B86 was subjected to chiral separation to provide Examples B86A and B86B: (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-5,7-dihydro- Fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[0750] Example B86A

[0751] LCMS: m / z 742 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.30 (s, 2H), 8.11 (s, 1H), 7.95 (d, J = 4Hz, 1H), 7.79 ( d,J=4Hz,1H),7.32(t,J=8Hz,1H),6.48(s,2H),6.03-5.98(m,1H),4.21-4.05 (m,2H),3.38(s,3H),3.10-2.99(m,2H),2.71-2.68(m,1H),2.55-2.53(m,1H) ,2.07-2.03(m,1H),2.00-1.94(m,1H),1.89-1.70(m,3H),1.65-1.43(m,6H).

[0752] Example B86B

[0753] LCMS: m / z 742 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.30(s,2H),8.20(s,1H),7.93(d,J=4Hz,1H),7.77(d,J= 4Hz,1H),7.32(t,J=8Hz,1H),6.56(s,2H),6.06-6.01(m,1H),4.18-4.02(m,2H),3 .41(s,3H),3.10-2.99(m,2H),2.70-2.67(m,1H),2.55-2.53(m,1H),2.06-2.01(m ,1H),1.98-1.92(m,1H),1.87-1.84(m,1H),1.81-1.69(m,2H),1.65-1.43(m,6H).

[0754] Example B87: 2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[0755] LCMS: m / z 652 (M+H) + .

[0756] Example B88: 2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[0757] LCMS: m / z 653 (M+H) + .

[0758] Examples B89A, B89B, B89C and B89D:

[0759] (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((S)-1-((2S,4R)-4-fluoro-1,2-dimethylpyrrolidin-2-yl)ethoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0760] (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((S)-1-((2R,4R)-4-fluoro-1,2-dimethylpyrrolidin-2-yl)ethoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0761] (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((R)-1-((2S,4R)-4-fluoro-1,2-dimethylpyrrolidin-2-yl)ethoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0762] and (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((R)-1-((2R,4R)-4-fluoro-1,2-dimethylpyrrolidin-2-yl)ethoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0763] Example B89A

[0764] LCMS: m / z 681 (M+H) + .

[0765] Example B89B

[0766] LCMS: m / z 681 (M+H) + .

[0767] Example B89C

[0768] LCMS: m / z 681 (M+H) + .

[0769] Example B89D

[0770] LCMS: m / z 681 (M+H) + .

[0771] Example B90 (4R)-2-amino-4-(6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-4-((1-(imidazole[1,2-a]pyrazin-5-yl)ethyl)(methyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0772] LCMS: m / z 748 (M+H) + .

[0773] Example B91 (4R)-2-amino-4-(6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoro-4-((1-(imidazo[1,2-a]pyrazin-5-yl)ethyl)(methyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0774] LCMS: m / z 659 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ9.12(s,1H),8.10(s,3H),7.88(d,J=1.1Hz,1H),7.85(s,1H),7.81(s,1H),7.23(dd,J =8.3,5.3Hz,1H),7.14(t,J=8.9Hz,1H),6.29–6.16(m,1H),3.77(d,J=8.4Hz,1H),3.47–3.38(m,3H),3.23(s, 3H), 2.06 (s, 6H), 1.85 (d, J = 6.9Hz, 3H), 1.20 (s, 3H).

[0775] Example B92 (4R)-2-amino-4-(4-((1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0776] LCMS: m / z 635 (M+H) + . 1 H NMR(400MHz, DMSO-d6)δ8.09(s,2H),7.93(d,J=1.6Hz,1H),7.89(d,J=2.7Hz, 1H),7.73(d,J=2.7Hz,1H),7.20(dd,J=8.4,5.3Hz,1H),7.13(t,J=8.9Hz,1H) ,6.52(s,2H),5.97–5.79(m,1H),3.93–3.76(m,1H),3.68(d,J=8.3Hz,1H),3. 64–3.57(m,1H),3.36(s,3H),2.08(s,6H),1.61(d,J=6.8Hz,3H),1.22(s,3H).

[0777] Example B92 was subjected to chiral separation to provide Examples B92A and B92B: (4R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (4R)-2-amino-4-(4-(((S)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0778] Example B92A

[0779] LCMS: m / z 635 (M+H) + .

[0780] Example B92B

[0781] LCMS: m / z 635 (M+H) + .

[0782] Example B93 (4R)-2-amino-4-(4-((1-(5-amino-1-methyl-1H-pyrazol-4-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0783] LCMS: m / z 637 (M+H) + .

[0784] Example B94 (4R)-2-amino-4-(4-((1-(3-amino-1-methyl-1H-pyrazol-4-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0785] LCMS: m / z 637 (M+H) + .

[0786] Example B95 (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((7-methyl-7-azaspiro[3.5]nonan-2-yl)oxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0787] LCMS: m / z 675 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δ8.13(s,2H),8.02(d,1H),7.97(m,1H),7.60(m,1H),7.23(m,1H),7.16(t,1H),6.67(m,1H),5.9 4(d,1H),5.71(s,2H),5.20(t,1H),3.17(s,3H),2.44–2.21(m,6H),2.18(s,3H),1.86(d,2H),1.63(d,3H),1.59(t,4H).

[0788] Example B96 (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(3-methoxy-3-methylazetidin-1-yl)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0789] LCMS: m / z 621 (M+H) + .

[0790] Example B97 (R)-4-(2-([1,3'-diazetidine]-1'-yl)-4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoroquinazolin-7-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

[0791] LCMS: m / z 632 (M+H) + .

[0792] Example B98A and Example B98B (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(ethyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b] Thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((S)-1-(2-aminopyridin-3-yl)ethyl)(ethyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0793] Example B98A

[0794] LCMS: m / z 737 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.12(s,2H),8.00–7.85(m,2H),7.69(d,J=7.3Hz,1H),7.25(dd,J=8.4,5 .3Hz,1H),7.22–7.12(m,1H),6.68(dd,J=7.3,5.0Hz,1H),6.03(d,J=6.4Hz,1H),5.57(s,2H),4. 22(d,J=18.4Hz,2H),3.65(d,J=6.9Hz,3H),3.11(m,2H),2.74(m,1H),2.09(m,1H),2.01(m,1H), 1.90(m,1H),1.78(d,J=22.8Hz,4H),1.62(t,J=15.0Hz,5H),1.47(m,1H),1.00(t,J=6.8Hz,3H).

[0795] Example B98B

[0796] LCMS: m / z 737 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.12(s,2H),8.02(s,1H),7.96(d,J=3.8Hz,1H),7.69(d,J=7.1Hz ,1H),7.25(m,,1H),7.15(t,J=8.9Hz,1H),6.67(m,1H),6.18(d,J=6.7Hz,1H),5.80(s,2H ),4.19(s,2H),3.87–3.71(m,3H),3.06(d,J=31.6Hz,2H),2.77–2.65(m,1H),2.11(m,12H ),2.02(m,1H),1.92(m,1H),1.78(m,2H),1.61(m,5H),1.47(m,1H),0.91(t,J=6.8Hz,3H).

[0797] Example B99A and Example B99B (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b] Thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((S)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0798] Example B99A

[0799] LCMS: m / z 724 (M+H) + .

[0800] Example B99B

[0801] LCMS: m / z 724 (M+H) + .

[0802] Example B100A and Example B100B (R)-2-amino-4-(4-(((R)-1-(3-aminopyridazin-4-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b ]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((S)-1-(3-aminopyridazin-4-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0803] Example B100A

[0804] LCMS: m / z 724 (M+H) + .

[0805] Example B100B

[0806] LCMS: m / z 724 (M+H) + .

[0807] Example B101 (R)-2-amino-4-(4-((1-(5-amino-1-methyl-1H-pyrazol-4-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0808] LCMS: m / z 726 (M+H) + .

[0809] Example B102 (R)-2-amino-4-(4-((1-(3-amino-1-methyl-1H-pyrazol-4-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0810] LCMS: m / z 726 (M+H) + .

[0811] Example B103 (4R)-4-(4-((1-(1H-indazol-7-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

[0812] LCMS: m / z 747 (M+H) + .

[0813] Example B104 (4R)-4-(4-((1-(1H-indazol-7-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

[0814] LCMS: m / z 658 (M+H) + .

[0815] Example B105 (4R)-4-(4-((1-(1H-pyrazolo[3,4-c]pyridin-7-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

[0816] LCMS: m / z 748 (M+H) + .

[0817] Example B106 (4R)-4-(4-((1-(1H-pyrazolo[3,4-c]pyridin-7-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

[0818] LCMS: m / z 659 (M+H) + .

[0819] Example B107 (4R)-4-(4-((1-(3H-imidazole[4,5-c]pyridin-4-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

[0820] LCMS: m / z 748 (M+H) + .

[0821] Example B108 (4R)-4-(4-((1-(3H-imidazo[4,5-c]pyridin-4-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

[0822] LCMS: m / z 659 (M+H) + .

[0823] Example B109A and Example B109B: (R)-2-amino-4-(6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-4-(methyl((R)-1-(pyridazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[ b]thiophene-3-carbonitrile and (R)-2-amino-4-(6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidino]-7a'(5'H)-yl)methoxy)-8-fluoro-4-(methyl((S)-1-(pyridazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0824] Example B109A

[0825] LCMS: m / z 709 (M+H) + .

[0826] Example B109B

[0827] LCMS: m / z 709 (M+H) + .

[0828] Example B110A and Example B110B (R)-2-amino-4-(6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-3-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b ]thiophene-3-carbonitrile and (R)-2-amino-4-(6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-4-(methyl((S)-1-(pyrazin-3-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0829] LCMS: m / z 709 (M+H) + .

[0830] Example B111 (4R)-2-amino-4-(6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-4-((1-(5-methoxypyridin-3-yl)ethyl)(methyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0831] LCMS: m / z 738 (M+H) + . 1 H NMR(600MHz,DMSO-d6)δ11.05(s,1H),8.31(s,2H),8.14(d,2H),7.49(d,1H),7.34–7.04(m,2H),6.11(d,1H),4.64–4.55(m,2H),3.87(d,3H), 3.76(s,1H),3.70–3.60(m,1H),3.44(m,1H),3.28(d,3H),3.13(m,1H) ,2.43(s,2H),2.31–2.09(m,3H),2.09–1.90(m,2H),1.89–1.64(m,4H).

[0832] Example B112 (4R)-2-amino-4-(6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-4-((1-(2-methoxypyridin-3-yl)ethyl)(methyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0833] LCMS: m / z 738 (M+H) + . 1 H NMR(600MHz,DMSO-d6)δ10.94(s,1H),8.14(m,3H),8.00(d,1H),7.85(t,1H),7.27(m,1H),7.17(m,1H),7.07(m,1H),5.91(m,1H),4.67–4.54(m ,2H),3.78(d,1H),3.64(d,3H),3.44(d,1H),3.23–2.93(m,4H),2.47–2 .34(m,1H),2.19(m,3H),2.08–1.91(m,2H),1.85(m,2H),1.75(m,,3H).

[0834] Example B113 2-(1-((7-((R)-2-amino-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-4-yl)(methyl)amino)ethyl)-N,N-dimethylisonicotinamide

[0835] LCMS: m / z 779 (M+H) + .

[0836] Example B114 2-(1-((7-((R)-2-amino-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-4-yl)(methyl)amino)ethyl)-N,N-dimethylisonicotinamide

[0837] LCMS: m / z 690 (M+H) + .

[0838] Example B115 2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)thiophene[2,3-b]pyridine-3-carbonitrile

[0839] LCMS: m / z 706 (M+H) + .

[0840] Example B115 was subjected to chiral separation to provide Example B115A and Example B115B: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl) Thiopheno[2,3-b]pyridine-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)thiophene[2,3-b]pyridine-3-carbonitrile

[0841] Example B115A

[0842] LCMS: m / z 706 (M+H) + . 1 H NMR(600MHz,DMSO-d6)δ8.34(d,J=4Hz,1H),8.24(s,2H),8.07(s,1H),7.97-7.95(m,1H),7.64( d,J=8Hz,1H),7.26(d,J=4Hz,1H),6.68-6.64(m,1H),6.02-5.97(m,1H),5.85(s,2H),4.26-4.16 (m,2H),3.19(s,3H),3.11-3.01(m,2H),2.75-2.67(m,1H),2.56-2.55(m,1H),2.12-2.07(m,1H) ,2.03-1.98(m,1H),1.93-1.89(m,1H),1.81-1.75(m,2H),1.64-1.55(m,5H),1.51-1.48(m,1H).

[0843] Example B115B

[0844] LCMS: m / z 706 (M+H) + . 1 H NMR (600MHz, DMSO-d6) δ8.34(d,J=4Hz,1H),8.24(s,2H),8.13(s,1H),7.97-7.95(m,1H),7.65(d,J= 8Hz,1H),7.27(d,J=4Hz,1H),6.68-6.65(m,1H),6.10-6.05(m,1H),5.91(s,2H),4.24-4.14(m,2H),3 .17(s,3H),3.13-3.08(m,1H),3.04-2.99(m,1H),2.73-2.67(m,1H),2.56-2.55(m,1H),2.11-2.06(m ,1H),2.03-1.98(m,1H),1.92-1.89(m,1H),1.83-1.71(m,2H),1.63-1.53(m,5H),1.50-1.44(m,1H).

[0845] Example B116 2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)thiophene[2,3-b]pyridine-3-carbonitrile

[0846] LCMS: m / z 707 (M+H) + .

[0847] Examples B117A and B117B (S)-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-5-ethynyl-6 -fluoronaphthalen-2-ol and (R)-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0848] Example B117A

[0849] LCMS: m / z 718 (M+H) + .

[0850] Example B117B

[0851] LCMS: m / z 718 (M+H) + .

[0852] Example B118 N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-7-(5,7-difluoro-1H-indol-3-yl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy-8-fluoro-N-methylquinazolin-4-amine

[0853] LCMS: m / z 684 (M+H) + . 1 H NMR (600MHz, DMSO-d6) δ12.32(s,1H),8.09(s,1H),7.97(d,J=8Hz,1H),7.81(s,1H),7.64(d,J=8Hz, 1H),7.11-7.05(m,1H),6.92(t,J=12Hz,1H),6.68-6.65(m,1H),6.04-5.99(m,1H),5.90(s,2H),4.2 5-4.15(m,2H),3.19(s,3H),3.13-3.08(m,1H),2.73-2.67(m,1H),2.56-2.55(m,1H),2.10-2.06(m, 1H),2.03-1.97(m,1H),1.92-1.88(m,1H),1.84-1.71(m,2H),1.65-1.53(m,5H),1.50-1.44(m,1H).

[0854] Example B119 N-((R)-1-(3-aminopyrazin-2-yl)ethyl)-6-chloro-7-(5,7-difluoro-1H-indol-3-yl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0855] LCMS: m / z 685 (M+H)+ .

[0856] Example B120 4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0857] LCMS: m / z 708 (M+H) + .

[0858] Example B121 N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-7-(8-chloro-7-fluoronaphthalen-1-yl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0859] LCMS: m / z 711 (M+H) + . 1 H NMR (600MHz, DMSO-d6) δ8.43(d,J=12.6Hz,2H),8.33–8.17(m,3H),8.02(s,1H),7.75(dd,J=13.7,8.1Hz,3H),7.66–7.56(m,1H),7.41(m ,1H),4.19–4.09(m,2H),3.92(m,1H),3.00(d,J=25.6Hz,2H),2.70(m,1H),2.26(m,J=30.9Hz,4H),2.03–1.60(m,8H),1.60–0.97(m,3H).

[0860] Example B122 N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-7-(2,3-dichlorophenyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[0861] LCMS: m / z 677 (M+H) + .

[0862] Example B123 2-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-3-(trifluoromethyl)benzonitrile

[0863] LCMS: m / z 702 (M+H) + .

[0864] Example B124 2-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-3-(trifluoromethyl)benzonitrile

[0865] LCMS: m / z 703 (M+H) + .

[0866] Example B125 N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methyl-7-(4-methyl-1-(oxetane-3-yl)-1H-pyrazol-5-yl)quinazolin-4-amine

[0867] LCMS: m / z 669 (M+H) + .

[0868] Example B126 N-((R)-1-(3-aminopyrazin-2-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methyl-7-(4-methyl-1-(oxetane-3-yl)-1H-pyrazol-5-yl)quinazolin-4-amine

[0869] LCMS: m / z 670 (M+H) + .

[0870] Example B127 N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methyl-7-(4-methyl-1-(oxetane-3-yl)-1H-pyrazol-3-yl)quinazolin-4-amine

[0871] LCMS: m / z 669 (M+H) + .

[0872] Example B128 N-((R)-1-(3-aminopyrazin-2-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methyl-7-(4-methyl-1-(oxetane-3-yl)-1H-pyrazol-3-yl)quinazolin-4-amine

[0873] LCMS: m / z 670 (M+H) + .

[0874] Example B129 1-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)isoquinoline-8-carbonitrile

[0875] LCMS: m / z 685 (M+H) + .

[0876] Example B130 1-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)isoquinoline-8-carbonitrile

[0877] LCMS: m / z 686 (M+H) + .

[0878] Example B131 N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-7-(5-fluoroquinolin-8-yl)-N-methylquinazolin-4-amine

[0879] LCMS: m / z 678 (M+H) + .

[0880] Example B131 was subjected to chiral separation to provide Example B131A and Example B131B: (R)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-7-(5-fluoroquinoline- 8-yl)-N-methylquinazolin-4-amine and (S)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-7-(5-fluoroquinolin-8-yl)-N-methylquinazolin-4-amine

[0881] Example B131A

[0882] LCMS: m / z 678 (M+H) + . 1H NMR (600MHz, DMSO-d6) δ8.92(d,J=8Hz,1H),8.62(d,J=12Hz,1H),8.10(s,1H),7.97(d,J=4Hz,1H),7.84-7.80 (m,1H),7.73-7.69(m,1H),7.66-7.62(m,2H),6.68-6.65(m,1H),6.07-6.02(m,1H),5.92(s,2H),4.24-4.14( m,2H),3.21(s,3H),3.11-3.07(m,1H),3.03-2.98(m,1H),2.72-2.67(m,1H),2.55-2.53(m,1H),2.10-2.05(m ,1H),2.03-1.97(m,1H),1.91-1.88(d,J=12Hz,1H),1.83-1.70(m,2H),1.65-1.52(m,5H),1.49-1.43(m,1H).

[0883] Example B131B

[0884] LCMS: m / z 678 (M+H) + . 1 H NMR (600MHz, DMSO-d6) δ8.93(d,J=8Hz,1H),8.62(d,J=8Hz,1H),8.08(s,1H),7.97(d,J=4Hz,1H),7.84-7.80 (m,1H),7.73-7.69(m,1H),7.66-7.62(m,2H),6.68-6.65(m,1H),6.04-5.99(m,1H),5.87(s,2H),4.24-4.14( m,2H),3.21(s,3H),3.12-3.07(m,1H),3.03-2.98(m,1H),2.73-2.67(m,1H),2.56-2.53(m,1H),2.10-2.06(m ,1H),2.03-1.97(m,1H),1.91-1.88(d,J=12Hz,1H),1.84-1.71(m,2H),1.64-1.52(m,5H),1.49-1.43(m,1H).

[0885] Example B132 N-((R)-1-(3-aminopyrazin-2-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-7-(5-fluoroquinolin-8-yl)-N-methylquinazolin-4-amine

[0886] LCMS: m / z 679 (M+H) + .

[0887] Example B133 N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-7-(5-ethynylisoquinolin-4-yl)-8-fluoro-N-methylquinazolin-4-amine

[0888] LCMS: m / z 684 (M+H) + .

[0889] Example B134 N-((R)-1-(3-aminopyrazin-2-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-7-(5-ethynylisoquinolin-4-yl)-8-fluoro-N-methylquinazolin-4-amine

[0890] LCMS: m / z 685 (M+H) + .

[0891] Example B135 4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)isoquinoline-5-carbonitrile

[0892] LCMS: m / z 685 (M+H) + .

[0893] Example B136 4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)isoquinoline-5-carbonitrile

[0894] LCMS: m / z 686 (M+H) + .

[0895] Example B137 2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[0896] LCMS: m / z 653 (M+H) + .

[0897] Example B137 was subjected to chiral separation to provide Examples B137A and B137B: (S)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[0898] Example B137A

[0899] LCMS: m / z 653 (M+H) + .

[0900] Example B137B

[0901] LCMS: m / z 653 (M+H) + .

[0902] Example B138 2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[0903] LCMS: m / z 653 (M+H) + .

[0904] Example B138 was subjected to chiral separation to provide Examples B138A and B138B: (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile.

[0905] Example B138A

[0906] LCMS: m / z 653 (M+H) + .

[0907] Example B138B

[0908] LCMS: m / z 653 (M+H) + .

[0909] Example B139 2-(1-((7-((R)-2-amino-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-4-yl)(methyl)amino)ethyl)-N,N-dimethylisonicotinamide

[0910] LCMS: m / z 690 (M+H) + .

[0911] Example B140 5-(1-((7-((R)-2-amino-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-4-yl)(methyl)amino)ethyl)-N,N,1-trimethyl-1H-pyrazole-3-carboxamide

[0912] LCMS: m / z 693 (M+H) + .

[0913] Example B141 3-(1-((7-((R)-2-amino-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinazolin-4-yl)(methyl)amino)ethyl)-N,N,1-trimethyl-1H-pyrazole-5-carboxamide

[0914] LCMS: m / z 693 (M+H) + .

[0915] Example B142 (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(3)cyclobutyloxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0916] LCMS: m / z 635 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δ8.15(s,2H),8.04(d,1H),7.98(m,1H),7.62(m,1H),7.24(m,1H),7.16(t,1H),6.68(m,1H), 5.97(d,1H),5.71(s,2H),4.96(t,1H),3.17(d,3H),2.81–2.60(m,2H),2.44–2.22(s,6H),2.11(s,2H),1.63(d,3H).

[0917] Example B143 (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((trans)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0918] LCMS: m / z 652 (M+H) + .

[0919] Example B143 was subjected to chiral separation to provide the isomers Example B143A and Example B143B: (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0920] Example B143A

[0921] LCMS: m / z 652 (M+H) + .

[0922] Example B143B

[0923] LCMS: m / z 652 (M+H) + .

[0924] Example B144 (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((cis)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0925] LCMS: m / z 652 (M+H) + .

[0926] Example B144 was subjected to chiral separation to provide the isomers Example B144A and Example B144B: (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0927] Example B144A

[0928] LCMS: m / z 652 (M+H) + .

[0929] Example B144B

[0930] LCMS: m / z 652 (M+H) + .

[0931] Example B145 (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((trans)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0932] LCMS: m / z 652 (M+H) + .

[0933] Example B145 was subjected to chiral resolution to provide the isomers Example B145A and Example B145B: (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0934] Example B145A

[0935] LCMS: m / z 652 (M+H) + .

[0936] Example B145B

[0937] LCMS: m / z 652 (M+H) + .

[0938] Example B146 (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((cis)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0939] LCMS: m / z 652 (M+H) + .

[0940] Example B146 was subjected to chiral resolution to provide the isomers Example B146A and Example B146B: (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0941] Example B146A

[0942] LCMS: m / z 652 (M+H) + .

[0943] Example B146B

[0944] LCMS: m / z 652 (M+H) + .

[0945] Example B147 (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((trans)-4-methoxy-1-methylpyrrolin-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0946] LCMS: m / z 652 (M+H) + .

[0947] Example B148 (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((cis)-4-methoxy-1-methylpyrrolin-3-yl)oxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0948] LCMS: m / z 652 (M+H) + .

[0949] Example B149A and Example B149B: (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((2S,4R)-4-fluoro-1,2-dimethylpyrrolin-2-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((2R,4R)-4-fluoro-1,2-dimethylpyrrolin-2-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0950] Example B149A

[0951] LCMS: m / z 667 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.13(t,J=22.4Hz,3H),7.93(d,J=2.3Hz,1H),7.79(t,J=11.3Hz,1H ),7.23(dd,J=8.3,5.3Hz,1H),7.15(t,J=8.9Hz,1H),6.51(d,J=23.3Hz,2H),6.05–5.96(m, 1H),5.16(m,1H),4.23(m,1H),4.17–4.05(m,1H),3.41(s,3H),3.01(m,m1H),2.91–2.77(m, 1H),2.26(d,J=6.7Hz,3H),2.20–1.94(m,2H),1.65(d,J=6.7Hz,4H),0.99(d,J=12.0Hz,3H).

[0952] Example B149A

[0953] LCMS: m / z 667 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.13(d,J=13.0Hz,3H),7.94(d,J=2.6Hz,1H),7.75(d,J=2 .6Hz,1H),7.24(dd,J=8.4,5.3Hz,1H),7.16(t,J=8.9Hz,1H),6.54(s,2H),5.96(q, J=6.8Hz,1H),5.20(d,J=56.0Hz,1H),4.26(m,1H),4.01(m,1H),3.47(s,3H),3.19 (m,1H),2.87(m,1H),2.31(m,4H),1.82(m,1H),1.65(d,J=6.8Hz,3H),1.14(s,3H).

[0954] Example B150 (4R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-((4,4-difluoro-1,2-dimethylpyrrolin-2-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0955] LCMS: m / z 685 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δ8.09(dd,J=29.2,8.9Hz,3H),7.98–7.91(m,1H),7.78(m,1H) ,7.24(dd,J=8.4,5.3Hz,1H),7.16(t,J=8.9Hz,1H),6.49(m,2H),6.01–5.93(m,1H), 4.32(m,1H),4.12(m,1H),3.45(s,,3H),3.31–3.22(m,1H),3.04(m,1H),2.41(m,1H) ,2.29(t,J=24.7Hz,3H),2.15(m,,1H),1.66(d,J=6.7Hz,3H),1.11(d,J=8.4Hz,3H).

[0956] Examples B151A and B151B (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,Z)-4-(fluoromethylenyl)-1-methylpyrrolin-2-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,Z)-4-(fluoromethylenyl)-1-methylpyrrolin-2-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0957] LCMS: m / z 665 (M+H) + .

[0958] Examples B152A and B152B (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,Z)-4-(fluoromethylenyl)-1-methylpyrrolin-2-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,Z)-4-(fluoromethylenyl)-1-methylpyrrolin-2-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0959] LCMS: m / z 666 (M+H) + .

[0960] Examples B153A and B153B (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,Z)-4-(fluoromethylenyl)-1-methylpyrrolin-2-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,Z)-4-(fluoromethylenyl)-1-methylpyrrolin-2-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0961] LCMS: m / z 666 (M+H) + .

[0962] Example B154 (4R)-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((S)-4-(difluoromethyl)-1-methylpyrrolidin-2-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0963] LCMS: m / z 686 (M+H) + .

[0964] Example B155 (4R)-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((S)-4-(difluoromethyl)-1-methylpyrrolidin-2-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0965] LCMS: m / z 686 (M+H) + .

[0966] Examples B156A and B156B: (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-4-(difluoromethyl)-1,3-dimethylpiperidin-3-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-4-(difluoromethyl)-1,3-dimethylpiperidin-3-yl)methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0967] Example B156A

[0968] LCMS: m / z 714 (M+H) + .

[0969] Example B156B

[0970] LCMS: m / z 714 (M+H) + .

[0971] Examples B157A and B157B: (S)-2-Amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-4-(difluoromethyl)-1,3-dimethylpiperidin-3-yl)methoxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile and (S)-2-Amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-4-(difluoromethyl)-1,3-dimethylpiperidin-3-yl)methoxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[0972] Example B157A

[0973] LCMS: m / z 732 (M+H) + .

[0974] Example B157B

[0975] LCMS: m / z 732 (M+H) + .

[0976] Examples B158A and B158B: (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-4-(difluoromethyl)-1,3-dimethylpiperidin-3-yl)methoxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-4-(difluoromethyl)-1,3-dimethylpiperidin-3-yl)methoxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[0977] Example B158A

[0978] LCMS: m / z 732 (M+H) + .

[0979] Example B158B

[0980] LCMS: m / z 732 (M+H) + .

[0981] Examples B159A, 159B, 159C, and B159D:

[0982] (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,E)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0983] (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,Z)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[0984] (R)-2-Amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((R,E)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0985] and (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((R,Z)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[0986] Example B159A

[0987] LCMS: m / z 693 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.12(s,2H),8.02(s,1H),7.97(d,J=4Hz,1H),7.65(d,J=8Hz,1H) ,7.24-7.20(m,1H),7.14(t,J=8Hz,1H),6.85(s,0.5H),6.68-6.64(m,1.5H),5.98-5.91( m,3H),4.53(d,J=12Hz,1H),4.35(d,J=12Hz,1H),3.20(s,3H),2.69-2.66(m,2H),2.51(s ,1H),2.23-2.20(m,1H),2.15(s,3H),1.93-1.83(m,2H),1.65(d,J=8Hz,3H),1.11(s,3H).

[0988] Example B159B

[0989] LCMS: m / z 693 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.12(s,2H),8.00(s,1H),7.97(d,J=8Hz,1H),7.65(d,J=8Hz,1H) ,7.24-7.20(m,1H),7.15(t,J=8Hz,1H),6.73(s,0.5H),6.68-6.65(m,1H),6.51(s,0.5H), 5.97-5.92(m,1H),5.82(s,2H),4.65(d,J=12Hz,1H),4.34(d,J=12Hz,1H),3.17(s,3H),2 .51(s,1H),2.21-2.15(m,4H),2.10-1.98(m,4H),1.64(d,J=8Hz,3H),1.32(d,J=4Hz,3H).

[0990] Example B159C

[0991] LCMS: m / z 693 (M+H) + .

[0992] Example B159D

[0993] LCMS: m / z 693 (M+H) + .

[0994] Examples B160A, 160B, 160C, and B160D:

[0995] (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,E)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile,

[0996] (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,Z)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile,

[0997] (S)-2-Amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((R,E)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[0998] and (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((R,Z)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[0999] Example B160A

[1000] LCMS: m / z 711 (M+H) + .

[1001] Example B160B

[1002] LCMS: m / z 711 (M+H) + .

[1003] Example B160C

[1004] LCMS: m / z 711 (M+H) + .

[1005] Example B160D

[1006] LCMS: m / z 711 (M+H) + .

[1007] Examples B161A, 161B, 161C, and B161D:

[1008] (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,E)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1009] (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,Z)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1010] (R)-2-Amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((R,E)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1011] and (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((R,Z)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1012] Example B161A

[1013] LCMS: m / z 694 (M+H) + .

[1014] Example B161B

[1015] LCMS: m / z 694 (M+H) + .

[1016] Example B161C

[1017] LCMS: m / z 694 (M+H) + .

[1018] Example B161D

[1019] LCMS: m / z 694 (M+H) + .

[1020] Examples B162A, 162B, 162C, and B162D:

[1021] (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,E)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile,

[1022] (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,Z)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile,

[1023] (S)-2-Amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((R,E)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1024] and (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((R,Z)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1025] Example B162A

[1026] LCMS: m / z 712 (M+H) + .

[1027] Example B162B

[1028] LCMS: m / z 712 (M+H) + .

[1029] Example B162C

[1030] LCMS: m / z 712 (M+H) + .

[1031] Example B162D

[1032] LCMS: m / z 712 (M+H) + .

[1033] Examples B163A, 163B, 163C, and B163D:

[1034] (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,E)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1035] (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,Z)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1036] (R)-2-Amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((R,E)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1037] and (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((R,Z)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1038] Example B163A

[1039] LCMS: m / z 694 (M+H) + .

[1040] Example B163B

[1041] LCMS: m / z 694 (M+H) + .

[1042] Example B163C

[1043] LCMS: m / z 694 (M+H) + .

[1044] Example B163D

[1045] LCMS: m / z 694 (M+H) + .

[1046] Examples B164A, 164B, 164C, and B164D:

[1047] (S)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,E)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile,

[1048] (S)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((S,Z)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile,

[1049] (S)-2-Amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((R,E)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1050] and (S)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((R,Z)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1051] Example B164A

[1052] LCMS: m / z 712 (M+H) + .

[1053] Example B164B

[1054] LCMS: m / z 712 (M+H) + .

[1055] Example B164C

[1056] LCMS: m / z 712 (M+H) + .

[1057] Example B164D

[1058] LCMS: m / z 712 (M+H) + .

[1059] Examples B165A, B165B, B165C and B165D:

[1060] (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-1,1-difluoro-6-methyl-6-azaspiro[2.5]octan-4-yl))methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1061] (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4R)-1,1-difluoro-6-methyl-6-azaspiro[2.5]octan-4-yl))methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1062] (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4S)-1,1-difluoro-6-methyl-6-azaspiro[2.5]octan-4-yl))methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1063] and (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-1,1-difluoro-6-methyl-6-azaspiro[2.5]octan-4-yl))methoxy)-8-fluoroquinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1064] Example B165A

[1065] LCMS: m / z 712 (M+H) + .

[1066] Example B165B

[1067] LCMS: m / z 712 (M+H) + .

[1068] Example B165C

[1069] LCMS: m / z 712 (M+H) + .

[1070] Example B165D

[1071] LCMS: m / z 712 (M+H) +

[1072] Examples B166A, B166B, B166C and B166D:

[1073] (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3S,6S,8aS)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1074] (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3S,6S,8aR)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1075] (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3S,6R,8aS)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1076] and (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3S,6R,8aR)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1077] Example B166A

[1078] LCMS: m / z 692 (M+H) +

[1079] Example B166B

[1080] LCMS: m / z 692 (M+H) +

[1081] Example B166C

[1082] LCMS: m / z 692 (M+H) +

[1083] Example B166D

[1084] LCMS: m / z 692 (M+H) +

[1085] Examples B167A, B167B, B167C and B167D:

[1086] (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3R,6S,8aS)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1087] (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3R,6S,8aR)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1088] (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3R,6R,8aS)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1089] and (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3R,6R,8aR)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1090] Example B167A

[1091] LCMS: m / z 692 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.11(d,J=19.3Hz,3H),7.94(d,J=2.6Hz,1H),7.77(d,J=2.6Hz,1H),7.24(dd ,J=8.4,5.3Hz,1H),7.20–7.09(m,1H),6.43(s,2H),5.99(q,J=6.7Hz,1H),4.33(m,1H),4.24(m,1H), 3.90(m,1H),3.61(m,1H),3.43(d,J=13.9Hz,4H),2.91(d,J=10.9Hz,1H),2.62(s,1H),2.34(m,1H),2 .16(s,1H),1.93–1.76(m,1H),1.65(d,J=6.8Hz,4H),1.56(m,1H),1.29(m,1H),1.17(d,J=6.6Hz,3H).

[1092] Example B167B

[1093] LCMS: m / z 692 (M+H) + .

[1094] Example B167C

[1095] LCMS: m / z 692 (M+H) + .

[1096] Example B167D

[1097] LCMS: m / z 692 (M+H) + .

[1098] Examples B168A, B168B, B168C and B168D:

[1099] (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3S,6S,8aS)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1100] (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3S,6S,8aR)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1101] (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3S,6R,8aS)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1102] and (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3S,6R,8aR)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1103] Example B168A

[1104] LCMS: m / z 692 (M+H) + .

[1105] Example B168B

[1106] LCMS: m / z 692 (M+H) + .

[1107] Example B168C

[1108] LCMS: m / z 692 (M+H) + .

[1109] Example B168D

[1110] LCMS: m / z 692 (M+H) + .

[1111] Examples B169A, B169B, B169C and B169D:

[1112] (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3R,6S,8aS)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1113] (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3R,6S,8aR)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1114] (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3R,6R,8aS)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile,

[1115] and (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((3R,6R,8aR)-3-methylhexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-6-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1116] Example B169A

[1117] LCMS: m / z 692 (M+H) + .

[1118] Example B169B

[1119] LCMS: m / z 692 (M+H) + .

[1120] Example B169C

[1121] LCMS: m / z 692 (M+H) + .

[1122] Example B169D

[1123] LCMS: m / z 692 (M+H) + .

[1124] Example B170 (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-((4-(fluoromethylenyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1125] LCMS: m / z 737 (M+H) + .

[1126] Example B171 (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-((4-(fluoromethylenyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1127] LCMS: m / z 738 (M+H) + .

[1128] Example B172 (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-((4-(fluoromethylenyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1129] LCMS: m / z 720 (M+H) + .

[1130] Example B173 (S)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-((1-((4-(fluoromethylenyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1131] LCMS: m / z 738 (M+H) + .

[1132] Example B174 1-(4-(((R)-1-(2-2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-8-ethyl-7-fluoroisoquinolin-3(2H)-one

[1133] LCMS: m / z 722 (M+H) + .

[1134] Example B175 1-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-8-ethyl-7-fluoroisoquinolin-3(2H)-one

[1135] LCMS: m / z 723 (M+H) + .

[1136] Example B176 1-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-8-ethyl-7-fluoroisoquinolin-3(2H)-one

[1137] LCMS: m / z 723 (M+H) + .

[1138] Example B177 1-(4-(((R)-1-(2-2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-8-ethynyl-7-fluoroisoquinolin-3(2H)-one

[1139] LCMS: m / z 718 (M+H) + .

[1140] Example B178 1-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-8-ethynyl-7-fluoroisoquinolin-3(2H)-one

[1141] LCMS: m / z 719 (M+H) + .

[1142] Example B179 1-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-8-ethynyl-7-fluoroisoquinolin-3(2H)-one

[1143] LCMS: m / z 719 (M+H) + .

[1144] Examples B180A and B180B (S)-2-amino-4-(6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidino]-7a'(5'H)-yl)methoxy)-8-fluoro-4-(methyl((R)-1-(pyridazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b] Thiophene-3-carbonitrile and (S)-2-amino-4-(6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-4-(methyl((S)-1-(pyridazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1145] Example B180A

[1146] LCMS: m / z 727 (M+H) + .

[1147] Example B180B

[1148] LCMS: m / z 727 (M+H) + .

[1149] Example B181A and Example 181B (S)-2-amino-4-(6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-3-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b ]thiophene-3-carbonitrile and (S)-2-amino-4-(6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-4-(methyl((S)-1-(pyrazin-3-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1150] Example B181A

[1151] LCMS: m / z 727 (M+H) + .

[1152] Example B181B

[1153] LCMS: m / z 727 (M+H) + .

[1154] Example B182: (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((trans)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1155] LCMS: m / z 669 (M+H) + .

[1156] Example B182 was subjected to chiral separation to provide the isomers Example B182A and Example B182B: (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1157] Example B182A

[1158] LCMS: m / z 669 (M+H) + .

[1159] Example B182B

[1160] LCMS: m / z 669 (M+H) + .

[1161] Example B183: (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((cis)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1162] LCMS: m / z 651 (M+H) + .

[1163] Example B183 was subjected to chiral separation to provide the isomers Example B183A and Example B183B: (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1164] Example B183A

[1165] LCMS: m / z 669 (M+H) + .

[1166] Example B183B

[1167] LCMS: m / z 669 (M+H) + .

[1168] Example B184 (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((trans)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1169] LCMS: m / z 670 (M+H) + .

[1170] Example B184 was subjected to chiral separation to provide the isomers Example B184A and Example B184B: (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1171] Example B184A

[1172] LCMS: m / z 670 (M+H) + .

[1173] Example B184B

[1174] LCMS: m / z 670 (M+H) + .

[1175] Example B185 (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((cis)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1176] LCMS: m / z 670 (M+H) + .

[1177] Example B185 was subjected to chiral separation to provide the isomers Example B185A and Example B185B: (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1178] Example B185A

[1179] LCMS: m / z 670 (M+H) + .

[1180] Example B185B

[1181] LCMS: m / z 670 (M+H) + .

[1182] Example B186 (S)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((trans)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1183] LCMS: m / z 670 (M+H) + .

[1184] Example B186 was subjected to chiral separation to provide the isomers Example B186A and Example B186B: (S)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1185] Example B186A

[1186] LCMS: m / z 670 (M+H) + .

[1187] Example B186B

[1188] LCMS: m / z 670 (M+H) + .

[1189] Example B187 (S)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((cis)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1190] LCMS: m / z 670 (M+H) + .

[1191] Example B187 was subjected to chiral separation to provide the isomers Example B187A and Example B187B: (S)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3S,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-2-(((3R,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoroquinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1192] Example B187A

[1193] LCMS: m / z 670 (M+H) + .

[1194] Example B187B

[1195] LCMS: m / z 670 (M+H) + .

[1196] Example B188 (R)-2-amino-4-(6-chloro-2-(((trans)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1197] LCMS: m / z 637 (M+H) + .

[1198] Example B188 was subjected to chiral separation to provide the isomers Example B188A and Example B188B: (R)-2-amino-4-(6-chloro-2-(((3S,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(6-chloro-2-(((3R,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1199] Example B188A

[1200] LCMS: m / z 637 (M+H) + .

[1201] Example B188B

[1202] LCMS: m / z 637 (M+H) + .

[1203] Example B189 (R)-2-amino-4-(6-chloro-2-(((cis)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1204] LCMS: m / z 637 (M+H) + .

[1205] Example B189 was subjected to chiral separation to provide the isomers Example B189A and Example B189B: (R)-2-amino-4-(6-chloro-2-(((3S,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and (R)-2-amino-4-(6-chloro-2-(((3R,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1206] Example B189A

[1207] LCMS: m / z 637 (M+H) + .

[1208] Example B189B

[1209] LCMS: m / z 637 (M+H) + .

[1210] Example B190 (S)-2-amino-4-(6-chloro-2-(((trans)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1211] LCMS: m / z 655 (M+H) + .

[1212] Example B190 was subjected to chiral separation to provide the isomers Example B190A and Example B190B: (S)-2-amino-4-(6-chloro-2-(((3S,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile and (S)-2-amino-4-(6-chloro-2-(((3R,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1213] Example B190A

[1214] LCMS: m / z 655 (M+H) + .

[1215] Example B190B

[1216] LCMS: m / z 655 (M+H) + .

[1217] Example B191 (S)-2-amino-4-(6-chloro-2-(((cis)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1218] LCMS: m / z 655 (M+H) + .

[1219] Example B191 was subjected to chiral separation to provide the isomers Example B191A and Example B191B: (S)-2-amino-4-(6-chloro-2-(((3S,4S)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile and (S)-2-amino-4-(6-chloro-2-(((3R,4R)-4-(dimethylamino)tetrahydrofuran-3-yl)oxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1220] Example B191A

[1221] LCMS: m / z 655 (M+H) + .

[1222] Example B191B

[1223] LCMS: m / z 655 (M+H) + .

[1224] Example B192 (R)-2-amino-4-(6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1225] LCMS: m / z 620 (M+H) + .

[1226] Example B193 (S)-2-amino-4-(6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1227] LCMS: m / z 620 (M+H) + .

[1228] Example B194: (R)-2-amino-4-(6-chloro-8-fluoro-2-(((2S,4R)-4-(4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1229] LCMS: m / z 639 (M+H) + .

[1230] Example B195: (S)-2-amino-4-(6-chloro-8-fluoro-2-(((2S,4R)-4-(4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1231] LCMS: m / z 657 (M+H) + .

[1232] Example B196: (R)-2-amino-4-(6-chloro-8-fluoro-2-((S)-1-((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)ethoxy)-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1233] LCMS: m / z 653 (M+H) + .

[1234] Example B197: (S)-2-amino-4-(6-chloro-8-fluoro-2-((S)-1-((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)ethoxy)-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1235] LCMS: m / z 671 (M+H) + .

[1236] Example B198: (R)-2-amino-4-(6-chloro-2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1237] LCMS: m / z 635 (M+H) + .

[1238] Example B199: (S)-2-amino-4-(6-chloro-2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1239] LCMS: m / z 635 (M+H) + .

[1240] Example B200: (R)-2-amino-4-(6-chloro-2-(((3S,4S)-4-(difluoromethyl)-1,3-dimethylpiperidin-3-yl)methoxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1241] LCMS: m / z 699 (M+H) + .

[1242] Example B201: (S)-2-amino-4-(6-chloro-2-(((3S,4S)-4-(difluoromethyl)-1,3-dimethylpiperidin-3-yl)methoxy)-8-fluoro-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1243] LCMS: m / z 717 (M+H) + .

[1244] Example B202: (R)-2-amino-4-(6-chloro-8-fluoro-2-(((S,E)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1245] LCMS: m / z 679 (M+H) + .

[1246] Example B203: (S)-2-amino-4-(6-chloro-8-fluoro-2-(((S,E)-4-(fluoromethylenyl)-1,3-dimethylpiperidin-3-yl)methoxy)-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1247] LCMS: m / z 698 (M+H) + .

[1248] Example B204: (R)-2-amino-4-(6-chloro-8-fluoro-2-((1-((4-(fluoromethylenyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1249] LCMS: m / z 705 (M+H) + .

[1250] Example B205: (S)-2-amino-4-(6-chloro-8-fluoro-2-((1-((4-(fluoromethylenyl)piperidin-1-yl)methyl)cyclopropyl)methoxy)-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1251] LCMS: m / z 705 (M+H) + .

[1252] Example B206: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1253] LCMS: m / z 679 (M+H) + .

[1254] Example B207: (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1255] LCMS: m / z 697 (M+H) + .

[1256] Example B208: (R)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1257] LCMS: m / z 680 (M+H) + .

[1258] Example B209: (S)-2-amino-4-(4-(((R)-1-(3-aminopyrazin-2-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1259] LCMS: m / z 698 (M+H) + .

[1260] Example B210: (R)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1261] LCMS: m / z 680 (M+H) + .

[1262] Example B211: (S)-2-amino-4-(4-(((R)-1-(4-aminopyrimidin-5-yl)ethyl)(methyl)amino)-6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1263] LCMS: m / z 698 (M+H) + .

[1264] Example B212: (R)-2-amino-4-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile

[1265] LCMS: m / z 665 (M+H) + .

[1266] Example B213: (R)-2-amino-4-(6-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-bis-fused pyrrolidin-7a(5H)-yl)methoxy)-4-(methyl((R)-1-(pyrazin-4-yl)ethyl)amino)quinazolin-7-yl)-5,7-difluorobenzo[b]thiophene-3-carbonitrile

[1267] LCMS: m / z 683 (M+H) + .

[1268] Example B214: 2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-5-fluorobenzo[b]thiophene-3-carbonitrile

[1269] LCMS: m / z 723 (M+H) + .

[1270] Example B214 was subjected to chiral separation to provide Example B214A and Example B214B: (R)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl) -5-fluorobenzo[b]thiophene-3-carbonitrile and (S)-2-amino-4-(4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinazolin-7-yl)-5-fluorobenzo[b]thiophene-3-carbonitrile

[1271] Example B214A

[1272] LCMS: m / z 723 (M+H) + .

[1273] Example B214B

[1274] LCMS: m / z 723 (M+H) + .

[1275] Example BD1: (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl-5',5'-d2)methoxy-d2)-8-fluoro-N-methylquinazolin-4-amine

[1276] LCMS: m / z 711 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.03(s,1H),7.97(d,J=3.7Hz,1H),7.64(d,J=7.2Hz,1H),6.86(s,2H),6.67(dd,J=7.4,4. 9Hz,1H),6.50(s,1H),6.00(m,1H),5.81(s,2H),3.16(s,3H),3.09(m,2H),2.38(s,3H),1.96(m,5H),1.63(m,6H).

[1277] Example BD2: (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-(methyl-d3)quinazolin-4-amine

[1278] LCMS: m / z 710 (M+H) + . 1 H NMR(400MHz, DMSO-d6)δ8.01(s,1H),7.95(dd,J=4.8,1.7Hz,1H),7.62(dd,J =7.5,1.7Hz,1H),6.82(s,2H),6.65(dd,J=7.5,4.9Hz,1H),6.49(s,1H),6.0 4–5.89(m,3H),4.26(s,2H),3.05–3.13(m,2H),2.85(m,1H),2.63(m,1H),2. 37(d,J=2.2Hz,3H),2.18–2.13(m,1H),2.08–1.92(m,3H),1.70–1.53(m,6H).

[1279] Example BD3: (7R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-(1-(2-aminopyridin-3-yl)ethyl-1,2,2,2-d4)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[1280] LCMS: m / z 711 (M+H) + .

[1281] Example BD3 was subjected to chiral separation to provide the isomers Example BD3A and Example BD3B: (7R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl-1,2,2,2-d4)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy) -8-fluoro-N-methylquinazolin-4-amine and (7R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-N-((S)-1-(2-aminopyridin-3-yl)ethyl-1,2,2,2-d4)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bisfused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoro-N-methylquinazolin-4-amine

[1282] Example BD3A

[1283] LCMS: m / z 711 (M+H) + .

[1284] Example BD3B

[1285] LCMS: m / z 711 (M+H) + .

[1286] Example C1: N-((R)-1-(2-aminopyridin-3-yl)ethyl)-7-(8-chloronaphthalen-1-yl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-N-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-amine trifluoroacetate

[1287] Step 1: Preparation of 7-(8-chloronaphth-1-yl)-2-(methylthio)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl trifluoromethanesulfonate

[1288] Dissolve 7-(8-chloronaphthalen-1-yl)-2-(methylthio)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-ol (200 mg, 0.56 mmol) and DIPEA (145 mg, 1.12 mmol) in dichloromethane (5 mL). Add trifluoromethanesulfonic anhydride (285 mg, 1.01 mmol) dropwise under ice-water bath. Stir the reaction mixture in an ice-water bath for 1 hour, then dilute with dichloromethane, wash with water and saturated sodium chloride solution, dry over anhydrous sodium sulfate, and filter. The filtrate is concentrated under reduced pressure, and the residue is separated by column chromatography to obtain the desired product (150 mg).

[1289] Step 2: Preparation of N-((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-(8-chloronaphth-1-yl)-N-methyl-2-(methylthio)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-amine

[1290] Under argon protection, 7-(8-chloronaphthalen-1-yl)-2-(methylthio)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl trifluoromethanesulfonate (150 mg, 0.31 mmol) and (R)-N,N-bis(4-methoxybenzyl)-3-(1-(methylamino)ethyl)pyridin-2-amine (242 mg, 0.62 mmol) were dissolved in DMSO (2 mL), and DIPEA (120 mg, 0.93 mmol) was added. The reaction solution was stirred at 80°C for 1 hour, diluted with ethyl acetate, washed with water and saturated sodium chloride solution, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was separated by column chromatography to obtain the target product (106 mg).

[1291] Step 3: Preparation of N-((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-(8-chloronaphthalen-1-yl)-N-methyl-2-(methylsulfoxide)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-amine

[1292] At 0°C, N-((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-(8-chloronaphthalen-1-yl)-N-methyl-2-(methylthio)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-amine (106 mg, 0.15 g) was dissolved in ethyl acetate (2 mL), followed by the dropwise addition of a solution of m-chloroperbenzoic acid (63 mg, 0.36 g) in ethyl acetate (2 mL). The reaction mixture was stirred at 0°C for 10 min, then quenched with saturated sodium bisulfite solution (30 mL), diluted with water (30 mL), and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was isolated by column chromatography to obtain the desired product (95 mg).

[1293] Step 4: Preparation of N-((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-(8-chloronaphthalen-1-yl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-N-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-amine

[1294] ((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methanol (79 mg, 0.39 mmol) was dissolved in tetrahydrofuran (1 mL), and sodium tert-butoxide (79 mg, 0.39 mmol) was added. The mixture was stirred for 1 minute, and then a solution of N-((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-(8-chloronaphthalen-1-yl)-N-methyl-2-(methylsulfoxy)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-amine (95 mg, 0.13 mmol) in tetrahydrofuran (1 mL) was added. After the addition was complete, the reaction mixture was stirred at room temperature for 1 hour, quenched with water, and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was separated by column chromatography to obtain the desired product (60 mg).

[1295] Step 5: Preparation of N-((R)-1-(2-aminopyridin-3-yl)ethyl)-7-(8-chloronaphthalen-1-yl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-N-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-amine trifluoroacetate

[1296] N-((R)-1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethyl)-7-(8-chloronaphthalen-1-yl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-N-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-amine (60 mg, 0.07 mmol) was dissolved in trifluoroacetic acid (2 mL). The resulting mixture was stirred at 60°C for 2 h and then concentrated under reduced pressure. The residue was separated by preparative liquid chromatography to give the desired product (10 mg).

[1297] LCMS: m / z 647 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δ10.90(s,1H),8.69–8.40(m,1H),8.12–7.77(m,6H),7.76–7.69(m,1H),7.6 9–7.60(m,1H),7.56–7.47(m,1H),6.99–6.90(m,1H),6.35–6.26(m,1H),5.78–5.65(m,1H),5.28–4 .99(m,2H),4.52–4.27(m,2H),3.76–3.60(m,2H),3.48–3.28(m,2H),3.17–3.05(m,1H),2.99(s,1. 5H),2.89(s,1.5H),2.81–2.66(m,1H),2.46–2.29(m,1H),2.26–1.82(m,7H),1.58(t,J=6.6Hz,3H).

[1298] The following compounds were synthesized using the same method as in Example C1 with different starting materials.

[1299] Example C2: 7-(3-amino-8-ethynyl-7-fluoronaphthalen-1-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-N-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-amine

[1300] LCMS: m / z 670 (M+H) + .

[1301] Example C3: 7-(3-amino-2-fluoro-5-(prop-1-yn-1-yl)-6-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-N-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-amine

[1302] LCMS: m / z 702 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ7.95–7.88(m,1H),7.59–7.44(m,1H),7.17(s,2H),6.88(d,J=8.4Hz,1H),6.67–6.55(m,1H),6.21 -6.05(m,2H),5.77–5.54(m,1H),5.38–5.29(m,1H),5.04–4.94(m,1H),4.94–4.70(m,2H),4.12–3.95(m,2H),3.12–2.97( m,3H),2.81–2.74(m,2H),2.71–2.61(m,3H),2.06–2.00(m,4H),1.88–1.83(m,1H),1.80–1.69(m,2H),1.56–1.44(m,7H).

[1303] Example D1: N-((R)-1-(2-aminopyridin-3-yl)ethyl)-7-(8-chloro-7-fluoronaphthalen-1-yl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-N-methyl-5,6,7,8-tetrahydropyridin-3-yl]pyrimidin-4-amine

[1304] LCMS: m / z 664 (M+H) + .

[1305] Example D2: 7-(3-amino-8-ethynyl-7-fluoronaphthalen-1-yl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-N-methyl-5,6,7,8-tetrahydropyridin[3,4-d]pyrimidin-4-amine

[1306] LCMS: m / z 669 (M+H) + .

[1307] Example D3: 7-(3-amino-2-fluoro-5-(prop-1-ynyl)-6-(trifluoromethyl)phenyl)-N-((R)-1-(2-aminopyridin-3-yl)ethyl)-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-N-methyl-5,6,7,8-tetrahydropyridin[3,4-d]pyrimidin-4-amine

[1308] LCMS: m / z 701 (M+H) + .

[1309] Example F1: 7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinoline-3-carbonitrile

[1310] Step 1: Preparation of 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-4-(((R)-1-(2-(bis(-4-methoxybenzyl)amino)pyridin-3-yl)ethyl)(methyl)amino)-2,6-dichloro-8-fluoroquinoline-3-carbonitrile trifluoroacetate

[1311] 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-2,4,6-trichloro-8-fluoroquinoline-3-carbonitrile (250 mg, 0.36 mmol) was dissolved in N,N-dimethylacetamide (3 mL), and N,N-diisopropylethylamine (140 mg, 1.09 mmol) and (R)-N,N-bis(4-methoxybenzyl)-3-(1-(methylamino)ethyl)pyridin-2-amine (156 mg, 0.40 mmol) were added. The resulting mixture was reacted at 100°C for 2 hours, then cooled to room temperature and directly purified by medium-pressure column chromatography to obtain the desired product (0.25 g, 60% yield).

[1312] LCMS: m / z 1044 (M+H) + .

[1313] Step 2: Preparation of 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-4-(((R)-1-(2-(bis(4-methoxyphenyl)amino)pyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinoline-3-carbonitrile

[1314] ((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methanol (46 mg, 0.23 mmol) was dissolved in tetrahydrofuran (2 mL), followed by the addition of sodium tert-butoxide (33 mg, 0.34 mmol). The resulting mixture was reacted for 10 minutes, followed by the addition of 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-4-(((R)-1-(2-(bis(-4-methoxybenzyl)amino)pyridin-3-yl)ethyl)(methyl)amino)-2,6-dichloro-8-fluoroquinoline-3-carbonitrile trifluoroacetate (130 mg, 0.11 mmol). The resulting mixture was reacted at room temperature for 1 hour, followed by the addition of water and extraction with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography to obtain the target product (90 mg, yield: 67%).

[1315] LCMS: m / z 1212 (M+H) + .

[1316] Step 3: Preparation of 7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinoline-3-carbonitrile

[1317] A solution of 7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-4-(((R)-1-(2-(bis(4-methoxyphenyl)amino)pyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinoline-3-carbonitrile (90 mg, 0.074 mmol) in trifluoroacetic acid (3 mL) was reacted at 50° C. for 2 hours and then concentrated under reduced pressure. The residue was separated by preparative liquid chromatography to give the desired product (11 mg, yield: 20%).

[1318] LCMS: m / z 731 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.32(s,1H),8.27(s,1H),7.85(s,1H),7.22(d,J=8Hz,2H),6.86(d,J=8Hz,2H),6.58(s,1H),4.42-4.30(m,2H),4.23( s,2H),3.71(s,3H),3.36-3.35(m,3H),3.18-3.06(m,2H),2.70(s,1H) ,2.36(s,3H),2.10-2.01(m,2H),1.91-1.81(m,3H),1.64-1.43(m,4H).

[1319] Example F1 was subjected to chiral separation to provide the isomers Example F1A and Example F1B: (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methyl (S)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(((1S,7a'S)-2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-bis-fused pyrrolidine]-7a'(5'H)-yl)methoxy)-8-fluoroquinoline-3-carbonitrile

[1320] Example F1A

[1321] LCMS: m / z 731 (M+H) + .

[1322] Example F1B

[1323] LCMS: m / z 731 (M+H) + .

[1324] The following compounds were synthesized using the same method as in Example F1 with different starting materials:

[1325] Example F2: 7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinoline-3-carbonitrile

[1326] LCMS: m / z 642 (M+H) + .

[1327] Example F2 was subjected to chiral separation to provide the isomers Example F2A and Example F2B: (R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinoline-3-carbonitrile and (S)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-4-(((R)-1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-6-chloro-2-(3-(dimethylamino)-3-methylazetidin-1-yl)-8-fluoroquinoline-3-carbonitrile

[1328] Example F2A

[1329] LCMS: m / z 642 (M+H) + .

[1330] Example F2B

[1331] LCMS: m / z 642 (M+H) + .

[1332] Example pharmaceutical composition

[1333] Oral tablets:

[1334] Example A2 or A3 was added with the auxiliary fillers microcrystalline cellulose (101) and lactose monohydrate, the internal disintegrant croscarmellose sodium, the binder hypromellose (E15), the external disintegrant croscarmellose sodium, and the lubricant magnesium stearate to prepare a 10 mg oral tablet.

[1335] Injection:

[1336] Example A2 or A3 is prepared into an injection preparation by adding sodium sulfobutyl beta-cyclodextrin, sodium chloride, water for injection, etc.

[1337] Biological test examples

[1338] Biological test evaluation

[1339] The following biological test examples further describe and explain the present invention, but these examples are not intended to limit the scope of the present invention.

[1340] 1. Cell Proliferation Assay

[1341] Positive reference: MRTX1133

[1342] Experimental procedures

[1343] Using a nanoliter pipette system, add the diluted test compound to a 384-well cell culture plate, setting up replicates. Add an equal volume of culture medium to the positive control group and an equal volume of DMSO to the negative control group. Centrifuge at 1000 rpm for 1 minute at room temperature.

[1344] A) Seed the cells into a 384 culture plate. For the negative control group, add an equal volume of cells, while for the positive control group, add an equal volume of culture medium alone. Centrifuge at 1000 rpm for 1 minute at room temperature. Add the final compound to a DMSO concentration of 0.5%. Incubate in a 37°C, 5% CO2 incubator for 7 days.

[1345] Add 20 μL / well 3D to b) Place in a 384-well cell culture plate, shake at 320 rpm for 20 min in the dark, and incubate at room temperature for 2 hrs in the dark.

[1346] The luminescence value was read using an Envision multi-function microplate reader.

[1347] 3. Data Analysis

[1348] The inhibition rate (IR) of the test compound was calculated using the following formula: IR (%) = (1 – (RLU 化合物 –RLU 空白对照 ) / (RLU 溶媒对照 –RLU 空白对照 ))*100%. The inhibition rates of compounds at different concentrations were calculated in Excel, and then inhibition curves were plotted and related parameters, including minimum inhibition rate, maximum inhibition rate, and IC, were calculated using GraphPad Prism software. 50 .

[1349] The results showed that the compounds of the present invention showed good inhibitory activity against KRAS mutations.

[1350] Table 1 Anti-cell proliferation activity of compounds

[1351] Pharmacokinetic testing evaluation

[1352] Male ICR mice weighing approximately 18-25 g were fasted overnight and orally administered with a 100 mg / kg solution of the compound of the invention or a control compound (10% DMSO / 60% polyethylene glycol 400 / 30% aqueous solution as the vehicle). Blood was collected at 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0, and 24 hours after administration of the compound of the invention, and plasma concentrations of the compound of the invention or the control compound were determined by LC / MS / MS.

[1353] Table 2 Main pharmacokinetic parameters in plasma

[1354] The test results show that the compound of the present invention has good oral pharmacokinetic properties.

[1355] Pharmacokinetic testing evaluation

[1356] Male SD rats weighing approximately 220 g were fasted overnight and orally administered with a 100 mg / kg solution of the compound of the present invention or a control compound (10% DMSO / 60% polyethylene glycol 400 / 30% aqueous solution as the vehicle). Blood was collected at 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0, and 24 hours after administration of the compound of the present invention, and the plasma concentration of the compound of the present invention or the control compound was determined by LC / MS / MS.

[1357] Table 3 Main pharmacokinetic parameters in plasma

[1358] Table 4 Main pharmacokinetic parameters in plasma

[1359] The test results show that the compound of the present invention has good oral pharmacokinetic properties.

[1360] Pharmacodynamic evaluation of antitumor activity (NCI-H727 CDX tumor model)

[1361] 100uL containing 5x10 6 NCI-H727 tumor cell suspension was subcutaneously inoculated into the right posterior abdomen of nude mice. The health of the mice was monitored daily, and measurements were taken when the tumor grew to a palpable size. Tumor volume was calculated using the formula: 0.5 x L x W 2 , where L and W represent the length and width of the tumor, respectively. The tumor grows to 200 mm 3 Mice were randomly divided into groups. The corresponding dose of compound was administered orally daily, and their general condition was monitored. Tumors were measured three times a week, and body weights were measured twice a week.

[1362] The test results show that the compound of the present invention has a good anti-tumor effect.

[1363] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.

Claims

1. A compound of formula (I0), its stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug: In the formula, Select from the following group: in, Select from the following group: Ring B is selected from the following substituted or unsubstituted groups: C6-C 14 Aryl, 5-14 membered heteroaryl; wherein the substitution refers to substitution by one or more R; R 1a are independently selected from the group consisting of substituted or unsubstituted hydrogen, deuterium, C1-C 10 Alkyl, C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group, C3-C 20 Cycloalkyl C1-C6 alkylene, 4-20 membered saturated or unsaturated heterocyclic C1-C6 alkylene; wherein the substitution refers to substitution by one or more R; R 1b are independently selected from the group consisting of substituted or unsubstituted hydrogen, deuterium, C1-C 10 Alkyl, C1-C 10 Alkoxy, C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group, C1-C 10 Alkoxy C1-C6 alkylene, C3-C 20 Cycloalkyl C1-C6 alkylene, 4-20 membered saturated or unsaturated heterocyclic C1-C6 alkylene; wherein the substitution refers to substitution by one or more R; R 1c Independently selected from the following substituted or unsubstituted groups: C1-C 10 Alkyl, C1-C 10 Alkoxy, C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group, C1-C 10 Alkoxy C1-C6 alkylene, C3-C 20 Cycloalkyl C1-C6 alkylene, 4-20 membered saturated or unsaturated heterocyclic C1-C6 alkylene; wherein the substitution refers to substitution by one or more R; or R 1a and R 1c Connected to form 4-7 membered rings; R 2 Selected from the following substituted or unsubstituted groups: C6-C 14 Aryl, 5-14 membered heteroaryl; wherein the substitution refers to substitution by one or more R; R 3 Each independently selected from the following substituted or unsubstituted groups: H, deuterium, halogen, cyano, ester, amine, amide, sulfone, urea, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C1-C6 alkyloxy, C3-C6 cycloalkyloxy, 4-6 membered heterocyclyloxy; wherein the substitution refers to the substitution of one or multiple R substitutions; m is an integer of 0, 1, 2, 3, 4, 5 or 6; X is selected from: bond, O, NH, N(C1-C3 alkyl), C≡C; Y is selected from: a bond, a substituted or unsubstituted C1-C6 alkylene; wherein the substitution refers to substitution by one or more R; 1) Z is selected from: Wherein, ring W1 is selected from the following substituted or unsubstituted groups: C3-C 20 Cycloalkyl, 4-20 membered saturated or unsaturated heterocyclic group; wherein the substitution refers to substitution by one or more R; R 4 Selected from: H, deuterium, alkenyl, fluoroalkenyl, ethynyl, C1-C6 alkyl, deuterated C1-C6 alkyl, halogenated C1-C6 alkyl, (C3-C6 cycloalkyl)C1-C6 alkyl, (4-6 membered heterocyclyl)C1-C6 alkyl, (C1-C6 alkoxy)C1-C6 alkyl, (C3-C6 cycloalkyloxy)C1-C6 alkyl, (4-6 membered heterocyclyloxy)C1-C6 alkyl, (C1-C6 alkyl)vinyl, deuterated (C1-C6 alkyl) )vinyl, halogenated (C1-C6 alkyl)vinyl, (C1-C6 alkyl)ethynyl, deuterated (C1-C6 alkyl)ethynyl, halogenated (C1-C6 alkyl)ethynyl, (C3-C6 cycloalkyl)ethynyl, (4-6 membered heterocyclyl)ethynyl, C1-C6 alkoxy, deuterated C1-C6 alkoxy, halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, 4-6 membered heterocyclyloxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C6-C 10 Aryl, 5-10 membered heteroaryl, halogen, nitro, hydroxy, oxo (═O), cyano, ester, amine, amide, sulfone or urea; n is an integer selected from: 0, 1, 2, 3, 4, 5 or 6; or 2) Z is selected from: -L4-Q2 or Wherein, ring W2 is selected from the following group of substituted or unsubstituted groups: C3-C6 cycloalkylene, 4-6 membered saturated or unsaturated heterocyclylene; wherein, the substitution refers to substitution by one or more R; Each L4 is independently selected from the group consisting of a substituted or unsubstituted bond, a C1-C6 alkylene group, and a deuterated C1-C6 alkylene group; wherein the substitution refers to substitution by one or more R; Each Q2 is independently selected from the following groups: substituted or unsubstituted: C1-C6 alkoxy, C3-C 10 Cycloalkyloxy, 4-10 membered heterocyclyloxy, C3-C 10 Cycloalkyl C1-C6 alkyleneoxy, 4-10 membered heterocyclic C1-C6 alkyleneoxy, C3-C 10 Cycloalkyl, 4-10 membered heterocyclic group, NHR 9 NR 9 R 10 ; R 9 and R 10 Each is independently selected from the following groups: substituted or unsubstituted: C1-C6 alkyl, C3-C 10 Cycloalkyl, 4-10 membered heterocyclic group, (C3-C 10 cycloalkyl)C1-C6 alkylene, (4-10 membered heterocyclic)C1-C6 alkylene, or R 9 and R 10 The N atom connected thereto together forms a substituted or unsubstituted 4-10 membered heterocyclic group; wherein the substitution refers to substitution by one or more R; Each R is the same or different and is independently selected from the group consisting of: H, deuterium, alkenyl, fluoroalkenyl, ethynyl, C1-C6 alkyl, deuterated C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkylene, halogenated C1-C6 alkylene, (C3-C6 cycloalkyl)C1-C6 alkyl, (4-6 membered heterocyclyl)C1-C6 alkyl, (C1-C6 alkoxy)C1-C6 alkyl, (C3-C6 cycloalkyloxy)C1-C6 alkyl, (4-6 membered heterocyclyl)C1-C6 alkyl heterocyclyloxy) C1-C6 alkyl, (C1-C6 alkyl) vinyl, deuterated (C1-C6 alkyl) vinyl, halogenated (C1-C6 alkyl) vinyl, (C1-C6 alkyl) ethynyl, deuterated (C1-C6 alkyl) ethynyl, halogenated (C1-C6 alkyl) ethynyl, (C3-C6 cycloalkyl) ethynyl, (4-6 membered heterocyclyl) ethynyl, C1-C6 alkoxy, deuterated C1-C6 alkoxy, halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, 4-6 membered heterocyclyloxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C6-C 10 aryl, 5-10 membered heteroaryl, halogen, nitro, hydroxyl, oxo (=O), cyano, ester, amine, amide, sulfone or urea.

2. The compound according to claim 1, its stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate or prodrug, characterized in that: It has the structure shown in formula (I): In the formula, B.R 1a , R 1b , R 1c , R 2 , R 3 , X, Y, Z and m are as defined in claim 1.

3. The compound according to claim 2, its stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug, characterized in that: It has a structure shown in formula (II-A) or formula (II-B): In the formula, Ring B, R 1a , R 1b , R 1c , R 2 , R 3 , X, Y, Z and m are as defined in claim 1.

4. The compound, stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof according to any one of claims 1 to 3, characterized in that: It has a structure shown by formula (III-A1), formula (III-A2) or formula (III-B1), formula (III-B2): In the formula, ring B, R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , X, Y, W1, W2, L4, Q2, m and n are defined as in claim 1; Preferably, it has a structure represented by formula (III-A1) or formula (III-B1).

5. The compound according to any one of claims 1 to 4, its stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug, characterized in that: It has a structure shown by formula (IV-A1), formula (IV-A2) or formula (IV-B1), formula (IV-B2): In the formula, Ring B, R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , Y, W1, W2, L4, Q2, m and n are defined as in claim 1.

6. The compound, stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof according to any one of claims 1 to 5, characterized in that: It has a structure shown by formula (V-A1), formula (V-A2) or formula (V-B1), formula (V-B2): In the formula, ring B, R 2 , R 3 , R 4 , Y, W1, W2, L4, Q2, m and n are defined as in claim 1.

7. The compound, stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof according to any one of claims 1 to 6, characterized in that: It has a structure shown in formula (VI-A1) or formula (VI-B1): In the formula, ring B, R 2 , R 3 , m and n are as defined in claim 1; each R 5 The same or different, each independently selected from hydrogen or deuterium.

8. The compound according to claim 1, its stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug, characterized in that: It has a structure shown in formula (VII-A1) or formula (VII-B1): In the formula, P 1 , P 2 , P 3 Each independently selected from CH, CF, C-Cl, C-CN, C-CF 3 , or N; Ring B, R 1a , R 1b , R 1c , R 3 , R 4 , X, Y, W1, W2, L4, Q2, m and n are defined as in claim 1.

9. The compound, stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof according to any one of claims 1 to 8, characterized in that: W1 is selected from: substituted or unsubstituted 4-7 membered monocyclic heterocyclic group, substituted or unsubstituted C3-C7 monocyclic cycloalkyl group, substituted or unsubstituted 6-10 membered bicyclic heterocyclic group, substituted or unsubstituted C6-C 10 bicyclic cycloalkyl, substituted or unsubstituted 7-12 membered tricyclic heterocyclic group, substituted or unsubstituted C7-C 12 tricyclic cycloalkyl, preferably, W1 is a substituted or unsubstituted 8-12 membered N-containing heterocyclic group, wherein the substitution refers to substitution by one or more R, and R is defined as described in claim 1; Preferably, Selected from: wherein n' is an integer of 0, 1, 2, 3, 4, 5, or 6; R, R 4 and n are as defined in claim 1, R, R 4 It can be substituted on any ring of a polycyclic ring (such as a bridged ring or a spiro ring); More preferably, Selected from: wherein n' is an integer of 0, 1, 2, 3, 4, 5 or 6; R, R 4 and n are as defined in claim 1, and R may be substituted on any one of the polycyclic (eg bridged or spiro) rings.

10. The compound according to claim 1, its stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug, characterized in that: for Preferably, Selected from: Or choose from:

11. The compound, stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof according to any one of claims 1 to 10, characterized in that: R 2 is selected from the following substituted or unsubstituted groups: phenyl, naphthyl, 5-6 membered monocyclic heteroaryl (such as pyridyl), 9-10 membered bicyclic heteroaryl (such as indazolyl, benzothiazole, benzothiophene, benzofuran), wherein the substitution is substituted by one or more groups selected from the following groups: halogen, hydroxyl, cyano, NH2, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C2-C6 alkenyl, C2-C6 alkynyl, ester, amine, amide, sulfone, urea, sulfonamide, C3-C6 cycloalkyl O-, 4-6 membered heterocyclyl O-, C3-C6 cycloalkyl OH, 4-6 membered heterocyclyl OH; preferably, R 2 Selected from: Or choose from: Or choose from: Or choose from:

12. The compound according to any one of claims 1 to 11, its stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate or prodrug, characterized in that: Ring B is selected from the following substituted or unsubstituted groups: phenyl, naphthyl, 5-6 membered monocyclic heteroaryl (such as pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl), 9-10 membered bicyclic heteroaryl (such as indazolyl, benzothiazole, benzothiophene, benzofuran), wherein the substitution is substituted by one or more groups selected from the following group: halogen, hydroxyl, cyano, NH2, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, C3-C6 cycloalkyl, 4-6 membered heterocyclyl, C2-C6 alkenyl, C2-C6 alkynyl, ester, amine, amide, sulfone, urea, sulfonamide, C3-C6 cycloalkyl O-, 4-6 membered heterocyclyl O-, C3-C6 cycloalkyl OH, 4-6 membered heterocyclyl OH; preferably, ring B is selected from: Or choose from: More preferably, Ring B is selected from: Or choose from:

13. The compound, stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof according to any one of claims 1 to 12, characterized in that: The compound is selected from the group consisting of: Or choose from: Or choose from: Or choose from: Or choose from: Or choose from: Or choose from: Or choose from: Or choose from: Or choose from: Or choose from: Or choose from: Or choose from: Or choose from: Or choose from:

14. A pharmaceutical composition, characterized in that Comprising one or more compounds according to any one of claims 1 to 13, their stereoisomers, tautomers, crystalline forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs; and a pharmaceutically acceptable carrier.

15. A use of the compound according to any one of claims 1 to 13, its stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug, or the pharmaceutical composition according to claim 14, characterized in that: Used for preparing a drug for preventing and / or treating a disease associated with the activity or expression of KRAS mutations, preferably, the disease is a tumor or a disorder.

Citation Information

Patent Citations

  • Bicyclic BET bromodomain inhibitors and uses thereof

    CN109641886A

  • Aminoquinazoline derivatives as P2X3 inhibitors

    CN114269432A

  • Azaquinazoline pan-kras inhibitors

    WO2022132200A1

  • Tetrahydropyridopyrimidine pan-kras inhibitors

    WO2022133038A1

  • Pyridine fused pyrimidine derivatives and use thereof

    WO2023020521A1

Cited By

  • Cereblon-based KRAS degrading PROTACs and uses related thereto

    US12448399B2

  • KRAS G12D modulating compounds

    US12448400B2

  • KRAS inhibitors

    US12624033B2

  • Ras inhibitors

    WO2025240847A1

  • Methods of treating a ras protein-related disease or disorder

    WO2025255438A1